
<html lang="en"     class="pb-page"  data-request-id="12fed4ec-8bf4-4297-bb33-e876788bdc90"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:10.1021/jm201449n;wgroup:string:ACHS website Group;website:website:acspubs;issue:issue:10.1021/jmcmar.2012.55.issue-2;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Synthesis and Biological Profile of the pan-Vascular Endothelial Growth Factor Receptor/Tyrosine Kinase with Immunoglobulin and Epidermal Growth Factor-Like Homology Domains 2 (VEGF-R/TIE-2) Inhibitor 11-(2-Methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4H-indazolo[5,4-a]pyrrolo[3,4-c]carbazol-4-one (CEP-11981): A Novel Oncology Therapeutic Agent" /></meta><meta name="dc.Creator" content="Robert L.  Hudkins" /></meta><meta name="dc.Creator" content="Nadine C.  Becknell" /></meta><meta name="dc.Creator" content="Allison L.  Zulli" /></meta><meta name="dc.Creator" content="Ted L.  Underiner" /></meta><meta name="dc.Creator" content="Thelma S.  Angeles" /></meta><meta name="dc.Creator" content="Lisa D.  Aimone" /></meta><meta name="dc.Creator" content="Mark S.  Albom" /></meta><meta name="dc.Creator" content="Hong  Chang" /></meta><meta name="dc.Creator" content="Sheila J.  Miknyoczki" /></meta><meta name="dc.Creator" content="Kathryn  Hunter" /></meta><meta name="dc.Creator" content="Susan  Jones-Bolin" /></meta><meta name="dc.Creator" content="Hugh  Zhao" /></meta><meta name="dc.Creator" content="Edward R.  Bacon" /></meta><meta name="dc.Creator" content="John P.  Mallamo" /></meta><meta name="dc.Creator" content="Mark A.  Ator" /></meta><meta name="dc.Creator" content="Bruce A.  Ruggeri" /></meta><meta name="dc.Description" content="A substantial body of evidence supports the utility of antiangiogenesis inhibitors as a strategy to block or attenuate tumor-induced angiogenesis and inhibition of primary and metastatic tumor grow..." /></meta><meta name="Description" content="A substantial body of evidence supports the utility of antiangiogenesis inhibitors as a strategy to block or attenuate tumor-induced angiogenesis and inhibition of primary and metastatic tumor grow..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="January 6, 2012" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/jm201449n" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Â© 2011 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Fjm201449n" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Fjm201449n" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Fjm201449n" /></link>
        
    
    

<title>Synthesis and Biological Profile of the pan-Vascular Endothelial Growth Factor Receptor/Tyrosine Kinase with Immunoglobulin and Epidermal Growth Factor-Like Homology Domains 2 (VEGF-R/TIE-2) Inhibitor 11-(2-Methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4H-indazolo[5,4-a]pyrrolo[3,4-c]carbazol-4-one (CEP-11981): A Novel Oncology Therapeutic Agent | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/jm201449n" /></meta><meta property="og:title" content="Synthesis and Biological Profile of the pan-Vascular Endothelial Growth Factor Receptor/Tyrosine Kinase with Immunoglobulin and Epidermal Growth Factor-Like Homology Domains 2 (VEGF-R/TIE-2) Inhibitor 11-(2-Methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4H-indazolo[5,4-a]pyrrolo[3,4-c]carbazol-4-one (CEP-11981): A Novel Oncology Therapeutic Agent" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-2/jm201449n/production/images/large/jm-2011-01449n_0006.jpeg" /></meta><meta property="og:description" content="A substantial body of evidence supports the utility of antiangiogenesis inhibitors as a strategy to block or attenuate tumor-induced angiogenesis and inhibition of primary and metastatic tumor growth in a variety of solid and hematopoietic tumors. Given the requirement of tumors for different cytokine and growth factors at distinct stages of their growth and dissemination, optimal antiangiogenic therapy necessitates inhibition of multiple, complementary, and nonredundant angiogenic targets. 11-(2-Methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4H-indazolo[5,4-a]pyrrolo[3,4-c]carbazol-4-one (11b, CEP-11981) is a potent orally active inhibitor of multiple targets (TIE-2, VEGF-R1, 2, and 3, and FGF-R1) having essential and nonredundant roles in tumor angiogenesis and vascular maintenance. Outlined in this article are the design strategy, synthesis, and biochemical and pharmacological profile for 11b, which completed Phase I clinical assessing safety and pharmacokinetics allowing for the initiation of proof of concept studies." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/jm201449n"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/jm201449n">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=âtrueâ></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=âtrueâ></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=âtrueâ></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=âtrueâ></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Fjm201449n&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Fjm201449n&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/jm201449n&amp;href=/doi/10.1021/jm201449n" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2012</span><span class="cit-fg-volume">, 55</span><span class="cit-fg-issue">, 2</span><span class="cit-fg-pageRange">, 903-913</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/55/2" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/jm2014293" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/jm2014748" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="article_relation"><span class="article_relation-correction"><i class="icon-asterisk"></i><span class="relation-text"><a href="/doi/10.1021/jm300413f"><span class="relation-type">ADDITION / CORRECTION</span><span class="relation-desc">This article has been corrected. View the notice.</span></a></span></span></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Synthesis and Biological Profile of the pan-Vascular Endothelial Growth Factor Receptor/Tyrosine Kinase with Immunoglobulin and Epidermal Growth Factor-Like Homology Domains 2 (VEGF-R/TIE-2) Inhibitor 11-(2-Methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4<i>H</i>-indazolo[5,4-a]pyrrolo[3,4-c]carbazol-4-one (CEP-11981): A Novel Oncology Therapeutic Agent</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Robert+L.++Hudkins">Robert L. Hudkins</a></span><span class="author-xref-symbol "><sup>*</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Nadine+C.++Becknell">Nadine C. Becknell</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Allison+L.++Zulli">Allison L. Zulli</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ted+L.++Underiner">Ted L. Underiner</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Thelma+S.++Angeles">Thelma S. Angeles</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Lisa+D.++Aimone">Lisa D. Aimone</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Mark+S.++Albom">Mark S. Albom</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Hong++Chang">Hong Chang</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Sheila+J.++Miknyoczki">Sheila J. Miknyoczki</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Kathryn++Hunter">Kathryn Hunter</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Susan++Jones-Bolin">Susan Jones-Bolin</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Hugh++Zhao">Hugh Zhao</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Edward+R.++Bacon">Edward R. Bacon</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=John+P.++Mallamo">John P. Mallamo</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Mark+A.++Ator">Mark A. Ator</a></span></span></li><span class="comma-separator">,Â andÂ </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Bruce+A.++Ruggeri">Bruce A. Ruggeri</a></span><span class="author-xref-symbol "><sup>*</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-text">Discovery Research, Cephalon, Inc., 145 Brandywine Parkway, West Chester, Pennsylvania 19380, United States</span></div><div class="corresp-info"><strong>*</strong>Phone: 610-738-6283. Fax: 610-738-6558. E-mail: <a href="/cdn-cgi/l/email-protection#e7958f92838c8e8994a78482978f868b8889c984888a"><span class="__cf_email__" data-cfemail="ccbea4b9a8a7a5a2bf8cafa9bca4ada0a3a2e2afa3a1">[emailÂ protected]</span></a> or <a href="/cdn-cgi/l/email-protection#11437e737463653f5964757a787f625165746770617970637c3f727e7c"><span class="__cf_email__" data-cfemail="580a373a3d2a2c76102d3c3331362b182c3d2e392830392a35763b3735">[emailÂ protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Fjm201449n&amp;href=/doi/10.1021%2Fjm201449n" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2012</span></span><span class="cit-volume">, 55</span><span class="cit-issue">, 2</span><span class="cit-pageRange">, 903â913</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">December 12, 2011</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>26 October 2011</li><li><span class="item_label"><b>Published</b> online</span>6 January 2012</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 26 January 2012</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/jm201449n" title="DOI URL">https://doi.org/10.1021/jm201449n</a></div><div class="article_header-article-copyright"><strong>Copyright Â© 2011 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D903%26pageCount%3D11%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DRobert%2BL.%2BHudkins%252C%2BNadine%2BC.%2BBecknell%252C%2BAllison%2BL.%2BZulli%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D55%26issueNum%3D2%26contentID%3Djm201449n%26title%3DSynthesis%2Band%2BBiological%2BProfile%2Bof%2Bthe%2Bpan-Vascular%2BEndothelial%2BGrowth%2BFactor%2BReceptor%252FTyrosine%2BKinase%2Bwith%2BImmunoglobulin%2Band%2BEpidermal%2BGrowth%2BFactor-Like%2BHomology%2BDomains%2B2%2B%2528VEGF-R%252FTIE-2%2529%2BInhibitor%2B11-%25282-Methylpropyl%2529-12%252C13-dihydro-2-methyl-8-%2528pyrimidin-2-ylamino%2529-4H-indazolo%255B5%252C4-a%255Dpyrrolo%255B3%252C4-c%255Dcarbazol-4-one%2B%2528CEP-11981%2529%253A%2BA%2BNovel%2BOncology%2BTherapeutic%2BAgent%26numPages%3D11%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D913%26publicationDate%3DJanuary%2B2012">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/jm201449n"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1870</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">30</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/jm201449n" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Synthesis and Biological Profile of the pan-Vascular Endothelial Growth Factor Receptor/Tyrosine Kinase with Immunoglobulin and Epidermal Growth Factor-Like Homology Domains 2 (VEGF-R/TIE-2) Inhibitor 11-(2-Methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4H-indazolo[5,4-a]pyrrolo[3,4-c]carbazol-4-one (CEP-11981): A Novel Oncology Therapeutic Agent&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Robert&quot;,&quot;last_name&quot;:&quot;L. Hudkins&quot;},{&quot;first_name&quot;:&quot;Nadine&quot;,&quot;last_name&quot;:&quot;C. Becknell&quot;},{&quot;first_name&quot;:&quot;Allison&quot;,&quot;last_name&quot;:&quot;L. Zulli&quot;},{&quot;first_name&quot;:&quot;Ted&quot;,&quot;last_name&quot;:&quot;L. Underiner&quot;},{&quot;first_name&quot;:&quot;Thelma&quot;,&quot;last_name&quot;:&quot;S. Angeles&quot;},{&quot;first_name&quot;:&quot;Lisa&quot;,&quot;last_name&quot;:&quot;D. Aimone&quot;},{&quot;first_name&quot;:&quot;Mark&quot;,&quot;last_name&quot;:&quot;S. Albom&quot;},{&quot;first_name&quot;:&quot;Hong&quot;,&quot;last_name&quot;:&quot;Chang&quot;},{&quot;first_name&quot;:&quot;Sheila&quot;,&quot;last_name&quot;:&quot;J. Miknyoczki&quot;},{&quot;first_name&quot;:&quot;Kathryn&quot;,&quot;last_name&quot;:&quot;Hunter&quot;},{&quot;first_name&quot;:&quot;Susan&quot;,&quot;last_name&quot;:&quot;Jones-Bolin&quot;},{&quot;first_name&quot;:&quot;Hugh&quot;,&quot;last_name&quot;:&quot;Zhao&quot;},{&quot;first_name&quot;:&quot;Edward&quot;,&quot;last_name&quot;:&quot;R. Bacon&quot;},{&quot;first_name&quot;:&quot;John&quot;,&quot;last_name&quot;:&quot;P. Mallamo&quot;},{&quot;first_name&quot;:&quot;Mark&quot;,&quot;last_name&quot;:&quot;A. Ator&quot;},{&quot;first_name&quot;:&quot;Bruce&quot;,&quot;last_name&quot;:&quot;A. Ruggeri&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2012&quot;,&quot;month&quot;:&quot;01&quot;,&quot;day&quot;:&quot;06&quot;,&quot;issue&quot;:&quot;2&quot;,&quot;volume&quot;:&quot;55&quot;,&quot;pages&quot;:&quot;903-913&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/jm201449n&quot;},&quot;abstract&quot;:&quot;A substantial body of evidence supports the utility of antiangiogenesis inhibitors as a strategy to block or attenuate tumor-induced angiogenesis and inhibition of primary and metastatic tumor growth in a variety of solid and hematopoietic tumors. Given the requirement of tumors for different cytokine and growth factors at distinct stages of their growth and dissemination, optimal antiangiogenic therapy necessitates inhibition of multiple, complementary, and nonredundant angiogenic targets. 11-(2-Methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4H-indazolo[5,4-a]pyrrolo[3,4-c]carbazol-4-one (11b, CEP-11981) is a potent orally active inhibitor of multiple targets (TIE-2, VEGF-R1, 2, and 3, and FGF-R1) having essential and nonredundant roles in tumor angiogenesis and vascular maintenance. Outlined in this article are the design strategy, synthesis, and biochemical and pharmacological profile for 11b, which completed Phase I clinical assessing safety and pharmacokinetics allowing for the initiation o&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Fjm201449n&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm201449n" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm201449n&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=jm201449n" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm201449n&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=jm201449n" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Fjm201449n&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm201449n&amp;href=/doi/10.1021/jm201449n" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/jm201449n" /></input><a href="/doi/pdf/10.1021/jm201449n" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (2 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/jm201449n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Fjm201449n%26sid%3Dliteratum%253Aachs%26pmid%3D22148921%26genre%3Darticle%26aulast%3DHudkins%26date%3D2012%26atitle%3DSynthesis%2Band%2BBiological%2BProfile%2Bof%2Bthe%2Bpan-Vascular%2BEndothelial%2BGrowth%2BFactor%2BReceptor%252FTyrosine%2BKinase%2Bwith%2BImmunoglobulin%2Band%2BEpidermal%2BGrowth%2BFactor-Like%2BHomology%2BDomains%2B2%2B%2528VEGF-R%252FTIE-2%2529%2BInhibitor%2B11-%25282-Methylpropyl%2529-12%252C13-dihydro-2-methyl-8-%2528pyrimidin-2-ylamino%2529-4H-indazolo%255B5%252C4-a%255Dpyrrolo%255B3%252C4-c%255Dcarbazol-4-one%2B%2528CEP-11981%2529%253A%2BA%2BNovel%2BOncology%2BTherapeutic%2BAgent%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D55%26issue%3D2%26spage%3D903%26epage%3D913%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292258" title="Cancer">Cancer</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=292153" title="Tumors">Tumors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/55/2" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-2/jmcmar.2012.55.issue-2/production/jmcmar.2012.55.issue-2.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-2/jm201449n/production/images/medium/jm-2011-01449n_0006.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-2/jm201449n/production/images/large/jm-2011-01449n_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201449n&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">A substantial body of evidence supports the utility of antiangiogenesis inhibitors as a strategy to block or attenuate tumor-induced angiogenesis and inhibition of primary and metastatic tumor growth in a variety of solid and hematopoietic tumors. Given the requirement of tumors for different cytokine and growth factors at distinct stages of their growth and dissemination, optimal antiangiogenic therapy necessitates inhibition of multiple, complementary, and nonredundant angiogenic targets. 11-(2-Methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4<i>H</i>-indazolo[5,4-a]pyrrolo[3,4-c]carbazol-4-one (<b>11b</b>, CEP-11981) is a potent orally active inhibitor of multiple targets (TIE-2, VEGF-R1, 2, and 3, and FGF-R1) having essential and nonredundant roles in tumor angiogenesis and vascular maintenance. Outlined in this article are the design strategy, synthesis, and biochemical and pharmacological profile for <b>11b</b>, which completed Phase I clinical assessing safety and pharmacokinetics allowing for the initiation of proof of concept studies.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_86130" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_86130" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Angiogenesis, the development of new blood vessels from the endothelium of a pre-existing vasculature, is a critical process required by the majority of solid tumors to maintain localized growth and metastatic dissemination within the host.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> The clinical application of kinase inhibitors and antivascular endothelial growth factor (VEGF) antibodies to halt angiogenesis in tumors has been validated as a therapeutic strategy by positive clinical results with bevacizumab,<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> sorafenib <b>1</b>,<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> sunitinib <b>2</b>,<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> and pazopanib <b>3</b><a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>). The dual vascular endothelial growth factor receptor kinase 2/fibroblast growth factor receptor 1 (VEGF-R2/FGF-R1) inhibitor <b>4</b> (brivanib, BMS-582664) advanced to phase III.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> There is a substantial body of literature detailing the utility of antiangiogenesis inhibitors as a strategy to block or attenuate tumor-induced angiogenesis and inhibit primary and metastatic tumor growth in a variety of solid and hematopoietic tumor models. Given the heterogeneity and organ-specificity of the tumor-associated vasculature and the requirement of tumors for different cytokine and growth factors at distinct stages of their growth and dissemination, optimal antiangiogenic therapies may necessitate the inhibition of multiple, complementary, and nonredundant angiogenic targets.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> Several angiogenic ligands and their corresponding receptor tyrosine kinases have been implicated in angiogenesis and vasculogenesis, acting at distinct phases spatially and temporally in the angiogenic process in coordinated and complementary roles to that of the VEGFâVEGF-R kinase axes. Principal among these is the angiopoietin family of angiogenic growth factors (Ang-1â4) and their endothelial cell-specific receptor tyrosine kinases, tyrosine kinase with immunoglobulin and EGF-like domains 1 and 2 (TIE-1 and TIE-2), which have been implicated in vessel stabilization, maturation, and remodeling, and the proper hierarchical organization of the rudimentary vasculature.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-2/jm201449n/production/images/medium/jm-2011-01449n_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-2/jm201449n/production/images/large/jm-2011-01449n_0008.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of angiogenesis inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-2/jm201449n/production/images/large/jm-2011-01449n_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201449n&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The inhibition of tumor angiogenesis and vascular remodeling achieved in nonclinical studies by modulating the angiopoietin-TIE-2 axis alone, and in concert with the VEGFâVEGF-R2 axis, has been demonstrated using biochemical, molecular, and small molecule-based approaches against a variety of human tumors.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> Application of adenoviral delivered anti-TIE-2 and anti-VEGF-R2 have also demonstrated improved activity when both the TIE-2 and VEGF-R2 signaling pathways are targeted relative to targeting each pathway alone.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> Inhibition of multiple angiogenic targets such as VEGF-R2 and TIE-2 are currently being evaluated clinically and preclinically.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a></div><div class="NLM_p">Previously, we reported on our first generation VEGF-R candidate <b>5b</b> (CEP-7055), a prodrug of <b>5a</b> (CEP-5214).<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> Indenocarbazole <b>5a</b> had potent activity for VEGF-R1, R2, and R3 (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>) but had weak activity for TIE-2 (IC<sub>50</sub> > 10 Î¼M) as well as several other angiogenesis targets.<a onclick="showRef(event, 'cit12a'); return false;" href="javascript:void(0);" class="ref cit12a">(12a)</a> The objective for a second generation follow-on compound was to design in TIE-2 activity and advance a broad-based angiogenesis inhibitor with superior biochemical, pharmacokinetic (PK), pharmacodynamic and in vivo antitumor efficacy compared to that of <b>5b</b>. As outlined in a series of publications, structural modification to the indenocarbazole core identified the N2-methyl-12,13-dihydroindazolo[5,4-<i>a</i>]pyrrolo[3,4-c]carbazole scaffold (DHI) with improved dual activity and PK properties for further lead optimization.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> Modification to the 8-position identified several series and leads with cellular potency, PK, and in vivo antitumor efficacy such as tetrahydropyrans (THP),<a onclick="showRef(event, 'cit13d'); return false;" href="javascript:void(0);" class="ref cit13d">(13d)</a> oximes,<a onclick="showRef(event, 'cit13c'); return false;" href="javascript:void(0);" class="ref cit13c">(13c)</a> thienyl ketones,<a onclick="showRef(event, 'cit13b'); return false;" href="javascript:void(0);" class="ref cit13b">(13b)</a> and carbamates.<a onclick="showRef(event, 'cit13a'); return false;" href="javascript:void(0);" class="ref cit13a">(13a)</a> The isopropyl carbamate <b>6</b> met the dual TIE-2/VEGF-R2 enzyme (VEGF-R2 IC<sub>50</sub> = 5 nM; TIE-2 = 11 nM) and cellular potency criteria (VEGF-R2 cell IC<sub>50</sub> < 10 nM) and showed significant dose-related antitumor efficacy at oral doses as low as 0.3 mg/kg bid.<a onclick="showRef(event, 'cit13a'); return false;" href="javascript:void(0);" class="ref cit13a">(13a)</a> However, <b>6</b> suffered from suboptimal pharmacokinetic properties and showed dose-limited toxicity that prevented further advancement. An additional concern for <b>6</b> and the carbamate/urea series was the theoretical toxicity associated with the potential aniline metabolite. Therefore, motivated to remove the aniline red flag and improve the pharmacokinetic properties, a series of constrained pyrimidinyl-2-amines were designed as bioisosteric replacements for the carbamate/urea moiety. In this article, we report the synthesis and structureâactivity relationships (SAR) for the 2-pyrimidin-2-ylamine-DHI series and the identification of the clinical candidate <b>11b</b>.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-2/jm201449n/production/images/medium/jm-2011-01449n_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-2/jm201449n/production/images/large/jm-2011-01449n_0009.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. First and second generation angiogenesis inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-2/jm201449n/production/images/large/jm-2011-01449n_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201449n&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_06846" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_06846" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The 8-(pyrimidin-2-ylamino)-4<i>H</i>-indazolo[5,4-<i>a</i>]pyrrolo[3,4-c]carbazol-4-one analogues were synthesized from 5-cyano-4-ethoxycarbonyl-12,13-dihydro-2-methyl-indazolo[5,4-<i>a</i>]carbazole intermediate <b>7</b>.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> The DHI core and intermediate <b>7</b>were constructed via a regioselective DielsâAlder reaction as described in detail previously.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> The key transformation to elaborate the N<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> position for SAR development was the efficient N-alkylation of <b>7</b> to cyano-esters <b>8a</b>â<b>c</b> using NaOH in acetone, without hydrolysis of the ester or nitrile. Alkylation at the lactam stage produced multiple inseparable mixtures including the mono and N,N-dialkylated products. Intermediates <b>8a</b>â<b>c</b> were selectively nitrated at the C-8 position to give <b>9a</b>â<b>c</b> using exactly two equivalents of HNO<sub>3</sub> in AcOH at 80 Â°C for 1 h.<a onclick="showRef(event, 'cit14a'); return false;" href="javascript:void(0);" class="ref cit14a">(14a)</a> A one-pot, reductive cyclization procedure was developed to convert the nitro-cyano-esters <b>9a</b>â<b>c</b> (Raney-Ni/H<sub>2</sub> in DMF-MeOH) to the amino-lactam intermediates <b>10a</b>â<b>c</b>.<a onclick="showRef(event, 'cit14d'); return false;" href="javascript:void(0);" class="ref cit14d">(14d)</a> Anilines <b>10a</b>â<b>c</b> were reacted with 2-chloropyrimidines, 4-chloro-pyridine, or 2-chloropyridazine at <i>n</i>-butanol or <i>t</i>-butanol reflux to efficiently produce the target amino-heteroaryls <b>11a</b>â<b>j</b> (Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>). The 1-methyl regioisomer <b>15</b> was synthesized for comparison in an analogous manner starting with 5-(1<i>H</i>-indol-2-yl)-1-methyl-6,7-dihydro-1<i>H</i>-indazole <b>12</b> (Scheme <a class="ref internalNav" href="#sch2" aria-label="2">2</a>).<a onclick="showRef(event, 'cit13c cit13d cit14a cit14b cit14c'); return false;" href="javascript:void(0);" class="ref cit13c cit13d cit14a cit14b cit14c">(13c, 13d, 14a-14c)</a></div><figure id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-2/jm201449n/production/images/medium/jm-2011-01449n_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-2/jm201449n/production/images/large/jm-2011-01449n_0002.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. <sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-2/jm201449n/production/images/large/jm-2011-01449n_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201449n&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) alkyl iodide, NaOH, acetone, reflux, 18 h, 87â93% ; (b) HNO<sub>3</sub>, AcOH, 80 Â°C, 1 h 70â87%; (c) H<sub>2</sub>, Raney-Ni, DMF-MeOH, 81â97%; (d) heteroaryl-chloride, 1-butanol, reflux, 40â65%.</p></p></figure><figure id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-2/jm201449n/production/images/medium/jm-2011-01449n_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-2/jm201449n/production/images/large/jm-2011-01449n_0003.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. <sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-2/jm201449n/production/images/large/jm-2011-01449n_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201449n&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) 1-iodo-2-methyl-propane, NaOH, acetone, reflux, 18 h, 90%; (b) HNO<sub>3</sub>, AcOH, 80 Â°C, 1 h, 85%; (c) H<sub>2</sub>, Raney-Ni, DMF-MeOH, 80% ; (d) 2-chloropyrimidine, 1-butanol, reflux, 45%.</p></p></figure></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i5">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_78177" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_78177" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6"> In Vitro VEGF-R2 and TIE-2 StructureâActivity Relationships</h3><div class="NLM_p">The pyrimidin-2-ylamino DHI analogues were screened against recombinant human VEGF-R2 and TIE-2 using a heterogeneous time-resolved fluorescence (TRF) readout and recombinant human phospholipase C-Î³/glutathione <i>S</i>-transferase (GST) as substrate.<a onclick="showRef(event, 'cit12a ref13'); return false;" href="javascript:void(0);" class="ref cit12a ref13">(12a, 13)</a> The enzyme inhibitory data is shown in Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>. Dual TIE-2/VEGF-R2 inhibitors with IC<sub>50</sub> values less than 25 nM that demonstrated acceptable cell potency, and pharmacokinetic properties were advanced for in vivo evaluation. Previous dual TIE-2/VEGF-R2 SAR studies on the core revealed that a three or four carbon alkyl unit at <i>N</i>-R<sup>11</sup> was optimum for balanced dual potency and PK.<a onclick="showRef(event, 'cit13a cit13c'); return false;" href="javascript:void(0);" class="ref cit13a cit13c">(13a, 13c)</a> Ideal dual target potency and PK properties were achieved with an <i>n</i>-propyl, <i>i</i>-propyl, and <i>i</i>-butyl group and further increasing or decreasing the size of the R<sup>11</sup> alkyl reduced the balanced dual profile. In thepyrimidinyl-amine series, the focus was therefore on optimizing 8-pyrimidinyl-amine region while maintaining the best R<sup>11</sup> alkyl. The constrained pyrimidinyl <i>n</i>-propyl <b>11a</b> retained dual potency with VEGF-R2 and TIE-2 IC<sub>50</sub> values of 6 nM and 27 nM, respectively. Varying the <i>N</i>-R<sup>11</sup> alkyl to <i>i</i>-butyl <b>11b</b> showed comparable potency (VEGF-R2 IC<sub>50</sub> = 4 nM; TIE-2 IC<sub>50</sub> = 22 nM), while <i>i</i>-propyl <b>11c</b> had a 3-fold drop in TIE-2 potency (VEGF-R2 IC<sub>50</sub> = 3 nM; TIE-2 IC<sub>50</sub> = 76 nM) and did not meet discovery criteria. Metabolic stability studies were conducted on <b>11a</b> and <b>11b</b> using hepatic S9 fractions from mouse, rat, dog, monkey, and human. Both compounds showed 65â77% of the parent remaining after 2 h in mouse, rat, and dog liver S9, while monkey was lower (<b>11a</b> = 44%; <b>11b</b> = 54%). In human S9, <b>11b</b> showed 79% remaining after 2 h compared to <b>11a</b>, which was 54%. Compounds <b>11a</b> and <b>11b</b> were further evaluated for pharmacokinetic properties in the rat. Compound <b>11b</b> showed acceptable oral exposure and intrinsic pharmacokinetic parameters in the rat (Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>), while the oral exposure for <b>11a</b> (% F = 22) was lower. The oral bioavailability for <b>11b</b> was 44% after determining the plasma level exposure after i.v. (0.8 mg/kg) and p.o. (5 mg/kg) administration over a 24 h period. The i.v. terminal half-life was 1.9 h (oral half-life = 3 h), with a volume of distribution of 1.3 L/kg and a low clearance rate of 4.3 mL/min/kg. Compound <b>11b</b> also showed acceptable selectivity against CYP isoforms 2D6, 3A4, and 2C19 (IC<sub>50</sub> > 30 Î¼M for 3A4 and 2D6; 9 Î¼M for 2C19) and no issues with CYP3A4 induction. The permeability was evaluated in the Caco-2 intestinal epithelial cell line where it was classified as high permeability (Papp = > 4 Ã 10<sup>â6</sup> cm/sec). Compound <b>11b</b> binding to human plasma proteinswas 95%, markedly lower than that of approved kinase inhibitors such as dasatinib, sorafenib, lapatanib, or nilotinib.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> Next, the effect of substitution around the pyrimidine ring was explored with selected alkyl, methoxy, and CF<sub>3</sub> groups. The 5-ethylpyrimidinyl showed improved TIE-2 potency about 6-fold with an <i>n</i>-propyl (<b>11d</b>: TIE-2 IC<sub>50</sub> = 4 nM) and 2-fold with an isobutyl (<b>11e</b>: TIE-2 IC<sub>50</sub> = 10 nM). However, both <b>11d</b> and <b>11e</b> showed poor metabolic stability and poor rat pharmacokinetic properties and were not further advanced. The SAR further revealed that substitutions in the 4-position or combined 4,6-positions were not tolerated. 4-Methoxy <b>11g</b> and 4-trifluoromethyl <b>11h</b> reduced VEGF-R2 and abolished TIE-2 activity, while 4,6-dimethyl <b>11f</b> abolished both VEGF-R2 and TIE-2 activity. The requirement for the pyrimidinyl group for TIE-2 activity was further demonstrated by changing it to a 3-pyridazinyl <b>11i</b> or 4-pyridyl <b>11j</b>, both of which were weak to inactive for TIE-2. The position of the methyl group was important as the 1-methyl isomer <b>15</b> displayed IC<sub>50</sub> values that were 11- and 16-fold weaker compared with the corresponding N-2 methyl <b>11b</b>.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. In Vitro TIE-2 and VEGF-R2 Data</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-2/jm201449n/production/images/medium/jm-2011-01449n_0004.gif" alt="" id="fx1" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-2/jm201449n/production/images/medium/jm-2011-01449n_0005.gif" alt="" id="fx2" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>Table a</sup><p class="last">IC<sub>50</sub> in nM Â± SEM.</p></div><div class="footnote" id="t1fn2"><sup>Table b</sup><p class="last">NT = not tested.</p></div><div class="footnote" id="t1fn3"><sup>Table c</sup><p class="last">N1 methyl analogue.</p></div></div><div></div></div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Pharmacokinetic Properties of <b>11b</b></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Â </th><th class="colsep0 rowsep0" align="center">Â </th><th class="colsep0 rowsep0" align="center">rat<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">monkey<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">i.v.</td><td class="colsep0 rowsep0" align="left"><i>t</i><sub>1/2</sub> (h)</td><td class="colsep0 rowsep0" align="left">1.9</td><td class="colsep0 rowsep0" align="left">1.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left"><i>V</i><sub>d</sub>(L/kg)</td><td class="colsep0 rowsep0" align="left">1.3</td><td class="colsep0 rowsep0" align="left">2.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">CL (mL/min/kg)</td><td class="colsep0 rowsep0" align="left">4.3</td><td class="colsep0 rowsep0" align="left">18</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">p.o. </td><td class="colsep0 rowsep0" align="left">AUC (ngÂ·h/mL)</td><td class="colsep0 rowsep0" align="left">8559</td><td class="colsep0 rowsep0" align="left">2482</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left"><i>C</i><sub>max</sub> (ng/mL)</td><td class="colsep0 rowsep0" align="left">1330</td><td class="colsep0 rowsep0" align="left">491</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left"><i>t</i><sub>1/2</sub> (h)</td><td class="colsep0 rowsep0" align="left">3.0</td><td class="colsep0 rowsep0" align="left">2.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left"><i>t</i><sub>max</sub> (h)</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left"><i>F</i> (%)</td><td class="colsep0 rowsep0" align="left">44</td><td class="colsep0 rowsep0" align="left">93</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>a</sup><p class="last">Male rat administered at 0.8 mg/kg i.v. and 5 mg/kg p.o. Parameters were calculated from composite mean plasma concentrationâtime data (<i>n</i> = 12).</p></div><div class="footnote" id="t2fn2"><sup>b</sup><p class="last">Administered at 0.5 mg/kg i.v. and 3 mg/kg p.o. for monkey. Parameters were calculated using plasma concentrationâtime data for individual animals (monkey <i>n</i> = 4).</p></div></div></div><div class="NLM_p last">The VEGF-R2 cellular activity was evaluated using a porcine endothelial cell line transfected with a chimeric receptor consisting of the extracellular portion of rat TRK-A (rTRK-A) and the intracellular domain of human vascular endothelial growth factor receptor (VEGF-R2/KDR) as described previously.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> In general, the series demonstrated very potent cellular activity. Ligand induced stimulation of VEGF-R2 phosphorylation was blocked by <b>11a</b>â<b>e</b> with IC<sub>50</sub> values of less than 10 nM. Further, <b>11b</b> inhibited ligand-induced human TIE-2 phosphorylation in an analogous rTRK-A-human TIE-2 chimeric endothelial cell line with an IC<sub>50</sub> value of approximately 50 nM, in acceptable agreement with the enzyme activity on isolated recombinant human TIE-2 (IC<sub>50</sub> = 22 nM). On the basis of the enzyme and cellular dual target potency and metabolic and pharmacokinetic profiles, <b>11b</b> was selected for advanced discovery flow profiling,</div></div><div id="sec3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> Selectivity Profile for <b>11b</b></h3><div class="NLM_p">Compound <b>11b</b> was screened for kinase selectivity against a panel of 126 kinases at 1 Î¼M screening concentration and 100 Î¼M ATP concentration (Upstate KinaseProfiler). The S(90)<sub>126</sub> value was 0.18 (fraction of kinases inhibited greater than 90%). In a separate screen of 101 selected kinases using an ATP concentration close to the <i>K</i><sub>m</sub> of the enzyme showed a comparable and favorable selectivity S(90)<sub>101</sub> value of 0.15. Subsequent IC<sub>50</sub> values were generated for 23 kinases that demonstrated greater than 80% inhibition. In addition to TIE-2 (22 Â± 6 nM) and VEGF-R2 (4 Â± 1 nM), compound <b>11b</b> demonstrated inhibitory activity against angiogenesis targets VEGF-R1 (3 Â± 1 nM) and FGF-R1 (13 Â± 2) with IC<sub>50</sub> values within the potency range observed for inhibition of the primary targets. Compound <b>11b</b> also inhibited TRK-A (IC<sub>50</sub> = 3 nM), TRK-B (IC<sub>50</sub> = 5 nM), Ret (IC<sub>50</sub> = 5 nM), BLK (IC<sub>50</sub> = 8 nM), TAK1 (IC<sub>50</sub> = 14 nM), and MST2 (21 nM) with IC<sub>50</sub> values less than 25 nM (Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>). Compound <b>11b</b> showed weak activity for ABL, ALK, CDKs, CHK2, cMET, EGFR, GSK3Î², IGF-R1, IRK, JAK2, JNKs, MEK, MKKs, PDGFR, PKBs, and PKCs. A broad profile screen of <b>11b</b> in binding assays for 75 receptors, ion channels, and transporters (Cerep screen) revealed 7 targets (adenosine A<sub>2A</sub>, A<sub>3</sub>; angiotensin AT1; muscarinic M<sub>2</sub> and M<sub>4</sub>; neurokinin NK<sub>1</sub> and NK<sub>2</sub>) that displayed â¥80% inhibition at a screening concentration of 10 Î¼M. Follow-up <i>K</i><sub>i</sub> values revealed generally weak activity for these targets, with the adenosine A<sub>2A</sub> receptor displaying the most potent activity with a <i>K</i><sub>i</sub> value of 0.5 Î¼M and the muscarinic M<sub>4</sub> subtype the weakest activity with a <i>K</i><sub>i</sub> of 2.9 Î¼M. In addition, <b>11b</b> showed acceptable selectivity for the hERG channel with an IC<sub>50</sub> value of 20 Î¼M in Chinese Hamster Ovary cells and did not produce any significant effects on QTc interval or on action potential duration in vitro in the dog Purkinje fiber assay.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Kinase Selectivity Data for <b>11b</b></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">kinase</th><th class="colsep0 rowsep0" align="center">IC<sub>50</sub> (nM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ALK (h)</td><td class="colsep0 rowsep0" align="left">132</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AURK-A (h)</td><td class="colsep0 rowsep0" align="left">42</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BLK (m)</td><td class="colsep0 rowsep0" align="left">8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BTK (h)</td><td class="colsep0 rowsep0" align="left">93</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CHK2 (h)</td><td class="colsep0 rowsep0" align="left">140</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CK1</td><td class="colsep0 rowsep0" align="left">48</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">cSRC (h)</td><td class="colsep0 rowsep0" align="left">37</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">FGF-R1 (h)</td><td class="colsep0 rowsep0" align="left">13</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">FGF-R3 (h)</td><td class="colsep0 rowsep0" align="left">89</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">VEGF-R1 (h)</td><td class="colsep0 rowsep0" align="left">3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">FLT3 (h)</td><td class="colsep0 rowsep0" align="left">71</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">FMS (h)</td><td class="colsep0 rowsep0" align="left">78</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MST2 (h)</td><td class="colsep0 rowsep0" align="left">21</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PDGF-RÎ± (h)</td><td class="colsep0 rowsep0" align="left">246</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">RET (h)</td><td class="colsep0 rowsep0" align="left">5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">TAK1(h)</td><td class="colsep0 rowsep0" align="left">14</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">TRK-A (h)</td><td class="colsep0 rowsep0" align="left">3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">TRK-B (h)</td><td class="colsep0 rowsep0" align="left">5</td></tr></tbody></table></div></div></div><div id="sec3_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> Molecular Modeling</h3><div class="NLM_p">A TIE-2 cocrystal structure with a THP-DHI analogue (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3L8P">3L8P</a>) was solved at 2.4 Ã resolution was subsequently used for docking experiments with new analogues.<a onclick="showRef(event, 'cit13d cit16a'); return false;" href="javascript:void(0);" class="ref cit13d cit16a">(13d, 16a)</a> Compound <b>11b</b> docked in the TIE-2 model represents a DFG-in Type I kinase inhibitor binding mode.<a onclick="showRef(event, 'cit16b cit16c'); return false;" href="javascript:void(0);" class="ref cit16b cit16c">(16b, 16c)</a> Key interactions identified in the predicted model were the lactam NH/CO bidentate donor/acceptor with Glu903 (gk +1)/Ala905 (gk +3) at the hinge region, the N1 pyrimidine nitrogen H-bonding with Asp982 (DFG) backbone amide, and the amino potential NH donor with the Asp982 side chain (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>). The 8-pyrimidine moiety occupies a hydrophobic pocket flanked by gatekeeper Ile902 and Phe983 (DFG-in), with the cavity defined by Leu903, Leu888, Ile886, Leu876, and Leu985.</div><figure id="fig3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-2/jm201449n/production/images/medium/jm-2011-01449n_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-2/jm201449n/production/images/large/jm-2011-01449n_0010.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Predicted binding mode of <b>11b</b> with TIE-2.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-2/jm201449n/production/images/large/jm-2011-01449n_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201449n&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">A similar exercise was carried out to explore putative binding interactions of <b>11b</b> with a DFG-in inhibitor binding model of VEGF-R2 described previously.<a onclick="showRef(event, 'cit12a cit13b cit13c cit13d'); return false;" href="javascript:void(0);" class="ref cit12a cit13b cit13c cit13d">(12a, 13b-13d)</a> The proposed binding mode for <b>11b</b> was consistent with the lactam moiety mimicking the ATP donorâacceptor interactions at the hinge region with the lactam NâH sharing a hydrogen bond with the Glu917 carbonyl and the lactam CâO accepting a hydrogen bond with the backbone amide of Cys919. The pyrimidine occupied the hydrophobic pocket analogous, as reported, with <b>5a</b> with the N1 nitrogen forming a significant hydrogen bond with Asp1046 and the N3 nitrogen potentially interacting with a Lys868 (not shown).<a onclick="showRef(event, 'cit12a cit13d'); return false;" href="javascript:void(0);" class="ref cit12a cit13d">(12a, 13d)</a></div></div><div id="sec3_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> Pharmacokinetic Properties of <b>11b</b> in Rats and Monkeys</h3><div class="NLM_p last">Compound <b>11b</b> was absorbed with higher oral bioavailability in monkeys (F = 93%) and slightly lower in rats (F = 44%). In rats, the systemic clearance was low relative to the estimated hepatic plasma flow, and the volume of distribution was approximately equal to total body water. In monkeys, the i.v. half-life (<i>t</i><sub>1/2</sub> = 1.7 h) was comparable to that in rat, but the clearance (18 mL/min/kg) and the volume of distribution (2.6 L/kg) were larger (Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>). The oral <i>T</i><sub>max</sub> was 2 h in both species, consistent with the oral half-life. An oral dose escalation study in rat (10, 30, 55, and 100 mg/kg po) showed dose-dependence near proportional exposure up to 55 mg/kg, with further dose related exposure to 100 mg/kg p.o. In monkeys (5, 25, and 100 mg/kg p.o.), a similar experiment showed dose dependent exposure to 100 mg/kg.</div></div><div id="sec3_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> In Vitro and Ex Vivo Antiangiogenic Profile of <b>11b</b></h3><div class="NLM_p">The antiangiogenic activity of <b>11b</b> was evaluated in both functional (ex vivo rat aortic ring explant cultures) and target-directed (in vitro HUVEC capillary-tube formation) bioassays in order to assess their antiangiogenic activities and potential cytotoxic profiles in primary cell and organ cultures upon prolonged exposure.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>A,B summarizes the results obtained with <b>11b</b> in the ex vivo rat aortic ring collagen gel explants in serum-free conditions and in vitro HUVEC capillary tube formation assays. Compound <b>11b</b> exhibited dose-related inhibitory effects on peak phase microvessel growth (day 8â10 in culture) in rat aortic ring explants in 3D-collagen gels under serum-free conditions with an EC<sub>50</sub> of approximately 4 nM, and inhibition of complete capillary-tube formation by HUVECs on Matrigel with an EC<sub>50</sub> of approximately 2 nM. These effects were observed in the absence of apparent cytotoxicity. In addition to the potential synergistic effects of TIE-2 and pan-VEGF-R inhibition on the readout of these bioassays, the contributions of additional kinase inhibitory properties by <b>11b</b> (for e.g. FGF-R1) may contribute to the significant antiangiogenic activities observed. To evaluate inhibition of TIE-2-mediated biological activity independent of VEGF-R, the dose-related inhibition of recombinant human angiopoietin 1-stimulated HUVEC chemotaxis was evaluated in a modified Boyden chamber assay. Compound <b>11b</b> exhibited significant inhibitory activity against Ang-1-stimulated HUVEC chemotaxis at concentrations â¥50 nM in absence of HUVEC cytotoxicity (data not shown). This result is consistent with the human TIE-2 IC<sub>50</sub> for <b>11b</b> (Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>). Similarly, in vitro bioassays evaluating VEGF- and FGF-induced effects on the proliferation, migration, and survival of HUVEC, HMVEC, and BAEC demonstrated EC<sub>50</sub> values of 8â38 nM (data not shown), consistent with the biological activities highlighted above. Collectively, these data confirm the robust, dose-related antiangiogenic activity of <b>11b</b> across a panel of target-directed bioassays.</div><figure id="fig4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-2/jm201449n/production/images/medium/jm-2011-01449n_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-2/jm201449n/production/images/large/jm-2011-01449n_0011.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Antiangiogenic activity of <b>11b</b> ex vivo rat aortic ring explant cultures and in vitro HUVEC capillary-tube formation bioassays. Ex vivo rat aortic ring explant cultures and target-directed in vitro HUVEC capillary-tube formation to assess their antiangiogenic activities and potential cytotoxic profiles in primary cell and organ cultures. Compound <b>11b</b> exhibited dose-related inhibitory effects on peak phase microvessel growth (day 8â10 in culture) in rat aortic ring explants in 3D-collagen gels under serum-free conditions with an EC<sub>50</sub> of approximately 4 nM, and inhibition of complete capillary-tube formation by HUVECs on Matrigel with an EC<sub>50</sub> of approximately 2 nM. <i>P</i> < 0.05**, <i>p</i> < 0.01* relative to control cultures.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-2/jm201449n/production/images/large/jm-2011-01449n_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201449n&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> In Vivo Profile for <b>11b</b></h3><div class="NLM_p">The in vivo antitumor efficacy of <b>11b</b> was assessed on the A375 human melanoma and U251MG human glioblastomas, two highly angiogenic VEGF-R2 and TIE-2 dependent solid tumors. Oral administration of <b>11b</b> (1.0 to 30 mg/kg bid; Tween: methylcellulose) to nude mice bearing established U251MG human glioblastoma xenografts resulted in a sustained dose-related (3 mg/kg, 61% (<i>p</i> < 0.01); 10 mg/kg, 75% (<i>p</i> < 0.001); and 30 mg/kg, 88% (<i>p</i> < 0.001)) maximum inhibition of tumor xenograft growth relative to that of vehicle-treated controls after 29 days with a minimum effective dose (MED) of 3 mg/kg bid (Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a> and Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>). A 20% and 44% incidence of partial tumor regressions was achieved with 10 and 30 mg/kg bid, respectively. At 30 mg/kg bid <i>C</i><sub>max</sub> plasma and tumor levels of <b>11b</b> were 1200 Â± 79 ng/mL and 401 Â± 62 ng/g, respectively. Similarly, oral administration of <b>11b</b> to nude mice bearing established A375 human melanoma xenografts resulted in a MED of 0.3â1 mg/kg bid for sustained antitumor efficacy. Significant inhibition of A375 tumor xenograft growth (maximally 98% at 10 mg/kg bid; <i>p</i> < 0.001) and sustained partial and complete tumor regressions (maximally 50% and 40%, respectively, at 10 mg/kg bid) were achieved and were directly related to tumor and plasma exposure (Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a> and Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>). At 10 mg/kg bid, <i>C</i><sub>max</sub> plasma and tumor levels of <b>11b</b> were 456 Â± 44 ng/mL and 140 Â± 20 ng/g, respectively. Administration of <b>11b</b> was well-tolerated, with no apparent toxicity or significant body weight loss or morbidity in solid tumor-bearing animals.</div><figure id="fig5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-2/jm201449n/production/images/medium/jm-2011-01449n_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-2/jm201449n/production/images/large/jm-2011-01449n_0012.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Oral antitumor activity of <b>11b</b> in the U251 MG human glioblastoma xenograft. Tumor cells were injected subcutaneously in serum-free media into the right flank of athymic female nude mice. Twelve days post-implantation, mice with established tumors were randomized into treatment groups (<i>n</i> = 10 mice/group) and administered <b>11b</b> orally (100 Î¼L/dose) at the doses indicated and tumor volumes measured as defined in the <a class="ref internalNav" href="#sec5" aria-label="Experimental Section">Experimental Section</a>. Statistical analyses for efficacy of <b>11b</b> are detailed in Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-2/jm201449n/production/images/large/jm-2011-01449n_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201449n&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Effects of <b>11 b</b> in the U251 MG Human Glioblastoma Model</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Â </th><th class="colsep0 rowsep0" align="center">Â </th><th class="rowsep1 colsep0" colspan="2" align="center">% incidence of tumor regressions</th><th class="colsep0 rowsep0" align="center">Â </th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">treatment</th><th class="colsep0 rowsep0" align="center">dose</th><th class="colsep0 rowsep0" align="center">partial/stasis</th><th class="colsep0 rowsep0" align="center">complete</th><th class="colsep0 rowsep0" align="center">% maximum tumor growth inhibition vs vehicle control</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">11b (p.o. bid)</td><td class="colsep0 rowsep0" align="left">1 mg/kg</td><td class="colsep0 rowsep0" align="left">0</td><td class="colsep0 rowsep0" align="left">0</td><td class="colsep0 rowsep0" align="left">43% NS</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">3 mg/kg</td><td class="colsep0 rowsep0" align="left">0</td><td class="colsep0 rowsep0" align="left">0</td><td class="colsep0 rowsep0" align="left">61% <i>p</i>Â <Â 0.01</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">10 mg/kg</td><td class="colsep0 rowsep0" align="left">20%</td><td class="colsep0 rowsep0" align="left">0</td><td class="colsep0 rowsep0" align="left">75% <i>p</i>Â <Â 0.001</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">30 mg/kg</td><td class="colsep0 rowsep0" align="left">44%</td><td class="colsep0 rowsep0" align="left">0</td><td class="colsep0 rowsep0" align="left">88% <i>p</i>Â <Â 0.001</td></tr></tbody></table></div></div><figure id="fig6" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-2/jm201449n/production/images/medium/jm-2011-01449n_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-2/jm201449n/production/images/large/jm-2011-01449n_0013.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Oral antitumor activity of <b>11b</b> in the A375 human melanoma xenograft model. Tumor cells were injected subcutaneously in serum-free media into the right flank of athymic female nude mice. Ten days post-implantation, mice with established tumors were randomized into treatment groups (<i>n</i> = 10 mice/group) and administered <b>11b</b> orally (100 Î¼L/dose) at the doses indicated and relative tumor volume to those at day 1 of treatment with <b>11b</b> measured as defined in the <a class="ref internalNav" href="#sec5" aria-label="Experimental Section">Experimental Section</a>. Statistical analyses for efficacy of <b>11b</b> are detailed in Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-2/jm201449n/production/images/large/jm-2011-01449n_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201449n&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Effects of <b>11b</b> in the A375 Human Melanoma Model</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Â </th><th class="colsep0 rowsep0" align="center">Â </th><th class="rowsep1 colsep0" colspan="2" align="center">% incidence of tumor regressions</th><th class="colsep0 rowsep0" align="center">Â </th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">treatment</th><th class="colsep0 rowsep0" align="center">dose</th><th class="colsep0 rowsep0" align="center">partial/stasis</th><th class="colsep0 rowsep0" align="center">complete</th><th class="colsep0 rowsep0" align="center">% maximum tumor growth inhibition vs vehicle control</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11b</b>(p.o. bid)</td><td class="colsep0 rowsep0" align="left">0.3 mg/kg</td><td class="colsep0 rowsep0" align="left">20%</td><td class="colsep0 rowsep0" align="left">10%</td><td class="colsep0 rowsep0" align="left">71% <i>p</i>Â <Â 0.05</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">1 mg/kg</td><td class="colsep0 rowsep0" align="left">10%</td><td class="colsep0 rowsep0" align="left">20%</td><td class="colsep0 rowsep0" align="left">73% <i>p</i>Â <Â 0.01</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">3 mg/kg</td><td class="colsep0 rowsep0" align="left">11%</td><td class="colsep0 rowsep0" align="left">22%</td><td class="colsep0 rowsep0" align="left">90% <i>p</i>Â <Â 0.001</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">10 mg/kg</td><td class="colsep0 rowsep0" align="left">50%</td><td class="colsep0 rowsep0" align="left">40%</td><td class="colsep0 rowsep0" align="left">98% <i>p</i>Â <Â 0.001</td></tr></tbody></table></div></div><div class="NLM_p">Compound <b>11b</b> was further evaluated in the P388 murine leukemia model to assess effects of varying dose schedules on survival in a systemic hematological tumor model. An improvement in median survival was observed at 30 mg/kg bid monotherapy in P388 leukemic DBA/2 mice relative to vehicle-treated tumor-bearing mice. Both continuous bid and qd oral administration and all intermittent oral dosing regimens bid and qd evaluated at 30 mg/kg in leukemic mice conferred sustained improvements in median survival (<i>p</i> < 0.05 or greater) relative to that of vehicle-treated leukemic animals. Survival data generated by KaplanâMeier analyses for continuous and intermittent bid and qd administration of <b>11b</b> in the murine P388 leukemia ascite model in DBA/2 mice are shown in Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a>.</div><figure id="fig7" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-2/jm201449n/production/images/medium/jm-2011-01449n_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-2/jm201449n/production/images/large/jm-2011-01449n_0001.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Survival benefit of continuous and intermittent oral administration of <b>11b</b> in the P388 systemic murine leukemia model in mice. KaplanâMeier survival plot of continuous versus intermittent once and twice daily oral dosing regimens of <b>11b</b> (30 mg/kg po) on median survival of DBA/2 mice implanted with murine P388 leukemia cells. Details of analyses are defined in the <a class="ref internalNav" href="#sec5" aria-label="Experimental Section">Experimental Section</a> and the text.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-2/jm201449n/production/images/large/jm-2011-01449n_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201449n&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i17">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_37313" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_37313" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">Compound <b>11b</b> was identified as a potent, orally active inhibitor of human TIE-2, VEGF-R1 and 2, and FGF-R1. Collectively, it exhibits excellent permeability, metabolic stability and pharmacokinetic properties across multiple species and was advanced into full development. The in vitro, ex vivo, and in vivo pharmacologic activities conducted across a panel of angiogenesis assays and subcutaneous and orthotopic rodent and human tumor models demonstrated sustained and concentration (dose) related antiangiogenic and antitumor efficacy (tumor growth inhibition, tumor regressions, and survival benefits) consistent with a potent TIE-2/VEGF-R1, R2 inhibitor with a broader kinase inhibitory profile. Clinical phase I studies assessing the safety and pharmacokinetics of <b>11b</b> have been completed and are the subject of a separate publication. Nonetheless, these clinical studies indicate linear, dose related increases in plasma pharmacokinetic exposure (mean <i>C</i><sub>max</sub> and AUC) with oral administration of <b>11b</b> at doses of 3.0 to 126 mg/m<sup>2</sup> and an oral half-life of 8â15 h on a 28 day once daily treatment cycle, with a 14 day treatment free period. Further, exposure-related increases in VEGF-R2 inhibition ex vivo were demonstrated with <b>11b</b> in a human plasma-based cellular bioassay using the rTRK-A-human/VEGF-R2 chimeric endothelial cells described in this article. Normalized cellular VEGF-R2 inhibition greater than 90% in select patient plasma samples from the phase 1 study was observed, especially in the 73, 97.4, and 126.6 mg/m<sup>2</sup> dosing cohorts, suggestive of molecular target-directed biological activity of <b>11b</b> in humans (data not shown). Phase 2 proof-of-concept studies with <b>11b</b> are planned in select genotyped cancer patient populations to fully assess the therapeutic potential of this novel kinase inhibitor.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i18">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_43875" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_43875" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> Chemistry</h3><div class="NLM_p last">All reagents and anhydrous solvents were obtained from commercial sources and used as received. <sup>1</sup>H NMRs were obtained at 400 MHz in the solvent indicated with tetramethylsilane as an internal standard. Coupling constants (<i>J</i>) are in Hertz (Hz). Compounds were purified by normal phase flash silica gel chromatography or automated silica gel chromatography on a Combi-Flash Companion (ISCO, Inc.) monitored at 254 and 290 nm detection. Preparative TLC was run using Silica Gel GF 20 Ã 20 cm Ã 1000 Î¼m plates (Analtech). Liquid chromatographyâmass spectrometry (LC/MS) were obtained on a Bruker Esquire 2000 ion trap LCMS with the Agilent 1100 HPLC equipped with an Agilent Eclipse XDB-C8 2 Ã 30 cm 3.5 Î¼m column. All final compounds tested in Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a> had purity >96% determined by High Pressure Liquid Chromatography (HPLC) using a Zorbax RX-C8, 5 Ã 150 mm column eluting with a mixture of acetonitrile and water containing 0.1% trifluoroacetic acid with a gradient of 10â100%.</div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> 5-Cyano-11,12-dihydro-2-methyl-10-propyl-indazolo[5,4-a]carbazole-4-carboxylic Acid Ethyl Ester (<b>8a</b>)</h3><div class="NLM_p">5-Cyano-2,10,11,12-tetrahydro-2-methyl-indazolo[5,4-<i>a</i>]carbazole-4-carboxylic acid ethyl ester <b>7</b> (1.0 g, 2.7 mmol), 10 N NaOH (10 mL), and 1-iodopropane (2.7 mL, 27.0 mmol) in acetone (35 mL) was stirred at reflux overnight. The reaction was concentrated, triturated with water, and collected. The product was purified by flash chromatography (1% methanol in DCM) to afford 1.0 g (90%) as a tan solid. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) Î´: 8.44 (m, 1H), 7.80 (m, 1H), 7.64 (s, 1H), 7.62 (m, 1H), 7.36 (m, 1H), 4.59 (m, 2H), 4.52 (m, 2H), 3.87 (s, 3H), 3.53 (m, 2H), 2.88 (m, 2H), 1.83 (m, 2H), 1.37 (m, 3H), 0.91 (m, 3H). LCMS <i>m</i>/<i>z</i>: 413 (M + 1).</div><div class="NLM_p last">The intermediates <b>8b</b> and <b>8c</b> were synthesized from <b>7</b> using the method for <b>8a</b>.</div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> 5-Cyano-11,12-dihydro-2-methyl-10-(2-methylpropyl)indazolo[5,4-<i>a</i>]carbazole-4-carboxylic Acid Ethyl Ester (<b>8b</b>)</h3><div class="NLM_p last"><sup>1</sup>HNMR (DMSO-<i>d</i><sub>6</sub>) Î´: 8.45 (m, 1H), 7.84 (m, 1H), 7.64 (s, 1H), 7.62 (m, 1H), 7.35 (m, 1H), 4.52 (m, 4H), 3.87 (s, 3H), 3.51 (m, 2H), 2.87 (m, 2H), 1.37 (m, 4H), 0.80 (d, 6H, <i>J</i> = 7 Hz); LCMS <i>m</i>/<i>z</i>: 427 (M + 1).</div></div><div id="sec5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> 5-Cyano-11,12-dihydro-2-methyl-10-(1-methylethyl)indazolo[5,4-<i>a</i>]carbazole-4-carboxylic Acid Ethyl Ester (<b>8c</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) Î´: 8.44 (d, 1H, <i>J</i> = 8 Hz), 7.92 (d, 1H, <i>J</i> = 9 Hz), 7.66 (s, 1H), 7.57 (m, 1H), 7.36 (m, 1H), 5.27 (m, 1H), 4.51 (m, 2H), 3.87 (s, 3H), 3.48 (m, 2H), 2.82 (m, 2H), 1.63 (d, 6H, <i>J</i> = 7 Hz), 1.39 (m, 3H). LCMS <i>m</i>/<i>z</i>: 413 (M + 1).</div></div><div id="sec5_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> 11-Propyl-11,12-dihydro-2-methyl-8-amino-4<i>H</i>-indazolo[5,4-<i>a</i>]pyrrolo[3,4-<i>c</i>]carbazol-4-one (<b>10a</b>)</h3><div class="NLM_p">To <b>8a</b> (800 mg, 1.94 mmol) in acetic acid (70 mL) was added dropwise 70% nitric acid (248 Î¼L, 3.88 mmol). The reaction was heated at 80 Â°C for 1 h and then cooled to rt. The resulting precipitate was collected by filtration and washed with water, ether, and then dried. The crude nitro intermediate was dissolved in DMFâMeOH (30 mL, 1:1) and hydrogenated with excess Raney-Ni at 50 psi for 16 h on a Parr apparatus. The catalyst was removed by filtration through a bed of Celite, and the filtrate was concentrated under reduced pressure and dried to give <b>10a</b> (529 mg, 71%) as a tan solid. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) Î´: 8.83 (s, 1H), 8.30 (s, 1H), 7.37 (d, 1H, <i>J</i> = 9 Hz), 7.07 (s, 1H), 6.84 (d, 1H, <i>J</i> = 9 Hz), 4.82 (s, 2H), 4.67 (s, 2H), 4.43 (m, 2H), 3.85 (s, 3H), 3.41 (m, 2H), 2.82 (m, 2H), 1.77 (m, 2H), 0.88 (m, 3H). LCMS <i>m</i>/<i>z</i>: 386 (M + 1).</div><div class="NLM_p last">The intermediates <b>10b</b> and <b>10c</b> were synthesized from <b>8b</b> and <b>8c</b> using the method for <b>10a</b>.</div></div><div id="sec5_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> 11-(2-Methylpropyl)-12,13-dihydro-2-methyl-8-amino-4<i>H</i>-indazolo[5,4-<i>a</i>]pyrrolo[3,4-<i>c</i>]carbazol-4-one (<b>10b</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) Î´: 8.84 (s, 1H), 8.31 (s, 1H), 7.39 (m, 1H), 7.06 (m, 1H), 6.82 (m, 1H), 4.82 (s, 2H), 4.68 (s, 2H), 4.34 (m, 2H), 3.85 (s, 3H), 3.38 (m, 2H), 2.80 (m, 2H), 2.07 (m, 1H), 0.77 (d, 6H, <i>J</i> = 7 Hz). LCMS <i>m</i>/<i>z</i>: 400 (M + 1).</div></div><div id="sec5_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> 11-(1-Methylethyl)-12,13-dihydro-2-methyl-8-amino-4<i>H</i>-indazolo[5,4-<i>a</i>]pyrrolo[3,4-<i>c</i>]carbazol-4-one (<b>10c</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) Î´: 8.81 (s, 1H), 8.30 (s, 1H), 7.49 (d, 1H), 7.19 (s, 1H), 6.78 (d, 1H), 5.12 (m, 1H), 4.84 (s, 2H), 4.71 (s, 2H), 3.85 (s, 3H), 3.36 (m, 2H), 2.78 (m, 2H), 1.54 (d, 6H, <i>J</i> = 7 Hz); LCMS <i>m</i>/<i>z</i>: 386 (M + 1).</div></div><div id="sec5_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> 11-Propyl-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4<i>H</i>-indazolo[5,4-<i>a</i>]pyrrolo[3,4-<i>c</i>]carbazol-4-one (<b>11a</b>)</h3><div class="NLM_p">Intermediate <b>9a</b> (1.0 g, 2.6 mmol) and 2-chloropyrimidine (390 mg, 3.4 mmol) in 1-butanol (35 mL) were heated at reflux for 24 h. The mixture was then cooled to rt and concentrated under vacuum. The product was purified using silica gel column chromatography (9% MeOH in DCM) to give <b>11a</b> as a tan solid (633 mg, 53%). Purity 99%. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) Î´: 9.55 (s, 1H), 8.86 (s, 1H), 8.47 (m, 2H), 8.36 (s, 1H), 8.29 (m, 1H), 7.81 (m, 1H), 7.61 (m, 1H), 6.79 (m, 1H), 4.74 (s, 2H), 4.53 (m, 2H), 3.87 (s, 3H), 3.46 (m, 2H), 2.84 (m, 2H), 1.82 (m, 2H), 0.90 (m, 3H). LCMS <i>m</i>/<i>z</i>: 464 (M + H).</div><div class="NLM_p last">Compounds <b>11b</b>â<b>11j</b> were synthesized using the method for <b>11a</b>.</div></div><div id="sec5_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> 11-(2-Methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4<i>H</i>-indazolo[5,4-<i>a</i>]pyrrolo[3,4-<i>c</i>]carbazol-4-one (<b>11b</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) Î´: 9.57 (s, 1H), 8.87 (s, 1H), 8.47 (m, 2H), 8.40 (s, 1H), 8.29 (m, 1H), 7.81 (m, 1H), 7.64 (m, 1H), 6.80 (m, 1H), 4.75 (s, 2H), 4.43 (m, 2H), 3.87 (s, 3H), 3.43 (m, 2H), 2.83 (m, 2H), 2.12 (m, 1H), 0.80 (d, 6H, <i>J</i> = 7 Hz). LCMS <i>m</i>/<i>z</i> 478 (M + 1).</div></div><div id="sec5_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> 11-(1-Methylethyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4<i>H</i>-indazolo[5,4-<i>a</i>]pyrrolo[3,4-<i>c</i>]carbazol-4-one (<b>11c</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) Î´: 9.56 (s, 1H), 8.78 (s, 1H), 8.47 (d, 2H, <i>J</i> = 5 Hz), 8.36 (s, 1H), 8.28 (s, 1H), 7.78 (m, 2H), 6.81 (t, 1H, <i>J</i> = 5 Hz), 5.23 (m, 1H), 4.73 (s, 2H), 3.93 (s, 3H), 3.39 (m, 2H), 2.81 (m, 2H), 1.61 (d, 6H, <i>J</i> = 7 Hz). LCMS <i>m</i>/<i>z</i>: 464 (M + 1).</div></div><div id="sec5_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> 11-Propyl-12,13-dihydro-2-methyl-8-(5-ethyl-pyrimidin-2-ylamino)-4<i>H</i>-indazolo[5,4-<i>a</i>]pyrrolo[3,4-<i>c</i>]carbazol-4-one (<b>11d</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) Î´: 9.44 (s, 1H), 8.85 (s, 1H), 8.37 (s, 3H), 8.31 (m, 1H), 7.80 (m, 1H), 7.59 (m, 1H), 4.74 (s, 2H), 4.54 (m, 2H), 3.87 (s, 3H), 3.46 (m, 3H), 2.84 (m, 2H), 2.50 (m, 2H), 1.83 (m, 1H), 1.19 (m, 3H), 0.90 (m, 3H). LCMS <i>m</i>/<i>z</i>: 492 (M + 1).</div></div><div id="sec5_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> 11-(2-Methylpropyl)-12,13-dihydro-2-methyl-8-(5-ethylpyrimidin-2-ylamino)-4<i>H</i>-indazolo[5,4-<i>a</i>]pyrrolo[3,4-<i>c</i>]carbazol-4-one (<b>11e</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) Î´: 9.43 (s, 1H), 8.86 (s, 1H), 8.37 (s, 3H), 8.31 (s, 1H), 7.79 (m, 1H), 7.62 (m, 1H), 4.75 (s, 2H), 4.43 (m, 2H), 3.87 (s, 3H), 3.43 (m, 2H), 2.83 (m, 2H), 2.50 (m, 2H), 2.12 (m, 1H), 1.19 (m, 3H), 0.80 (d, 6H, <i>J</i> = 7 Hz). LCMS <i>m/z:</i> 506 (M + 1).</div></div><div id="sec5_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> 11-(2-Methylpropyl)-12,13-dihydro-2-methyl-8-(4,6-dimethylpyrimidin-2-ylamino)-4<i>H</i>-indazolo[5,4-<i>a</i>]pyrrolo[3,4-<i>c</i>]carbazol-4-one (<b>11f</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) Î´: 9.50 (s, 1H), 8.86 (s, 1H), 8.69 (m, 1H), 8.37 (s, 1H), 7.70 (m, 1H), 7.61 (m, 1H), 6.62 (s, 1H), 4.77 (s, 2H), 4.43 (m, 2H), 3.86 (s, 3H), 3.40 (m, 2H), 2.82 (m, 2H), 2.36 (s, 6H), 2.12 (m, 1H), 0.80 (d, 6H, <i>J</i> = 7 Hz). LCMS <i>m</i>/<i>z</i>: 506 (M + 1).</div></div><div id="sec5_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> 11-(2-Methylpropyl)-12,13-dihydro-2-methyl-8-(4-methoxypyrimidin-2-ylamino)-4<i>H</i>-indazolo[5,4-<i>a</i>]pyrrolo[3,4-<i>c</i>]carbazol-4-one (<b>11g</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) Î´: 9.50 (s, 1H), 8.86 (s, 1H), 8.35 (m, 2H), 8.20 (m, 1H), 7.80 (m, 1H), 7.65 (m, 1H), 6.25 (m, 1H), 4.75 (s, 2H), 4.43 (m, 2H), 3.98 (s, 3H), 3.86 (s, 3H), 3.43 (m, 2H), 2.83 (m, 2H), 2.57 (m, 1H), 0.80 (d, 6H, <i>J</i> = 7 Hz). LCMS <i>m</i>/<i>z</i>: 508 (M + 1).</div></div><div id="sec5_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> 11-(2-Methylpropyl)-12,13-dihydro-2-methyl-8-(4-trifluoromethyl-pyrimidin-2-ylamino)-4<i>H</i>-indazolo[5,4-<i>a</i>]pyrrolo[3,4-<i>c</i>]carbazol-4-one (<b>11h</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) Î´: 10.23 (s, 1H), 8.87 (s, 1H), 8.81 (m, 1H), 8.45 (m, 2H), 7.70 (s, 2H), 7.23 (m, 1H), 4.74 (s, 2H), 4.45 (m, 2H), 3.87 (s, 3H), 3.43 (m, 2H), 2.83 (m, 2H), 2.13 (m, 1H), 0.81 (d, 6H, <i>J</i> = 7 Hz). LCMS <i>m</i>/<i>z</i>: 546 (M + 1).</div></div><div id="sec5_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> 11-(2-Methylethyl)-12,13-dihydro-2-methyl-8-(3-pyridazinylamino)-4<i>H</i>-indazolo[5,4-<i>a</i>]pyrrolo[3,4-<i>c</i>]carbazol-4-one (<b>11i</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (DMSO<i>-d</i><sub><i>6</i></sub>) Î´: 9.26 (s, 1H), 8.78 (s, 1H), 8.63 (m, 1H), 8.38 (m, 1H), 8.30 (m, 1H), 7.77 (m, 1H), 7.70 (m, 1H), 7.45 (m, 1H), 7.15 (m, 1H), 5.23 (m, 1H), 4.73 (s, 2H), 3.93 (s, 3H), 3.39 (m, 2H), 2.81 (m, 2H), 1.62 (d, 6H, <i>J</i> = 7 Hz); LCMS <i>m</i>/<i>z</i>: 464 (M + 1).</div></div><div id="sec5_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> 11-(2-Methylethyl)-12,13-dihydro-2-methyl-8-(4-pyridinylamino)-4<i>H</i>-indazolo[5,4-<i>a</i>]pyrrolo[3,4-<i>c</i>]carbazol-4-one (<b>11j</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) Î´: 9.26 (s, 1H), 8.83 (s, 1H), 8.78 (s, 1H), 8.37 (s, 1H), 8.16 (m, 2H), 7.82 (d, 1H, <i>J</i> = 8 Hz), 7.68 (m, 1H), 7.29 (m, 1H), 6.89 (m, 2H), 5.30 (m, 1H), 4.75 (s, 2H), 3.86 (s, 3H), 3.41 (m, 2H), 2.79 (m, 2H), 1.62 (d, 6H, <i>J</i> = 7 Hz). LCMS <i>m</i>/<i>z</i>: 463 (M + 1).</div></div><div id="sec5_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> 5-Cyano-11,12-dihydro-1-methyl-10-(2-methylpropyl)indazolo[5,4-<i>a</i>]carbazole-4-carboxylic acid ethyl ester (<b>13</b>)</h3><div class="NLM_p last">This compound was synthesized from intermediate <b>12</b> using the method for <b>8a</b>. LCMS <i>m</i>/<i>z</i>: 427 (M + 1).</div></div><div id="sec5_19" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> 11-(2-Methylpropyl)-12,13-dihydro-1-methyl-8-amino-4<i>H</i>-indazolo[5,4-<i>a</i>]pyrrolo[3,4-<i>c</i>]carbazol-4-one (<b>14</b>)</h3><div class="NLM_p last">This compound was synthesized from <b>13</b> using the method for <b>10a</b>; tan solid. LCMS <i>m</i>/<i>z</i>: 400 (M + H).</div></div><div id="sec5_20" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> 11-(2-Methylpropyl)-12,13-dihydro-1-methyl-8-(pyrimidin-2-ylamino)-4<i>H</i>-indazolo[5,4-<i>a</i>]pyrrolo[3,4-<i>c</i>]carbazol-4-one (<b>15</b>)</h3><div class="NLM_p last">This compound was synthesized from <b>14</b> using the method for <b>11a</b>. <sup>1</sup>H NMR (DMSO<i>-d</i><sub><i>6</i></sub>) Î´: 9.55 (s, 1H), 8.75 (s, 1H), 8.47 (d, 2H, <i>J</i> = 5 Hz), 8.32 (s, 1H), 8.30 (s, 1H), 7.81 (m, 1H), 7.63 (d, 1H, <i>J</i> = 9 Hz), 6.81 (t, 1H, <i>J</i> = 5 Hz), 4.75 (s, 2H), 4.44 (d, 2H, <i>J</i> = 7 Hz), 3.81 (s, 3H), 3.48 (t, 2H, <i>J</i> = 7 Hz), 2.97 (t, 2H, <i>J</i> = 7 Hz), 2.12 (m, 1H), 0.81 (d, 6H, <i>J</i> = 7 Hz). LCMS <i>m</i>/<i>z</i>: 478 (M + 1).</div></div><div id="sec5_21" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39"> VEGF-R2 and TIE-2 Kinase Assays</h3><div class="NLM_p last">Compounds were tested for their ability to inhibit the kinase activity of baculovirus-expressed cytoplasmic domain of VEGF-R2 or TIE-2 using the TRF detection system. Briefly, each 96-well Costar high binding plate (Corning Costar #3922, Corning, NY) was coated with 100 Î¼L/well of 10 Î¼g/mL substrate solution (recombinant GST-PLCÎ³) in Tris-buffered saline (TBS). The kinase reaction mixture (total volume = 100 Î¼L/well) consisting of 20 mM HEPES, pH 7.2, 40 Î¼M ATP, 10 mM MnCl<sub>2</sub>, 0.1% bovine serum albumin (BSA), and test compound (diluted in DMSO; 2.5% DMSO final in assay) was then added to the assay plate. Enzyme (30 ng/mL VEGF-R2 or 200 ng/mL TIE-2) was added, and the reaction was allowed to proceed at 37 Â°C for 15 min. Detection of the phosphorylated product was performed by adding 100 Î¼L/well of EuâN1 labeled PY100 antibody (PerkinElmer # AD0160, Boston, MA) diluted 1:5,000 in TBS-T containing 0.25% BSA). Incubation at 37 Â°C then proceeded for 1 h, followed by the addition of 100 Î¼L of enhancement solution (PerkinElmer #1244-105). The plate was gently agitated, and after 30 min, the fluorescence of the resulting solution was measured using the PerkinElmer EnVision 2100 (or 2102) multilabel plate reader. Inhibition curves for compounds were generated by plotting percent control activity versus log<sub>10</sub> of the concentration of compound. IC<sub>50</sub> values were calculated by nonlinear regression using the sigmoidal doseâresponse (variable slope) equation in GraphPad Prism as follows:<span class="NLM_disp-formula" id="ueq1"><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-2/jm201449n/production/images/jm-2011-01449n_m001.gif" alt="" /></img></span>where <i>y</i> is the % kinase activity at a given concentration of compound, <i>x</i> is the logarithm of the concentration of compound, bottom is the % of control kinase activity at the highest compound concentration tested, and top is the % of control kinase activity at the lowest compound concentration examined. The values for bottom and top were fixed at 0 and 100, respectively. IC<sub>50</sub> values were reported as the average of two or more separate determinations.</div></div><div id="sec5_22" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40"> VEGF-R2 Cellular Assay</h3><div class="NLM_p last">The porcine aortic endothelial cell line (PAE 145) stably transfected with chimeric rTRK-A/KDR receptor containing the extracellular domain of rat TRK-A and the intracellular domain of human VEGF-R2 was used for this study. Subconfluent cells were serum-starved by replacing media with 5 mL of serum-free DMEM (Cellgro 10-013-CM; Mediatech, Inc., Herndon, VA) containing 0.05% BSA for 1 h at 37 Â°C. At the same time, test compound (various concentrations) or DMSO (control) was added to the cells (0.1% final DMSO in assay). To induce phosphorylation, cells were treated with nerve growth factor (NGF; Harlan Bioproducts for Science, Inc. BT-5017; Indianapolis, IN) at a concentration of 10 ng/mL for 5 min. Cells were lysed in FRAK buffer (10 mM Tris at pH 7.5, 50 mM NaCl, 1% Triton X-100, 20 mM NaF, 2 mM sodium pyrophosphate, 0.1% BSA, and 25 mM Î²-glycerophosphate) containing 1 mM activated sodium vanadate and protease inhibitors (Protease Inhibitor Cocktail Set III Calbiochem # 539134; San Diego, CA) sheared with a 27-gauge syringe, then centrifuged at 12,000<i>g</i> for 15 min at 4 Â°C. Clarified cell lysates were normalized to protein using the bicinchoninic acid (BCA; Pierce # 23235; Rockford, IL) method, immunoprecipitated with anti-VEGF-R2 antibody (CEP-133) for 1 h, followed by incubation with Protein A Sepharose (Sigma # P3391; St. Louis, MO) for another hour at 4 Â°C. Immunoprecipitates were washed three times with FRAK buffer containing protease/phosphatase inhibitors, 4Ã sample buffer was added, and then heated for 5 min at 85 Â°C. Samples were processed using the standard protocol involving gel separation (NuPAGE 3â8% Tris-acetate gel; NOVEX # EA-03585; Invitrogen, Carlsbad, CA) and transfer to nitrocellulose membrane. The membranes were blocked with Blocking Buffer (LiCor #927â40000; Lincoln, NE) overnight, then immunoblotted with 4G10 antiphosphotyrosine antibody, followed by incubation with Alexa Fluor 680 goat antimouse IgG (Molecular Probes #A-21058; Eugene, OR) at RT for 1 h. Phosphorylated proteins were visualized by scanning on the Odyssey Infrared Imaging System (LiCor). Inhibition of phosphorylation was calculated with the help of the Gel-Pro Analyzer 3.1 software (Fotodyne, Inc.; Hartland, WI).</div></div><div id="sec5_23" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41"> TIE-2 Cellular Assay</h3><div class="NLM_p last">The TIE-2 cell-based assay was performed as described above for VEGF-R2 except that the PAE 145 cell line stably transfected with chimeric rTRK-A/TIE-2 receptor containing the extracellular domain of rat TRK-A, and the intracellular domain of human TIE-2 was used.</div></div><div id="sec5_24" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42"> Rat Pharmacokinetics</h3><div class="NLM_p last">Adult male SpragueâDawley rats (275â350 g; Charles River, Kingston, New York) and male cynomolgus monkeys (2â4 kg, Covance Laboratories, Alice TX) were used in the experiments. All animal usage was approved by the Cephalon IACAC. For routine compound screening, rats were dosed via the lateral tail vein at the indicated dose for i.v. administration (3% DMSO, 30% solutol, 67% phosphate buffered saline) or via oral gavage (0.6% methylcellulose/Tween 80 (99.5:0.5) or Ora Plus) at the indicated dose. Rats were fasted overnight prior to p.o. administration. Serial blood samples were collected from the lateral tail vein into heparinized collection tubes (approximately 0.25 mL) at 7 sampling times over a 6 h or a 24 h period as indicated. The plasma was separated by centrifugation, and the sample was prepared for HPLC/MS analysis by protein precipitation with acetonitrile. The plasma samples were analyzed for drug and internal standard via LC-MS/MS protocol. The pharmacokinetic parameters were calculated by a noncompartmental method using WinNonlin software (Professional Version 4.1, Pharsight Corporation, Palo Alto, CA, 1997). For experiments to determine detailed rat PK parameters, rats were administered 1 mg/kg i.v. and 3 mg/kg p.o. in saline and parameters calculated from composite mean plasma concentrationâtime data (<i>n</i> = 12). Monkey PK (0.5 mg/kg i.v.; 47.4% polyethylene glycol (PEG) 400; 31.1% water; 20.7% hydroxyl-Î²-cyclodextrin (HPBCD); and 0.8% Pluronic F-68 and p.o. Three mg/kg; Ora Plus) parameters calculated using plasma concentrationâtime data for individual animals (monkey <i>n</i> = 4).</div></div><div id="sec5_25" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43"> In Vitro Capillary Tube Formation Assay with HUVECs on Matrigel and Ex Vivo Rat Aortic Ring Explant Assay in Collagen Gel Matrices</h3><div class="NLM_p last">The ability of <b>11b</b> to inhibit angiogenesis in vitro in a capillary tube formation assay utilizing human umbilical vein endothelial cells (HUVECs) cultured on a synthetic basement membrane matrix and ex vivo in rat aortic ring explant cultures was conducted using published methods.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a></div></div><div id="sec5_26" class="NLM_sec NLM_sec_level_2"><div id="ac_i44" class="anchor-spacer"></div><h3 class="article-section__title" id="_i44"> A375 Melanoma and U251 MG Glioblastoma Sc Xenograft Models</h3><div class="NLM_p last">Tumor cells were obtained from the American Type Culture Collection (Manassas, VA) and cultured to subconfluency in RPMI1620 medium with 10% FBS. Harvested cells (5 Ã 10<sup>6</sup>) were injected subcutaneously in serum-free media into the right flank of athymic female nude mice (Charles River). Twelve days post-implantation, mice with established tumors (approximately 60â100 mm<sup>3</sup>) were randomized into treatment groups (<i>n</i> = 10 mice/group) and administered <b>11b</b> bid (100 Î¼L/dose) at doses of 0.3 mg/kg, 1 mg/kg, 3 mg/kg, 10 mg/kg, and 30 mg/kg depending upon the specific model in an oral suspension of methylcelluloseâTween (Ora-Plus). Tumor volumes were determined every 3â5 days using vernier calipers and the formula: <i>V</i> (mm<sup>3</sup>) = 0.5236 Ã length (mm) Ã width (mm) [length (mm + width (mm)/2]. Relative tumor volumes to that at the start of treatment were calculated for the A375 melanoma model. Statistical analyses of changes in tumor volume (or relative tumor volume) with <b>11b</b> treatment were done using the MannâWhitney Rank Sum test, with <i>p</i> < 0.05 deemed significant.</div></div><div id="sec5_27" class="NLM_sec NLM_sec_level_2"><div id="ac_i45" class="anchor-spacer"></div><h3 class="article-section__title" id="_i45"> P388 Murine Leukemia Model</h3><div class="NLM_p last">P388 murine leukemia cells were obtained from the American Type Culture Collection (Manassas, VA) and cultured in suspension in RPMI1620 medium with 10% FBS. At approximately 6 weeks of age, female DBA/2 mice (Charles River) were implanted intraperitoneally with leukemic cells and the resultant ascites isolated and serially passaged in DBA/2 mice for three cycles to generate highly malignant leukemic clones for subsequent evaluation in efficacy studies. Upon intraperitoneal implantation of ascitic P388 leukemia cells into DBA/2 mice, animals were randomized into treatment groups (<i>n</i> = 12 mice/group) to receive <b>11b</b> orally at a 30 mg/kg dose in methylcellulose: Tween vehicle on four distinct continuous and alternate dosing schedules, bid continuous; qd continuous; bid and qd Ã 7 days followed by drug holiday Ã 7 days; bid and qd Ã 14 days followed by drug holiday Ã 7 days; bid and qd Ã 7 days followed by drug holiday Ã 14 days. Mice were weighed twice weekly and monitored daily. The effects of <b>11b</b> on the survival of tumor bearing mice were analyzed by the KaplanâMeier method as required for data sets using SAS (SAS 8.2, SAS Institute, Inc. Cary, NC). MannâWhitney Rank Sum test analyses were used to compare mean and median survival times and body weights between treatment groups.</div></div></div><div class="NLM_back"><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_86382" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_86382" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Robert L. Hudkins</span> - <span class="hlFld-Affiliation affiliation">Discovery Research, Cephalon, Inc., 145 Brandywine Parkway, West Chester, Pennsylvania 19380, United
States</span>;Â 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#f2809a8796999b9c81b29197829a939e9d9cdc919d9fd2a09d90978086dcba8796999b9c81b286978493829a93809fdc919d9f"><span class="__cf_email__" data-cfemail="02706a7766696b6c71426167726a636e6d6c2c616d6f">[emailÂ protected]</span> <span class="__cf_email__" data-cfemail="085a676a6d7a7c26407d6c6361667b487c6d7e697860697a65266b6765">[emailÂ protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Bruce A. Ruggeri</span> - <span class="hlFld-Affiliation affiliation">Discovery Research, Cephalon, Inc., 145 Brandywine Parkway, West Chester, Pennsylvania 19380, United
States</span>;Â 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#d6a4bea3b2bdbfb8a596b5b3a6beb7bab9b8f8b5b9bbf684b9b4b3a4a2f89ea3b2bdbfb8a596a2b3a0b7a6beb7a4bbf8b5b9bb"><span class="__cf_email__" data-cfemail="4a38223f2e212324390a292f3a222b26252464292527">[emailÂ protected]</span> <span class="__cf_email__" data-cfemail="25774a474057510b6d50414e4c4b566551405344554d4457480b464a48">[emailÂ protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Nadine C. Becknell</span> - <span class="hlFld-Affiliation affiliation">Discovery Research, Cephalon, Inc., 145 Brandywine Parkway, West Chester, Pennsylvania 19380, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Allison L. Zulli</span> - <span class="hlFld-Affiliation affiliation">Discovery Research, Cephalon, Inc., 145 Brandywine Parkway, West Chester, Pennsylvania 19380, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ted L. Underiner</span> - <span class="hlFld-Affiliation affiliation">Discovery Research, Cephalon, Inc., 145 Brandywine Parkway, West Chester, Pennsylvania 19380, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Thelma S. Angeles</span> - <span class="hlFld-Affiliation affiliation">Discovery Research, Cephalon, Inc., 145 Brandywine Parkway, West Chester, Pennsylvania 19380, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lisa D. Aimone</span> - <span class="hlFld-Affiliation affiliation">Discovery Research, Cephalon, Inc., 145 Brandywine Parkway, West Chester, Pennsylvania 19380, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mark S. Albom</span> - <span class="hlFld-Affiliation affiliation">Discovery Research, Cephalon, Inc., 145 Brandywine Parkway, West Chester, Pennsylvania 19380, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hong Chang</span> - <span class="hlFld-Affiliation affiliation">Discovery Research, Cephalon, Inc., 145 Brandywine Parkway, West Chester, Pennsylvania 19380, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sheila J. Miknyoczki</span> - <span class="hlFld-Affiliation affiliation">Discovery Research, Cephalon, Inc., 145 Brandywine Parkway, West Chester, Pennsylvania 19380, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kathryn Hunter</span> - <span class="hlFld-Affiliation affiliation">Discovery Research, Cephalon, Inc., 145 Brandywine Parkway, West Chester, Pennsylvania 19380, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Susan Jones-Bolin</span> - <span class="hlFld-Affiliation affiliation">Discovery Research, Cephalon, Inc., 145 Brandywine Parkway, West Chester, Pennsylvania 19380, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hugh Zhao</span> - <span class="hlFld-Affiliation affiliation">Discovery Research, Cephalon, Inc., 145 Brandywine Parkway, West Chester, Pennsylvania 19380, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Edward R. Bacon</span> - <span class="hlFld-Affiliation affiliation">Discovery Research, Cephalon, Inc., 145 Brandywine Parkway, West Chester, Pennsylvania 19380, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">John P. Mallamo</span> - <span class="hlFld-Affiliation affiliation">Discovery Research, Cephalon, Inc., 145 Brandywine Parkway, West Chester, Pennsylvania 19380, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mark A. Ator</span> - <span class="hlFld-Affiliation affiliation">Discovery Research, Cephalon, Inc., 145 Brandywine Parkway, West Chester, Pennsylvania 19380, United
States</span></div></li></ul></li><li></li><li></li><li></li></ul></div><div class="testing" data-doi="10.1021/jm201449n" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i46" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i46"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i47" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i47"> Abbreviations</h2><tr><td class="NLM_term">VEGF-R</td><td class="NLM_def"><p class="first last">vascular endothelial growth factor receptor kinase</p></td></tr><tr><td class="NLM_term">TIE-2</td><td class="NLM_def"><p class="first last">tyrosine kinase with immunoglobulin and EGF-like domains 2</p></td></tr><tr><td class="NLM_term">FGF-R</td><td class="NLM_def"><p class="first last">fibroblast growth factor receptor</p></td></tr><tr><td class="NLM_term">DHI</td><td class="NLM_def"><p class="first last">N2-methyl-12,13-dihydroindazolo[5,4-a]pyrrolo[3,4-c]carbazole</p></td></tr><tr><td class="NLM_term">HUVEC</td><td class="NLM_def"><p class="first last">primary human umbilical vein endothelial cells</p></td></tr><tr><td class="NLM_term">KDR</td><td class="NLM_def"><p class="first last">kinase insert domain receptor</p></td></tr><tr><td class="NLM_term">RTK</td><td class="NLM_def"><p class="first last">receptor tyrosine kinase</p></td></tr><tr><td class="NLM_term">PDGF-R</td><td class="NLM_def"><p class="first last">platelet-derived growth factor receptor</p></td></tr><tr><td class="NLM_term">TRF</td><td class="NLM_def"><p class="first last">heterogeneous time-resolved fluorescence</p></td></tr><tr><td class="NLM_term">GST</td><td class="NLM_def"><p class="first last">human phospholipase C-Î³/glutathione <i>S</i>-transferase</p></td></tr><tr><td class="NLM_term">PK</td><td class="NLM_def"><p class="first last">pharmacokinetics</p></td></tr><tr><td class="NLM_term">TRK-A</td><td class="NLM_def"><p class="first last">neurotrophic tyrosine kinase receptor type 1</p></td></tr><tr><td class="NLM_term">BAEC</td><td class="NLM_def"><p class="first last">bovine aortic endothelial cells</p></td></tr><tr><td class="NLM_term">HMVEC</td><td class="NLM_def"><p class="first last">human dermal microvascular endothelial cells</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i48">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_85526" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_85526" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 17 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Folkman, J.</span><span> </span><span class="NLM_article-title">Tumor angiogenesis: therapeutic implications</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1971</span><span class="NLM_x">, </span> <span class="NLM_volume">285</span><span class="NLM_x">, </span> <span class="NLM_fpage">1182</span><span class="NLM_x">â</span> <span class="NLM_lpage">1186</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=16&amp;doi=10.1021%2Fjm201449n&amp;key=10.1056%2FNEJM197111182852108" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=8&amp;doi=10.1021%2Fjm201449n&amp;key=4938153" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=32&amp;doi=10.1021%2Fjm201449n&amp;key=1%3ACAS%3A280%3ADyaE38%252FgvVCqsQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=285&publication_year=1971&pages=1182-1186&author=J.+Folkman&title=Tumor+angiogenesis%3A+therapeutic+implications"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1aR"><div class="casContent"><span class="casTitleNuber">1a</span><div class="casTitle"><span class="NLM_cas:atitle">Tumor angiogenesis: therapeutic implications</span></div><div class="casAuthors">Folkman J</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">1971</span>),
    <span class="NLM_cas:volume">285</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">1182-6</span>
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRA0C6odtE1LPxQvRxYU81tfW6udTcc2eannfrQlS_w0Lntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaE38%252FgvVCqsQ%253D%253D&md5=efdddcba0c04be542edd51fef2ef27b9</span></div><a href="/servlet/linkout?suffix=cit1a&amp;dbid=16384&amp;doi=10.1056%2FNEJM197111182852108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJM197111182852108%26sid%3Dliteratum%253Aachs%26aulast%3DFolkman%26aufirst%3DJ.%26atitle%3DTumor%2520angiogenesis%253A%2520therapeutic%2520implications%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D1971%26volume%3D285%26spage%3D1182%26epage%3D1186" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit1b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Folkman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shing, Y.</span><span> </span><span class="NLM_article-title">Angiogenesis</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1992</span><span class="NLM_x">, </span> <span class="NLM_volume">267</span><span class="NLM_x">, </span> <span class="NLM_fpage">10931</span><span class="NLM_x">â</span> <span class="NLM_lpage">10934</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=267&publication_year=1992&pages=10931-10934&author=J.+Folkmanauthor=Y.+Shing&title=Angiogenesis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFolkman%26aufirst%3DJ.%26aulast%3DShing%26aufirst%3DY.%26atitle%3DAngiogenesis%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1992%26volume%3D267%26spage%3D10931%26epage%3D10934" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit1c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Carmeliet, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jain, R. K.</span><span> </span><span class="NLM_article-title">Angiogenesis in cancer and other diseases</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">407</span><span class="NLM_x">, </span> <span class="NLM_fpage">249</span><span class="NLM_x">â</span> <span class="NLM_lpage">257</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1c&amp;dbid=16&amp;doi=10.1021%2Fjm201449n&amp;key=10.1038%2F35025220" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1c&amp;dbid=8&amp;doi=10.1021%2Fjm201449n&amp;key=11001068" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1c&amp;dbid=32&amp;doi=10.1021%2Fjm201449n&amp;key=1%3ACAS%3A528%3ADC%252BD3cXmvVSls74%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=407&publication_year=2000&pages=249-257&author=P.+Carmelietauthor=R.+K.+Jain&title=Angiogenesis+in+cancer+and+other+diseases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1cR"><div class="casContent"><span class="casTitleNuber">1c</span><div class="casTitle"><span class="NLM_cas:atitle">Angiogenesis in cancer and other diseases</span></div><div class="casAuthors">Carmeliet, Peter; Jain, Rakesh K.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">407</span>
        (<span class="NLM_cas:issue">6801</span>),
    <span class="NLM_cas:pages">249-257</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review with 75 refs.  Pathol. angiogenesis is a hallmark of cancer and various ischemic and inflammatory diseases.  Concd. efforts in this area of research are leading to the discovery of a growing no. of pro- and anti-angiogenic mols., some of which are already in clin. trials.  The complex interactions among these mols. and how they affect vascular structure and function in different environments are now beginning to be elucidated.  This integrated understanding is leading to the development of a no. of exciting and bold approaches to treat cancer and other diseases.  But owing to several unanswered questions, caution is needed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPQMelW0OMYbVg90H21EOLACvtfcHk0lg_3yTt_QcSsA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXmvVSls74%253D&md5=703cbcdbd32292a9238f0394220c853c</span></div><a href="/servlet/linkout?suffix=cit1c&amp;dbid=16384&amp;doi=10.1038%2F35025220&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F35025220%26sid%3Dliteratum%253Aachs%26aulast%3DCarmeliet%26aufirst%3DP.%26aulast%3DJain%26aufirst%3DR.%2BK.%26atitle%3DAngiogenesis%2520in%2520cancer%2520and%2520other%2520diseases%26jtitle%3DNature%26date%3D2000%26volume%3D407%26spage%3D249%26epage%3D257" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit1d"><span><span class="NLM_label">(d) </span><span> </span><span class="NLM_article-title">Folkman, Angiogenesis in cancer, vascular, rheumatoid and other disease</span>. J. Nat. Med.<span class="NLM_x"> </span><span class="NLM_year">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">27</span><span class="NLM_x">â</span> <span class="NLM_lpage">31</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1d&amp;dbid=16&amp;doi=10.1021%2Fjm201449n&amp;key=10.1038%2Fnm0195-27" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1d&amp;dbid=8&amp;doi=10.1021%2Fjm201449n&amp;key=7584949" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1d&amp;dbid=32&amp;doi=10.1021%2Fjm201449n&amp;key=1%3ACAS%3A528%3ADyaK2MXjs1KnsLk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Folkman%2C+Angiogenesis+in+cancer%2C+vascular%2C+rheumatoid+and+other+disease.+J.+Nat.+Med.+1995%2C+1%2C+27%E2%80%9331."target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1dR"><div class="casContent"><span class="casTitleNuber">1d</span><div class="casTitle"><span class="NLM_cas:atitle">Angiogenesis in cancer, vascular, rheumatoid and other disease</span></div><div class="casAuthors">Folkman, Judah</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York)</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">27-31</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Co.</span>)
        </div><div class="casAbstract">A review with â¼72 refs.  Recent discoveries of endogenous neg. regulators of angiogenesis, thrombospondin, angiostatin and glioma-derived angiogenesis inhibitory factor, all assocd. with neovascularized tumors, suggest a new paradigm of tumorigenesis.  It is now helpful to think of the switch to the angiogenic phenotype as a net balance of pos. and neg. regulators of blood vessel growth.  The extent to which the neg. regulators are decreased during this switch may dictate whether a primary tumor grows rapidly or slowly and whether metastases grow at all.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpF2nWHt2eJbVg90H21EOLACvtfcHk0lg_3yTt_QcSsA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXjs1KnsLk%253D&md5=849f4f3828ac5d78886d666787f72d4f</span></div><a href="/servlet/linkout?suffix=cit1d&amp;dbid=16384&amp;doi=10.1038%2Fnm0195-27&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26id%3Ddoi%3A10.1038%252Fnm0195-27%26sid%3Dliteratum%253Aachs%26atitle%3DFolkman%252C%2520Angiogenesis%2520in%2520cancer%252C%2520vascular%252C%2520rheumatoid%2520and%2520other%2520disease%26jtitle%3DJ.%2520Nat.%2520Med.%26date%3D1995%26volume%3D1%26spage%3D27%26epage%3D31" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Hurwitz, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fehrenbacher, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Novotny, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cartwright, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hainsworth, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heim, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berlin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baron, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffing, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holmgren, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferrara, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fyfe, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rogers, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ross, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kabbinavar, F.</span><span> </span><span class="NLM_article-title">Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer</span> <span class="citation_source-journal">N. Engl J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">350</span><span class="NLM_x">, </span> <span class="NLM_fpage">2335</span><span class="NLM_x">â</span> <span class="NLM_lpage">2342</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Fjm201449n&amp;key=10.1056%2FNEJMoa032691" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Fjm201449n&amp;key=15175435" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Fjm201449n&amp;key=1%3ACAS%3A528%3ADC%252BD2cXks1Gjt74%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=350&publication_year=2004&pages=2335-2342&author=H.+Hurwitzauthor=L.+Fehrenbacherauthor=W.+Novotnyauthor=T.+Cartwrightauthor=J.+Hainsworthauthor=W.+Heimauthor=J.+Berlinauthor=A.+Baronauthor=S.+Griffingauthor=E.+Holmgrenauthor=N.+Ferraraauthor=G.+Fyfeauthor=B.+Rogersauthor=R.+Rossauthor=F.+Kabbinavar&title=Bevacizumab+plus+irinotecan%2C+fluorouracil%2C+and+leucovorin+for+metastatic+colorectal+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer</span></div><div class="casAuthors">Hurwitz, Herbert; Fehrenbacher, Louis; Novotny, William; Cartwright, Thomas; Hainsworth, John; Heim, William; Berlin, Jordan; Baron, Ari; Griffing, Susan; Holmgren, Eric; Ferrara, Napoleone; Fyfe, Gwen; Rogers, Beth; Ross, Robert; Kabbinavar, Fairooz</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">350</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">2335-2342</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, has shown promising preclin. and clin. activity against metastatic colorectal cancer, particularly in combination with chemotherapy.  Of 813 patients with previously untreated metastatic colorectal cancer, we randomly assigned 402 to receive irinotecan, bolus fluorouracil, and leucovorin (IFL) plus bevacizumab (5 mg per kg of body wt. every two weeks) and 411 to receive IFL plus placebo.  The primary end point was overall survival.  Secondary end points were progression-free survival, the response rate, the duration of the response, safety, and the quality of life.  The median duration of survival was 20.3 mo in the group given IFL plus bevacizumab, as compared with 15.6 mo in the group given IFL plus placebo, corresponding to a hazard ratio for death of 0.66 (P<0.001).  The median duration of progression-free survival was 10.6 mo in the group given IFL plus bevacizumab, as compared with 6.2 mo in the group given IFL plus placebo (hazard ratio for disease progression, 0.54; P<0.001); the corresponding rates of response were 44.8 % and 34.8 % (P = 0.004).  The median duration of the response was 10.4 mo in the group given IFL plus bevacizumab, as compared with 7.1 mo in the group given IFL plus placebo (hazard ratio for progression, 0.62; P = 0.001).  Grade 3 hypertension was more common during treatment with IFL plus bevacizumab than with IFL plus placebo (11.0 % vs. 2.3 %) but was easily managed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5r6uP5oxZU7Vg90H21EOLACvtfcHk0lh812s-92WSzw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXks1Gjt74%253D&md5=6a1289cdbf1501f121eb0482e5a1f536</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa032691&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa032691%26sid%3Dliteratum%253Aachs%26aulast%3DHurwitz%26aufirst%3DH.%26aulast%3DFehrenbacher%26aufirst%3DL.%26aulast%3DNovotny%26aufirst%3DW.%26aulast%3DCartwright%26aufirst%3DT.%26aulast%3DHainsworth%26aufirst%3DJ.%26aulast%3DHeim%26aufirst%3DW.%26aulast%3DBerlin%26aufirst%3DJ.%26aulast%3DBaron%26aufirst%3DA.%26aulast%3DGriffing%26aufirst%3DS.%26aulast%3DHolmgren%26aufirst%3DE.%26aulast%3DFerrara%26aufirst%3DN.%26aulast%3DFyfe%26aufirst%3DG.%26aulast%3DRogers%26aufirst%3DB.%26aulast%3DRoss%26aufirst%3DR.%26aulast%3DKabbinavar%26aufirst%3DF.%26atitle%3DBevacizumab%2520plus%2520irinotecan%252C%2520fluorouracil%252C%2520and%2520leucovorin%2520for%2520metastatic%2520colorectal%2520cancer%26jtitle%3DN.%2520Engl%2520J.%2520Med.%26date%3D2004%26volume%3D350%26spage%3D2335%26epage%3D2342" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Escudier, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eisen, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stadler, W. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szczylik, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oudard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Staehler, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Negrier, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chevreau, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Desai, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rolland, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demkow, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hutson, T. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gore, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hofilena, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pena, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lathia, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bukowski, R. M.</span><span> </span><span class="NLM_article-title">Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">3312</span><span class="NLM_x">â</span> <span class="NLM_lpage">3318</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Fjm201449n&amp;key=10.1200%2FJCO.2008.19.5511" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Fjm201449n&amp;key=19451442" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm201449n&amp;key=1%3ACAS%3A528%3ADC%252BD1MXpvFejt7w%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2009&pages=3312-3318&author=B.+Escudierauthor=T.+Eisenauthor=W.+M.+Stadlerauthor=C.+Szczylikauthor=S.+Oudardauthor=M.+Staehlerauthor=S.+Negrierauthor=C.+Chevreauauthor=A.+A.+Desaiauthor=F.+Rollandauthor=T.+Demkowauthor=T.+E.+Hutsonauthor=M.+Goreauthor=S.+Andersonauthor=G.+Hofilenaauthor=M.+Shanauthor=C.+Penaauthor=C.+Lathiaauthor=R.+M.+Bukowski&title=Sorafenib+for+treatment+of+renal+cell+carcinoma%3A+Final+efficacy+and+safety+results+of+the+phase+III+treatment+approaches+in+renal+cancer+global+evaluation+trial"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in Renal Cancer Global Evaluation Trial</span></div><div class="casAuthors">Escudier, Bernard; Eisen, Tim; Stadler, Walter M.; Szczylik, Cezary; Oudard, Stephane; Staehler, Michael; Negrier, Sylvie; Chevreau, Christine; Desai, Apurva A.; Rolland, Frederic; Demkow, Tomasz; Hutson, Thomas E.; Gore, Martin; Anderson, Sibyl; Hofilena, Gloria; Shan, Minghua; Pena, Carol; Lathia, Chetan; Bukowski, Ronald M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">3312-3318</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Mature survival data and evaluation of vascular endothelial growth factor (VEGF) as a prognostic biomarker from the Treatment Approaches in Renal Cancer Global Evaluation Trial (TARGET) study in patients with renal cell carcinoma (RCC) are reported.  Nine hundred three previously treated patients were randomly assigned to receive sorafenib vs. placebo.  On demonstration of progression-free survival (PFS) benefit with sorafenib, patients assigned to placebo were offered sorafenib.  Overall survival (OS) was detd. at two planned interim analyses and one final anal., with a secondary OS anal. conducted by censoring placebo patients who crossed over to sorafenib.  The relationships between baseline VEGF level and prognosis and efficacy were evaluated.  The final OS of patients receiving sorafenib was comparable with that of patients receiving placebo (17.8 v 15.2 mo, resp.; hazard ratio [HR] = 0.88; P = .146); however, when post-cross-over placebo survival data were censored, the difference became significant (17.8 v 14.3 mo, resp.; HR = 0.78; P = .029).  Adverse events at 16 mo after cross over were similar to those previously reported.  Baseline VEGF levels correlated with Eastern Cooperative Oncol. Group performance status (P < .0001), Memorial Sloan-Kettering Cancer Center score (P < .0001), and PFS and OS in univariate (PFS, P = .0013; OS, P = .0009) and multivariate (PFS, P = .0231; OS, P = .0416) analyses of placebo patients and with short OS by multivariate anal. of patients receiving sorafenib (P = .0145).  Both high-VEGF (P < .01) and low-VEGF (P < .01) groups benefited from sorafenib.  Although an OS benefit was not seen on a primary intent-to-treat anal., results of a secondary OS anal. censoring placebo patients demonstrated a survival advantage for those receiving sorafenib, suggesting an important cross-over effect.  VEGF levels are prognostic for PFS and OS in RCC.  The results of TARGET establish the efficacy and safety of sorafenib in advanced RCC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5GZeSGUwB9rVg90H21EOLACvtfcHk0lh812s-92WSzw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXpvFejt7w%253D&md5=aee6dc30eca5a92d6e225f5bd22d9a38</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1200%2FJCO.2008.19.5511&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2008.19.5511%26sid%3Dliteratum%253Aachs%26aulast%3DEscudier%26aufirst%3DB.%26aulast%3DEisen%26aufirst%3DT.%26aulast%3DStadler%26aufirst%3DW.%2BM.%26aulast%3DSzczylik%26aufirst%3DC.%26aulast%3DOudard%26aufirst%3DS.%26aulast%3DStaehler%26aufirst%3DM.%26aulast%3DNegrier%26aufirst%3DS.%26aulast%3DChevreau%26aufirst%3DC.%26aulast%3DDesai%26aufirst%3DA.%2BA.%26aulast%3DRolland%26aufirst%3DF.%26aulast%3DDemkow%26aufirst%3DT.%26aulast%3DHutson%26aufirst%3DT.%2BE.%26aulast%3DGore%26aufirst%3DM.%26aulast%3DAnderson%26aufirst%3DS.%26aulast%3DHofilena%26aufirst%3DG.%26aulast%3DShan%26aufirst%3DM.%26aulast%3DPena%26aufirst%3DC.%26aulast%3DLathia%26aufirst%3DC.%26aulast%3DBukowski%26aufirst%3DR.%2BM.%26atitle%3DSorafenib%2520for%2520treatment%2520of%2520renal%2520cell%2520carcinoma%253A%2520Final%2520efficacy%2520and%2520safety%2520results%2520of%2520the%2520phase%2520III%2520treatment%2520approaches%2520in%2520renal%2520cancer%2520global%2520evaluation%2520trial%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2009%26volume%3D27%26spage%3D3312%26epage%3D3318" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Demetri, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Oosterom, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garrett, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blackstein, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verweij, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McArthur, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Judson, I. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heinrich, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morgan, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Desai, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">George, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bello, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baum, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casali, P. G.</span><span> </span><span class="NLM_article-title">Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">368</span><span class="NLM_x">, </span> <span class="NLM_fpage">1329</span><span class="NLM_x">â</span> <span class="NLM_lpage">1338</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=368&publication_year=2006&pages=1329-1338&author=G.+D.+Demetriauthor=A.+T.+van+Oosteromauthor=C.+R.+Garrettauthor=M.+E.+Blacksteinauthor=M.+H.+Shahauthor=J.+Verweijauthor=G.+McArthurauthor=I.+R.+Judsonauthor=M.+C.+Heinrichauthor=J.+A.+Morganauthor=J.+Desaiauthor=C.+D.+Fletcherauthor=S.+Georgeauthor=C.+L.+Belloauthor=X.+Huangauthor=C.+M.+Baumauthor=P.+G.+Casali&title=Efficacy+and+safety+of+sunitinib+in+patients+with+advanced+gastrointestinal+stromal+tumour+after+failure+of+imatinib%3A+a+randomised+controlled+trial"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDemetri%26aufirst%3DG.%2BD.%26aulast%3Dvan%2BOosterom%26aufirst%3DA.%2BT.%26aulast%3DGarrett%26aufirst%3DC.%2BR.%26aulast%3DBlackstein%26aufirst%3DM.%2BE.%26aulast%3DShah%26aufirst%3DM.%2BH.%26aulast%3DVerweij%26aufirst%3DJ.%26aulast%3DMcArthur%26aufirst%3DG.%26aulast%3DJudson%26aufirst%3DI.%2BR.%26aulast%3DHeinrich%26aufirst%3DM.%2BC.%26aulast%3DMorgan%26aufirst%3DJ.%2BA.%26aulast%3DDesai%26aufirst%3DJ.%26aulast%3DFletcher%26aufirst%3DC.%2BD.%26aulast%3DGeorge%26aufirst%3DS.%26aulast%3DBello%26aufirst%3DC.%2BL.%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DBaum%26aufirst%3DC.%2BM.%26aulast%3DCasali%26aufirst%3DP.%2BG.%26atitle%3DEfficacy%2520and%2520safety%2520of%2520sunitinib%2520in%2520patients%2520with%2520advanced%2520gastrointestinal%2520stromal%2520tumour%2520after%2520failure%2520of%2520imatinib%253A%2520a%2520randomised%2520controlled%2520trial%26jtitle%3DLancet%26date%3D2006%26volume%3D368%26spage%3D1329%26epage%3D1338" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Xu, C. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bing, N. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ball, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rajagopalan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sternberg, C. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hutson, T. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Souza, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xue, Z. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCann, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">King, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ragone, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whittaker, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spraggs, C. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cardon, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mooser, V. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pandite, L. N.</span><span> </span><span class="NLM_article-title">Pazopanib efficacy in renal cell carcinoma: Evidence for predictive genetic markers in angiogenesis-related and exposure-related genes</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">2557</span><span class="NLM_x">â</span> <span class="NLM_lpage">2564</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=16&amp;doi=10.1021%2Fjm201449n&amp;key=10.1200%2FJCO.2010.32.9110" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=8&amp;doi=10.1021%2Fjm201449n&amp;key=21576632" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=32&amp;doi=10.1021%2Fjm201449n&amp;key=1%3ACAS%3A528%3ADC%252BC3MXpsVyqtrs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2011&pages=2557-2564&author=C.+F.+Xuauthor=N.+X.+Bingauthor=H.+A.+Ballauthor=D.+Rajagopalanauthor=C.+N.+Sternbergauthor=T.+E.+Hutsonauthor=P.+de+Souzaauthor=Z.+G.+Xueauthor=L.+McCannauthor=K.+S.+Kingauthor=L.+J.+Ragoneauthor=J.+C.+Whittakerauthor=C.+F.+Spraggsauthor=L.+R.+Cardonauthor=V.+E.+Mooserauthor=L.+N.+Pandite&title=Pazopanib+efficacy+in+renal+cell+carcinoma%3A+Evidence+for+predictive+genetic+markers+in+angiogenesis-related+and+exposure-related+genes"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5aR"><div class="casContent"><span class="casTitleNuber">5a</span><div class="casTitle"><span class="NLM_cas:atitle">Pazopanib efficacy in renal cell carcinoma: Evidence for predictive genetic markers in angiogenesis-related and exposure-related genes</span></div><div class="casAuthors">Xu, Chun-Fang; Bing, Nan X.; Ball, Howard A.; Rajagopalan, Dilip; Sternberg, Cora N.; Hutson, Thomas E.; de Souza, Paul; Xue, Zhengyu G.; McCann, Lauren; King, Karen S.; Ragone, Leigh J.; Whittaker, John C.; Spraggs, Colin F.; Cardon, Lon R.; Mooser, Vincent E.; Pandite, Lini N.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">2557-2564</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Pazopanib, an oral angiogenesis inhibitor, is approved for the treatment of advanced renal cell carcinoma (RCC).  Response to pazopanib monotherapy varies between patients, and no validated biomarkers predictive of treatment outcome have been identified.  We tested the hypothesis that this variability is partially dependent on germline genetic variants that may affect pazopanib exposure or angiogenesis pathways.  27 Functional polymorphisms within 13 genes were evaluated in 397 patients with RCC.  Genetic assocn. with progression-free survival (PFS) and objective response rate (RR) was analyzed using the Cox proportional hazards model and proportional odds model, resp.  3 Polymorphisms in IL8 and HIF1A and five polymorphisms in HIF1A, NR1I2, and VEGFA showed nominally significant assocn. (P â¤ .05) with PFS and RR, resp.  Compared with the wild-type AA genotype (median PFS, 48 wk), the IL8 2767TT variant genotype showed inferior PFS (27 wk, P = .009).  The HIF1A 1790AG genotype was assocd. with inferior PFS and reduced RR, compared with the wild-type GG genotype (median PFS, 20 v 44 wk; P = .03; RR, 30% v 43%, P = .02).  Redns. in RR were detected for the NR1I2-25385TT genotype, compared with the wild-type CC genotype (37% v 50%, P = .03), and for the VEGFA - 1498CC genotype compared with the TT genotypes (33% v 51%).  Germline variants in angiogenesis- and exposure-related genes may predict treatment response to pazopanib monotherapy in patients with RCC.  If validated, these markers may explain why certain patients fail antiangiogenesis therapy and they may support the use of alternative strategies to circumvent this issue.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYP-HZufZfhrVg90H21EOLACvtfcHk0ljW5TFu7wtb3Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXpsVyqtrs%253D&md5=434ae6fdf2b7ed6561d59eaefd32a92c</span></div><a href="/servlet/linkout?suffix=cit5a&amp;dbid=16384&amp;doi=10.1200%2FJCO.2010.32.9110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2010.32.9110%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DC.%2BF.%26aulast%3DBing%26aufirst%3DN.%2BX.%26aulast%3DBall%26aufirst%3DH.%2BA.%26aulast%3DRajagopalan%26aufirst%3DD.%26aulast%3DSternberg%26aufirst%3DC.%2BN.%26aulast%3DHutson%26aufirst%3DT.%2BE.%26aulast%3Dde%2BSouza%26aufirst%3DP.%26aulast%3DXue%26aufirst%3DZ.%2BG.%26aulast%3DMcCann%26aufirst%3DL.%26aulast%3DKing%26aufirst%3DK.%2BS.%26aulast%3DRagone%26aufirst%3DL.%2BJ.%26aulast%3DWhittaker%26aufirst%3DJ.%2BC.%26aulast%3DSpraggs%26aufirst%3DC.%2BF.%26aulast%3DCardon%26aufirst%3DL.%2BR.%26aulast%3DMooser%26aufirst%3DV.%2BE.%26aulast%3DPandite%26aufirst%3DL.%2BN.%26atitle%3DPazopanib%2520efficacy%2520in%2520renal%2520cell%2520carcinoma%253A%2520Evidence%2520for%2520predictive%2520genetic%2520markers%2520in%2520angiogenesis-related%2520and%2520exposure-related%2520genes%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2011%26volume%3D29%26spage%3D2557%26epage%3D2564" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit5b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Harris, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boloor, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheung, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumar, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crosby, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis-Ward, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Epperly, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hinkle, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunter, R. N.,  III</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knick, V. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laudeman, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luttrell, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mook, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nolte, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rudolph, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szewczyk, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Truesdale, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Veal, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stafford, J. A.</span><span> </span><span class="NLM_article-title">Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">4632</span><span class="NLM_x">â</span> <span class="NLM_lpage">4640</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm800566m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=4632-4640&author=P.+A.+Harrisauthor=A.+Boloorauthor=M.+Cheungauthor=R.+Kumarauthor=R.+M.+Crosbyauthor=R.+G.+Davis-Wardauthor=A.+H.+Epperlyauthor=K.+W.+Hinkleauthor=R.+N.+Hunterauthor=J.+H.+Johnsonauthor=V.+B.+Knickauthor=C.+P.+Laudemanauthor=D.+K.+Luttrellauthor=R.+A.+Mookauthor=R.+T.+Nolteauthor=S.+K.+Rudolphauthor=J.+R.+Szewczykauthor=A.+T.+Truesdaleauthor=J.+M.+Vealauthor=L.+Wangauthor=J.+A.+Stafford&title=Discovery+of+5-%5B%5B4-%5B%282%2C3-dimethyl-2H-indazol-6-yl%29methylamino%5D-2-pyrimidinyl%5Damino%5D-2-methyl-benzenesulfonamide+%28Pazopanib%29%2C+a+novel+and+potent+vascular+endothelial+growth+factor+receptor+inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5b&amp;dbid=16384&amp;doi=10.1021%2Fjm800566m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800566m%26sid%3Dliteratum%253Aachs%26aulast%3DHarris%26aufirst%3DP.%2BA.%26aulast%3DBoloor%26aufirst%3DA.%26aulast%3DCheung%26aufirst%3DM.%26aulast%3DKumar%26aufirst%3DR.%26aulast%3DCrosby%26aufirst%3DR.%2BM.%26aulast%3DDavis-Ward%26aufirst%3DR.%2BG.%26aulast%3DEpperly%26aufirst%3DA.%2BH.%26aulast%3DHinkle%26aufirst%3DK.%2BW.%26aulast%3DHunter%26aufirst%3DR.%2BN.%26aulast%3DJohnson%26aufirst%3DJ.%2BH.%26aulast%3DKnick%26aufirst%3DV.%2BB.%26aulast%3DLaudeman%26aufirst%3DC.%2BP.%26aulast%3DLuttrell%26aufirst%3DD.%2BK.%26aulast%3DMook%26aufirst%3DR.%2BA.%26aulast%3DNolte%26aufirst%3DR.%2BT.%26aulast%3DRudolph%26aufirst%3DS.%2BK.%26aulast%3DSzewczyk%26aufirst%3DJ.%2BR.%26aulast%3DTruesdale%26aufirst%3DA.%2BT.%26aulast%3DVeal%26aufirst%3DJ.%2BM.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DStafford%26aufirst%3DJ.%2BA.%26atitle%3DDiscovery%2520of%25205-%255B%255B4-%255B%25282%252C3-dimethyl-2H-indazol-6-yl%2529methylamino%255D-2-pyrimidinyl%255Damino%255D-2-methyl-benzenesulfonamide%2520%2528Pazopanib%2529%252C%2520a%2520novel%2520and%2520potent%2520vascular%2520endothelial%2520growth%2520factor%2520receptor%2520inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D4632%26epage%3D4640" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Cai, Z. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borzilleri, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qian, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbosa, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wautlet, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mortillo, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeyaseelan, R.,  Sr</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kukral, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamath, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marathe, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DâArienzo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Derbin, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrish, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robl, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunt, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lombardo, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fargnoli, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhide, R. S.</span><span> </span><span class="NLM_article-title">Discovery of brivanib alaninate ((S)-((R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-yl)2-aminopropanoate), a novel prodrug of dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinase inhibitor (BMS-540215)</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">1976</span><span class="NLM_x">â</span> <span class="NLM_lpage">1980</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm7013309" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=1976-1980&author=Z.+W.+Caiauthor=Y.+Zhangauthor=R.+M.+Borzilleriauthor=L.+Qianauthor=S.+Barbosaauthor=D.+Weiauthor=X.+Zhengauthor=L.+Wuauthor=J.+Fanauthor=Z.+Shiauthor=B.+S.+Wautletauthor=S.+Mortilloauthor=R.+Jeyaseelanauthor=D.+W.+Kukralauthor=A.+Kamathauthor=P.+Maratheauthor=C.+D%E2%80%99Arienzoauthor=G.+Derbinauthor=J.+C.+Barrishauthor=J.+A.+Roblauthor=J.+T.+Huntauthor=L.+J.+Lombardoauthor=J.+Fargnoliauthor=R.+S.+Bhide&title=Discovery+of+brivanib+alaninate+%28%28S%29-%28%28R%29-1-%284-%284-fluoro-2-methyl-1H-indol-5-yloxy%29-5-methylpyrrolo%5B2%2C1-f%5D%5B1%2C2%2C4%5Dtriazin-6-yloxy%29propan-2-yl%292-aminopropanoate%29%2C+a+novel+prodrug+of+dual+vascular+endothelial+growth+factor+receptor-2+and+fibroblast+growth+factor+receptor-1+kinase+inhibitor+%28BMS-540215%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1021%2Fjm7013309&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm7013309%26sid%3Dliteratum%253Aachs%26aulast%3DCai%26aufirst%3DZ.%2BW.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DBorzilleri%26aufirst%3DR.%2BM.%26aulast%3DQian%26aufirst%3DL.%26aulast%3DBarbosa%26aufirst%3DS.%26aulast%3DWei%26aufirst%3DD.%26aulast%3DZheng%26aufirst%3DX.%26aulast%3DWu%26aufirst%3DL.%26aulast%3DFan%26aufirst%3DJ.%26aulast%3DShi%26aufirst%3DZ.%26aulast%3DWautlet%26aufirst%3DB.%2BS.%26aulast%3DMortillo%26aufirst%3DS.%26aulast%3DJeyaseelan%26aufirst%3DR.%26aulast%3DKukral%26aufirst%3DD.%2BW.%26aulast%3DKamath%26aufirst%3DA.%26aulast%3DMarathe%26aufirst%3DP.%26aulast%3DD%25E2%2580%2599Arienzo%26aufirst%3DC.%26aulast%3DDerbin%26aufirst%3DG.%26aulast%3DBarrish%26aufirst%3DJ.%2BC.%26aulast%3DRobl%26aufirst%3DJ.%2BA.%26aulast%3DHunt%26aufirst%3DJ.%2BT.%26aulast%3DLombardo%26aufirst%3DL.%2BJ.%26aulast%3DFargnoli%26aufirst%3DJ.%26aulast%3DBhide%26aufirst%3DR.%2BS.%26atitle%3DDiscovery%2520of%2520brivanib%2520alaninate%2520%2528%2528S%2529-%2528%2528R%2529-1-%25284-%25284-fluoro-2-methyl-1H-indol-5-yloxy%2529-5-methylpyrrolo%255B2%252C1-f%255D%255B1%252C2%252C4%255Dtriazin-6-yloxy%2529propan-2-yl%25292-aminopropanoate%2529%252C%2520a%2520novel%2520prodrug%2520of%2520dual%2520vascular%2520endothelial%2520growth%2520factor%2520receptor-2%2520and%2520fibroblast%2520growth%2520factor%2520receptor-1%2520kinase%2520inhibitor%2520%2528BMS-540215%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D1976%26epage%3D1980" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Bergers, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benjamin, L. E.</span><span> </span><span class="NLM_article-title">Tumorigenesis and the angiogenic switch</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">401</span><span class="NLM_x">â</span> <span class="NLM_lpage">410</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Fjm201449n&amp;key=10.1038%2Fnrc1093" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Fjm201449n&amp;key=12778130" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Fjm201449n&amp;key=1%3ACAS%3A528%3ADC%252BD3sXktFOnsb8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2003&pages=401-410&author=G.+Bergersauthor=L.+E.+Benjamin&title=Tumorigenesis+and+the+angiogenic+switch"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Angiogenesis: Tumorigenesis and the angiogenic switch</span></div><div class="casAuthors">Bergers, Gabriele; Benjamin, Laura E.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">401-410</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  It has become evident that the authors cannot understand tumor growth without considering components of the stromal microenvironment, such as the vasculature.  At the same time, the tumor phenotype dets. the nature of the tumor vasculature.  Much research is now devoted to detg. the impact of angiogenesis on tumor development and progression, and the reciprocal influences of tumor products on the microvasculature.  A more detailed understanding of the complex parameters that govern the interactions between the tumor and vascular compartments will help to improve anti-angiogenic strategies - not only for cancer treatment, but also for preventing recurrence.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZSf-pIdliV7Vg90H21EOLACvtfcHk0lgdQx3AwICqJw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXktFOnsb8%253D&md5=1c2717ab1374694b7d9edc420d29583a</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fnrc1093&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1093%26sid%3Dliteratum%253Aachs%26aulast%3DBergers%26aufirst%3DG.%26aulast%3DBenjamin%26aufirst%3DL.%2BE.%26atitle%3DTumorigenesis%2520and%2520the%2520angiogenic%2520switch%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2003%26volume%3D3%26spage%3D401%26epage%3D410" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Lin, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buxton, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Acheson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Radziejewski, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maisonpierre, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yancopoulos, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Channon, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hale, L. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dewhirst, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">George, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peters, K. G.</span><span> </span><span class="NLM_article-title">Antiangiogenic gene therapy targeting the endothelium-specific receptor tyrosine kinase TIE-2</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">95</span><span class="NLM_x">, </span> <span class="NLM_fpage">8829</span><span class="NLM_x">â</span> <span class="NLM_lpage">8834</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=1998&pages=8829-8834&author=P.+Linauthor=J.+A.+Buxtonauthor=A.+Achesonauthor=C.+Radziejewskiauthor=P.+C.+Maisonpierreauthor=G.+D.+Yancopoulosauthor=K.+M.+Channonauthor=L.+P.+Haleauthor=M.+W.+Dewhirstauthor=S.+E.+Georgeauthor=K.+G.+Peters&title=Antiangiogenic+gene+therapy+targeting+the+endothelium-specific+receptor+tyrosine+kinase+TIE-2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DP.%26aulast%3DBuxton%26aufirst%3DJ.%2BA.%26aulast%3DAcheson%26aufirst%3DA.%26aulast%3DRadziejewski%26aufirst%3DC.%26aulast%3DMaisonpierre%26aufirst%3DP.%2BC.%26aulast%3DYancopoulos%26aufirst%3DG.%2BD.%26aulast%3DChannon%26aufirst%3DK.%2BM.%26aulast%3DHale%26aufirst%3DL.%2BP.%26aulast%3DDewhirst%26aufirst%3DM.%2BW.%26aulast%3DGeorge%26aufirst%3DS.%2BE.%26aulast%3DPeters%26aufirst%3DK.%2BG.%26atitle%3DAntiangiogenic%2520gene%2520therapy%2520targeting%2520the%2520endothelium-specific%2520receptor%2520tyrosine%2520kinase%2520TIE-2%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D1998%26volume%3D95%26spage%3D8829%26epage%3D8834" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit8b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Cristofanilli, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Charnsangavej, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hortobagyi, G. N.</span><span> </span><span class="NLM_article-title">Angiogenesis modulation in cancer research: novel clinical approaches</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">415</span><span class="NLM_x">â</span> <span class="NLM_lpage">426</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2002&pages=415-426&author=M.+Cristofanilliauthor=C.+Charnsangavejauthor=G.+N.+Hortobagyi&title=Angiogenesis+modulation+in+cancer+research%3A+novel+clinical+approaches"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCristofanilli%26aufirst%3DM.%26aulast%3DCharnsangavej%26aufirst%3DC.%26aulast%3DHortobagyi%26aufirst%3DG.%2BN.%26atitle%3DAngiogenesis%2520modulation%2520in%2520cancer%2520research%253A%2520novel%2520clinical%2520approaches%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2002%26volume%3D1%26spage%3D415%26epage%3D426" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit8c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Jones, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LLjin, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dumount, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alitalo, K.</span><span> </span><span class="NLM_article-title">TIE receptors: new modulators of angiogenic and lymphangiogenic responses</span> <span class="citation_source-journal">Nat. Rev. Mol. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">257</span><span class="NLM_x">â</span> <span class="NLM_lpage">267</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8c&amp;dbid=16&amp;doi=10.1021%2Fjm201449n&amp;key=10.1038%2F35067005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8c&amp;dbid=8&amp;doi=10.1021%2Fjm201449n&amp;key=11283723" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8c&amp;dbid=32&amp;doi=10.1021%2Fjm201449n&amp;key=1%3ACAS%3A528%3ADC%252BD3MXis12jtL4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2001&pages=257-267&author=N.+Jonesauthor=K.+LLjinauthor=D.+Dumountauthor=K.+Alitalo&title=TIE+receptors%3A+new+modulators+of+angiogenic+and+lymphangiogenic+responses"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8cR"><div class="casContent"><span class="casTitleNuber">8c</span><div class="casTitle"><span class="NLM_cas:atitle">Tie receptors: new modulators of angiogenic and lymphangiogenic responses</span></div><div class="casAuthors">Jones, Nina; Iljin, Kristiina; Dumont, Daniel J.; Alitalo, Kari</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">257-267</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review, with 107 refs.  Angiogenesis is required for normal embryonic vascular development and aberrant angiogenesis contributes to several diseases, including cancer, diabetes, and tissue ischemia.  What are the mol. mechanisms that regulate this important process.  The Tie family of receptors and their ligands, the angiopoietins, are beginning to provide insight into how vessels make decisions such as whether to grow or regress - processes that are important not only during development but throughout an organism's life.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq132ywhxGgW7Vg90H21EOLACvtfcHk0lgdQx3AwICqJw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXis12jtL4%253D&md5=60dfebc8d6a9e61625addbd67d1487d0</span></div><a href="/servlet/linkout?suffix=cit8c&amp;dbid=16384&amp;doi=10.1038%2F35067005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F35067005%26sid%3Dliteratum%253Aachs%26aulast%3DJones%26aufirst%3DN.%26aulast%3DLLjin%26aufirst%3DK.%26aulast%3DDumount%26aufirst%3DD.%26aulast%3DAlitalo%26aufirst%3DK.%26atitle%3DTIE%2520receptors%253A%2520new%2520modulators%2520of%2520angiogenic%2520and%2520lymphangiogenic%2520responses%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2001%26volume%3D2%26spage%3D257%26epage%3D267" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit8d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Uemura, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogawa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirashima, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujiwara, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koyama, S</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takagi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Honda, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiegand, S, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yancopoulos, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishikawa, S.</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">110</span><span class="NLM_x">, </span> <span class="NLM_fpage">1619</span><span class="NLM_x">â</span> <span class="NLM_lpage">1628</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Uemura%2C+A.%3B+Ogawa%2C+M.%3B+Hirashima%2C+M.%3B+Fujiwara%2C+T.%3B+Koyama%2C+S%3B+Takagi%2C+H.%3B+Honda%2C+Y.%3B+Wiegand%2C+S%2C+J.%3B+Yancopoulos%2C+G.+D.%3B+Nishikawa%2C+S.J.+Clin.+Invest.+2002%2C+110%2C+1619%E2%80%931628"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DUemura%26aufirst%3DA.%26aulast%3DOgawa%26aufirst%3DM.%26aulast%3DHirashima%26aufirst%3DM.%26aulast%3DFujiwara%26aufirst%3DT.%26aulast%3DKoyama%26aufirst%3DS%26aulast%3DTakagi%26aufirst%3DH.%26aulast%3DHonda%26aufirst%3DY.%26aulast%3DWiegand%26aufirst%3DS%252C%2BJ.%26aulast%3DYancopoulos%26aufirst%3DG.%2BD.%26aulast%3DNishikawa%26aufirst%3DS.%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2002%26volume%3D110%26spage%3D1619%26epage%3D1628" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit8e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Visconti, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richardson, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sato, T. N.</span><span> </span><span class="NLM_article-title">Orchestration of angiogenesis and arteriovenous contribution by angiopoietins and vascular endothelial growth factor (VEGF)</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">99</span><span class="NLM_x">, </span> <span class="NLM_fpage">8219</span><span class="NLM_x">â</span> <span class="NLM_lpage">8224</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2002&pages=8219-8224&author=R.+P.+Viscontiauthor=C.+D.+Richardsonauthor=T.+N.+Sato&title=Orchestration+of+angiogenesis+and+arteriovenous+contribution+by+angiopoietins+and+vascular+endothelial+growth+factor+%28VEGF%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8e&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVisconti%26aufirst%3DR.%2BP.%26aulast%3DRichardson%26aufirst%3DC.%2BD.%26aulast%3DSato%26aufirst%3DT.%2BN.%26atitle%3DOrchestration%2520of%2520angiogenesis%2520and%2520arteriovenous%2520contribution%2520by%2520angiopoietins%2520and%2520vascular%2520endothelial%2520growth%2520factor%2520%2528VEGF%2529%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2002%26volume%3D99%26spage%3D8219%26epage%3D8224" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit8f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group">Jain, R. K.</span><span> </span><span class="NLM_article-title">Molecular regulation of vessel maturation</span> <span class="citation_source-journal">Nature Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">685</span><span class="NLM_x">â</span> <span class="NLM_lpage">693</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2003&pages=685-693&author=R.+K.+Jain&title=Molecular+regulation+of+vessel+maturation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8f&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJain%26aufirst%3DR.%2BK.%26atitle%3DMolecular%2520regulation%2520of%2520vessel%2520maturation%26jtitle%3DNature%2520Med.%26date%3D2003%26volume%3D9%26spage%3D685%26epage%3D693" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Lin, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polverini, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dewhirst, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rao, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peters, K. G.</span><span> </span><span class="NLM_article-title">Inhibition of tumor angiogenesis using a soluble receptor establishes a role for TIE-2 in pathologic vascular growth</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">100</span><span class="NLM_x">, </span> <span class="NLM_fpage">2072</span><span class="NLM_x">â</span> <span class="NLM_lpage">2078</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=1997&pages=2072-2078&author=P.+Linauthor=P.+Polveriniauthor=M.+Dewhirstauthor=S.+Shanauthor=P.+S.+Raoauthor=K.+G.+Peters&title=Inhibition+of+tumor+angiogenesis+using+a+soluble+receptor+establishes+a+role+for+TIE-2+in+pathologic+vascular+growth"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DP.%26aulast%3DPolverini%26aufirst%3DP.%26aulast%3DDewhirst%26aufirst%3DM.%26aulast%3DShan%26aufirst%3DS.%26aulast%3DRao%26aufirst%3DP.%2BS.%26aulast%3DPeters%26aufirst%3DK.%2BG.%26atitle%3DInhibition%2520of%2520tumor%2520angiogenesis%2520using%2520a%2520soluble%2520receptor%2520establishes%2520a%2520role%2520for%2520TIE-2%2520in%2520pathologic%2520vascular%2520growth%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D1997%26volume%3D100%26spage%3D2072%26epage%3D2078" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit9b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Shim, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teh, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mack, P. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ge, R.</span><span> </span><span class="NLM_article-title">Inhibition of angiopoietin-1 expression in tumor cells by an antisense RNA approach inhibited xenograft tumor growth in immunodeficient mice</span> <span class="citation_source-journal">Int. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">94</span><span class="NLM_x">, </span> <span class="NLM_fpage">6</span><span class="NLM_x">â</span> <span class="NLM_lpage">15</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=16&amp;doi=10.1021%2Fjm201449n&amp;key=10.1002%2Fijc.1428" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=8&amp;doi=10.1021%2Fjm201449n&amp;key=11668472" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=32&amp;doi=10.1021%2Fjm201449n&amp;key=1%3ACAS%3A528%3ADC%252BD3MXms1Kgs7Y%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=2001&pages=6-15&author=W.+S.+Shimauthor=M.+Tehauthor=P.+O.+Mackauthor=R.+Ge&title=Inhibition+of+angiopoietin-1+expression+in+tumor+cells+by+an+antisense+RNA+approach+inhibited+xenograft+tumor+growth+in+immunodeficient+mice"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9bR"><div class="casContent"><span class="casTitleNuber">9b</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of angiopoietin-1 expression in tumor cells by an antisense RNA approach inhibited xenograft tumor growth in immunodeficient mice</span></div><div class="casAuthors">Shim, Winston S. N.; Teh, Ming; Mack, Peter O. P.; Ge, Ruowen</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">6-15</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Angiopoietin-1 (Ang1) is an angiogenic growth factor that functions through activation of its endothelium-specific tyrosine kinase receptor Tie2; it mediates the interaction between endothelial and surrounding cells to promote the remodeling, maturation and stabilization of blood vessels.  Although Ang1 is expressed constitutively in many adult tissues, its role in tumor growth and metastasis is not clear.  Here we describe expts. in which Ang1 expression was inhibited in HeLa cells by an antisense RNA approach.  The modified HeLa cells produced significantly less Ang1 protein both in cultured cells and in tumors formed when these cells were injected into immunodeficient mice.  The Ang1 antisense tumors grew much more slowly, with significantly reduced tumor angiogenesis compared with control tumors.  Furthermore, they also had substantially increased tumor cell apoptosis and decreased tumor necrosis.  Our results indicate that the perturbation of Ang1 expression in tumors could be an effective method to control tumor growth by inhibiting tumor angiogenesis and that antisense RNA is an efficient way to inhibit Ang1 protein prodn. in tumor cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGryNwUaCFxQ8bVg90H21EOLACvtfcHk0lhbcyTjRPMiRg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXms1Kgs7Y%253D&md5=a4d376df7f7f035c18523e4804851283</span></div><a href="/servlet/linkout?suffix=cit9b&amp;dbid=16384&amp;doi=10.1002%2Fijc.1428&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.1428%26sid%3Dliteratum%253Aachs%26aulast%3DShim%26aufirst%3DW.%2BS.%26aulast%3DTeh%26aufirst%3DM.%26aulast%3DMack%26aufirst%3DP.%2BO.%26aulast%3DGe%26aufirst%3DR.%26atitle%3DInhibition%2520of%2520angiopoietin-1%2520expression%2520in%2520tumor%2520cells%2520by%2520an%2520antisense%2520RNA%2520approach%2520inhibited%2520xenograft%2520tumor%2520growth%2520in%2520immunodeficient%2520mice%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2001%26volume%3D94%26spage%3D6%26epage%3D15" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit9c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Stratmann, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Acker, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burger, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amann, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Risau, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plate, K. H.</span><span> </span><span class="NLM_article-title">Differential inhibition of tumor angiogenesis by TIE-2 and vascular endothelial growth factor receptor-2 dominant-negative receptor mutants</span> <span class="citation_source-journal">Int. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">91</span><span class="NLM_x">, </span> <span class="NLM_fpage">273</span><span class="NLM_x">â</span> <span class="NLM_lpage">282</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9c&amp;dbid=16&amp;doi=10.1021%2Fjm201449n&amp;key=10.1002%2F1097-0215%28200002%299999%3A9999%3C%3A%3AAID-IJC1054%3E3.0.CO%3B2-Q" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9c&amp;dbid=8&amp;doi=10.1021%2Fjm201449n&amp;key=11169947" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9c&amp;dbid=32&amp;doi=10.1021%2Fjm201449n&amp;key=1%3ACAS%3A528%3ADC%252BD3MXmsFOktQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=2001&pages=273-282&author=A.+Stratmannauthor=T.+Ackerauthor=A.+M.+Burgerauthor=K.+Amannauthor=W.+Risauauthor=K.+H.+Plate&title=Differential+inhibition+of+tumor+angiogenesis+by+TIE-2+and+vascular+endothelial+growth+factor+receptor-2+dominant-negative+receptor+mutants"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9cR"><div class="casContent"><span class="casTitleNuber">9c</span><div class="casTitle"><span class="NLM_cas:atitle">Differential inhibition of tumor angiogenesis by TIE2 and vascular endothelial growth factor receptor-2 dominant-negative receptor mutants</span></div><div class="casAuthors">Stratmann, Astrid; Acker, Till; Burger, Angelika M.; Amann, Kerstin; Risau, Werner; Plate, Karl H.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">91</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">273-282</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Tumor growth is angiogenesis-dependent.  Current evidence suggests that vascular endothelial growth factor (VEGF), a major regulator of embryonic and hypoxia-mediated angiogenesis, is necessary for tumor angiogenesis.  VEGF is expressed in tumor cells in vivo, and its Tyr kinase receptors VEGFR-1 and VEGFR-2 are up-regulated in the tumor endothelium.  A second endothelial cell-specific ligand/receptor Tyr kinase system, consisting of the tie2 receptor, its activating ligand angiopoietin-1 and the inhibitory ligand angiopoietin-2, was characterized.  The authors have examd. 6 human primary breast-cancer samples and 4 murine breast-cancer cell lines (M6363, M6378, M6444, M6468), transplanted into nude mice, by in situ hybridization and/or Northern anal.  Expression of angiopoietin-1, angiopoietin-2 and tie2 was compared to VEGF and VEGFR-2 expression.  Human tumors expressed VEGFR-2 and tie2 but varied considerably in VEGF and angiopoietin-1/-2 expression.  In the murine tumor models, the authors obsd. high heterogeneity of receptor and ligand expression.  M6363 and M6378 tumors were analyzed in detail because they showed different expression of components of the tie2/angiopoietin signaling system.  M6363 tumors expressed VEGF, VEGFR-2 and angiopoietin-2 but not tie2 or angiopoietin-1, suggesting activation of VEGFR-2 and inhibition of tie2 signaling pathways, whereas M6378 tumors expressed VEGF, VEGFR-2, tie2 and angiopoietin-1 but little angiopoietin-2, suggesting activation of both VEGFR-2 and tie2 signaling pathways.  In vivo studies using truncated dominant-neg. tie2 and VEGFR-2 mutants revealed inhibition of M6363 tumor growth by 15% (truncated tie2) and 36% (truncated VEGFR-2), resp.  In contrast, M6378 tumor growth was inhibited by 57% (truncated tie2) and 47% (truncated VEGFR-2), resp.  These findings support the hypothesis that tumor angiogenesis is dependent on VEGFR-2 but suggest that, in addn., tie2-dependent pathways of tumor angiogenesis may exist.  For adequate application of angiogenesis inhibitors in tumor patients, anal. of prevailing angiogenesis pathways may be a prerequisite.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDdiCPRxhiV7Vg90H21EOLACvtfcHk0lhbcyTjRPMiRg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXmsFOktQ%253D%253D&md5=dcafe52efa95848d38d3381097ab6fc8</span></div><a href="/servlet/linkout?suffix=cit9c&amp;dbid=16384&amp;doi=10.1002%2F1097-0215%28200002%299999%3A9999%3C%3A%3AAID-IJC1054%3E3.0.CO%3B2-Q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F1097-0215%2528200002%25299999%253A9999%253C%253A%253AAID-IJC1054%253E3.0.CO%253B2-Q%26sid%3Dliteratum%253Aachs%26aulast%3DStratmann%26aufirst%3DA.%26aulast%3DAcker%26aufirst%3DT.%26aulast%3DBurger%26aufirst%3DA.%2BM.%26aulast%3DAmann%26aufirst%3DK.%26aulast%3DRisau%26aufirst%3DW.%26aulast%3DPlate%26aufirst%3DK.%2BH.%26atitle%3DDifferential%2520inhibition%2520of%2520tumor%2520angiogenesis%2520by%2520TIE-2%2520and%2520vascular%2520endothelial%2520growth%2520factor%2520receptor-2%2520dominant-negative%2520receptor%2520mutants%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2001%26volume%3D91%26spage%3D273%26epage%3D282" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Jendreyko, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Popkov, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rader, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbas, C. F.</span><span> </span><span class="NLM_article-title">Phenotypic knockout of VEGF-R2 and TIE-2 with an intradiabody reduces tumor growth and angiogenesis in vivo</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">102</span><span class="NLM_x">, </span> <span class="NLM_fpage">8293</span><span class="NLM_x">â</span> <span class="NLM_lpage">8298</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=16&amp;doi=10.1021%2Fjm201449n&amp;key=10.1073%2Fpnas.0503168102" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=8&amp;doi=10.1021%2Fjm201449n&amp;key=15928093" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=32&amp;doi=10.1021%2Fjm201449n&amp;key=1%3ACAS%3A528%3ADC%252BD2MXlsV2mtLs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2005&pages=8293-8298&author=N.+Jendreykoauthor=M.+Popkovauthor=C.+Raderauthor=C.+F.+Barbas&title=Phenotypic+knockout+of+VEGF-R2+and+TIE-2+with+an+intradiabody+reduces+tumor+growth+and+angiogenesis+in+vivo"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10aR"><div class="casContent"><span class="casTitleNuber">10a</span><div class="casTitle"><span class="NLM_cas:atitle">Phenotypic knockout of VEGF-R2 and Tie-2 with an intradiabody reduces tumor growth and angiogenesis in vivo</span></div><div class="casAuthors">Jendreyko, Nina; Popkov, Mikhail; Rader, Christoph; Barbas, Carlos F., III</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">8293-8298</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The endothelial cell receptor-tyrosine kinases, VEGF receptor 2 (VEGF-R2) and Tie-2, and their ligands, vascular endothelial growth factor (VEGF) and angiopoietins 1 and 2, resp., play key roles in tumor angiogenesis.  Several studies suggest that the VEGF receptor pathway and the Tie-2 pathway are independent and essential mediators of angiogenesis, leading to the hypothesis that simultaneous interference with both pathways should result in additive effects on tumor growth.  In this study, a human melanoma xenograft model (M21) was used to analyze the effects of simultaneous intradiabody depletion of vascular endothelial growth receptor-R2 and Tie-2 on tumor angiogenesis and tumor xenograft growth.  The intradiabodies were expressed from recombinant adenovirus delivered through subtumoral injection.  Blockade of both VEGF-R2 and Tie-2 pathways simultaneously or the VEGF receptor pathway alone resulted in a significant inhibition of tumor growth and tumor angiogenesis (92.2% and 74.4%, resp.).  In addn., immunohistochem. staining of intradiabody-treated tumors demonstrated a decreased no. of tumor-assocd. blood vessels vs. control treatment.  Previous studies with intrabodies had demonstrated that the Tie-2 receptor pathway was essential for tumor growth.  The simultaneous blockade of the VEGF and Tie-2 pathways resulted in effective inhibition of tumor growth and demonstrated the potential of simultaneous targeting of multiple pathways as a therapeutic strategy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZ9MF0zdW6YLVg90H21EOLACvtfcHk0lgJ7gsQgpgMFA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXlsV2mtLs%253D&md5=62c03cfdc0e2ba959b52f38c17b18631</span></div><a href="/servlet/linkout?suffix=cit10a&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0503168102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0503168102%26sid%3Dliteratum%253Aachs%26aulast%3DJendreyko%26aufirst%3DN.%26aulast%3DPopkov%26aufirst%3DM.%26aulast%3DRader%26aufirst%3DC.%26aulast%3DBarbas%26aufirst%3DC.%2BF.%26atitle%3DPhenotypic%2520knockout%2520of%2520VEGF-R2%2520and%2520TIE-2%2520with%2520an%2520intradiabody%2520reduces%2520tumor%2520growth%2520and%2520angiogenesis%2520in%2520vivo%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2005%26volume%3D102%26spage%3D8293%26epage%3D8298" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit10b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Popkov, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jendreyko, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGavern, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rader, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbas, C. F.</span><span> </span><span class="NLM_article-title">Targeting tumor angiogenesis with adenovirus-delivered anti-TIE-2 intrabody</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">65</span><span class="NLM_x">, </span> <span class="NLM_fpage">972</span><span class="NLM_x">â</span> <span class="NLM_lpage">991</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=8&amp;doi=10.1021%2Fjm201449n&amp;key=15705898" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=32&amp;doi=10.1021%2Fjm201449n&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVWntb0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2005&pages=972-991&author=M.+Popkovauthor=N.+Jendreykoauthor=D.+B.+McGavernauthor=C.+Raderauthor=C.+F.+Barbas&title=Targeting+tumor+angiogenesis+with+adenovirus-delivered+anti-TIE-2+intrabody"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10bR"><div class="casContent"><span class="casTitleNuber">10b</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting tumor angiogenesis with adenovirus-delivered anti-Tie-2 intrabody</span></div><div class="casAuthors">Popkov, Mikhail; Jendreyko, Nina; McGavern, Dorian B.; Rader, Christoph; Barbas, Carlos F., III</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">972-981</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Inhibition of tumor angiogenesis is a promising approach for cancer therapy.  As an endothelial cell-specific receptor kinase expressed almost exclusively on the surface of vascular endothelium, Tie-2 has an important role in tumor angiogenesis.  To explore the therapeutic potential of blocking Tie-2 receptor-interaction pathway, an adenoviral vector was used to deliver a recombinant single-chain antibody fragment rabbit intrabody (pAd-2S03) capable of inhibition of both mouse and human Tie-2 surface expression.  PAd-2S03 was given to mice with well-established primary tumors, either a human Kaposi's sarcoma (SLK) or a human colon carcinoma (SW1222).  The intrabody significantly inhibited growth of both tumors (75% and 63%, resp.) when compared with pAd-GFP control-treated tumors (P < 0.01).  Histopathol. anal. of cryosections taken from mice treated with pAd-2S03 revealed a marked decrease in vessel d., which was reduced by >87% in both tumor models when compared with control-treated tumors (P < 0.01).  In contrast, human Tie-2-monospecific pAd-1S05 intrabody did not affect the growth of tumors, indicating that the antitumor effect of pAd-2S03 was due to the inhibition of tumor angiogenesis in these murine models.  Our results show that the Tie-2 receptor pathway is essential for both SLK sarcoma and SW1222 colon carcinoma xenograft growth.  The present study shows the potential utility of antiangiogenic agents that target the endothelium-specific receptor Tie-2 for down-regulation or genetic deletion.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotTuWwaEkK6LVg90H21EOLACvtfcHk0lgJ7gsQgpgMFA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVWntb0%253D&md5=8f91fd95654011fff049197d333dc43c</span></div><a href="/servlet/linkout?suffix=cit10b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPopkov%26aufirst%3DM.%26aulast%3DJendreyko%26aufirst%3DN.%26aulast%3DMcGavern%26aufirst%3DD.%2BB.%26aulast%3DRader%26aufirst%3DC.%26aulast%3DBarbas%26aufirst%3DC.%2BF.%26atitle%3DTargeting%2520tumor%2520angiogenesis%2520with%2520adenovirus-delivered%2520anti-TIE-2%2520intrabody%26jtitle%3DCancer%2520Res.%26date%3D2005%26volume%3D65%26spage%3D972%26epage%3D991" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Beebe, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jani, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knauth, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goodwin, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Higdon, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rossi, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emerson, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finkelstein, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harriman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atherton, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hillerman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soderstrom, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kou, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gant, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noe, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foster, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rastinejad, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marx, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schaeffer, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whalen, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, W. G.</span><span> </span><span class="NLM_article-title">Pharmacological characterization of CP-547,632, a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for cancer therapy</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">63</span><span class="NLM_x">, </span> <span class="NLM_fpage">7301</span><span class="NLM_x">â</span> <span class="NLM_lpage">7309</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2003&pages=7301-7309&author=J.+S.+Beebeauthor=J.+P.+Janiauthor=E.+Knauthauthor=P.+Goodwinauthor=C.+Higdonauthor=A.+M.+Rossiauthor=E.+Emersonauthor=M.+Finkelsteinauthor=E.+Floydauthor=S.+Harrimanauthor=J.+Athertonauthor=S.+Hillermanauthor=C.+Soderstromauthor=K.+Kouauthor=T.+Gantauthor=M.+C.+Noeauthor=B.+Fosterauthor=F.+Rastinejadauthor=M.+A.+Marxauthor=T.+Schaefferauthor=P.+M.+Whalenauthor=W.+G.+Roberts&title=Pharmacological+characterization+of+CP-547%2C632%2C+a+novel+vascular+endothelial+growth+factor+receptor-2+tyrosine+kinase+inhibitor+for+cancer+therapy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBeebe%26aufirst%3DJ.%2BS.%26aulast%3DJani%26aufirst%3DJ.%2BP.%26aulast%3DKnauth%26aufirst%3DE.%26aulast%3DGoodwin%26aufirst%3DP.%26aulast%3DHigdon%26aufirst%3DC.%26aulast%3DRossi%26aufirst%3DA.%2BM.%26aulast%3DEmerson%26aufirst%3DE.%26aulast%3DFinkelstein%26aufirst%3DM.%26aulast%3DFloyd%26aufirst%3DE.%26aulast%3DHarriman%26aufirst%3DS.%26aulast%3DAtherton%26aufirst%3DJ.%26aulast%3DHillerman%26aufirst%3DS.%26aulast%3DSoderstrom%26aufirst%3DC.%26aulast%3DKou%26aufirst%3DK.%26aulast%3DGant%26aufirst%3DT.%26aulast%3DNoe%26aufirst%3DM.%2BC.%26aulast%3DFoster%26aufirst%3DB.%26aulast%3DRastinejad%26aufirst%3DF.%26aulast%3DMarx%26aufirst%3DM.%2BA.%26aulast%3DSchaeffer%26aufirst%3DT.%26aulast%3DWhalen%26aufirst%3DP.%2BM.%26aulast%3DRoberts%26aufirst%3DW.%2BG.%26atitle%3DPharmacological%2520characterization%2520of%2520CP-547%252C632%252C%2520a%2520novel%2520vascular%2520endothelial%2520growth%2520factor%2520receptor-2%2520tyrosine%2520kinase%2520inhibitor%2520for%2520cancer%2520therapy%26jtitle%3DCancer%2520Res.%26date%3D2003%26volume%3D63%26spage%3D7301%26epage%3D7309" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit11b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Hasegawa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishigaki, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Washio, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kano, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sato, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mori, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">West, R. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shibahara, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toyoda, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nolte, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Veal, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheung, M.</span><span> </span><span class="NLM_article-title">Discovery of novel benzimidazoles as potent inhibitors of TIE-2 and VEGF-R2 tyrosine kinase receptors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">4453</span><span class="NLM_x">â</span> <span class="NLM_lpage">4470</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0611051" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=4453-4470&author=M.+Hasegawaauthor=N.+Nishigakiauthor=Y.+Washioauthor=K.+Kanoauthor=P.+A.+Harrisauthor=H.+Satoauthor=I.+Moriauthor=R.+I.+Westauthor=M.+Shibaharaauthor=H.+Toyodaauthor=L.+Wangauthor=R.+T.+Nolteauthor=J.+M.+Vealauthor=M.+Cheung&title=Discovery+of+novel+benzimidazoles+as+potent+inhibitors+of+TIE-2+and+VEGF-R2+tyrosine+kinase+receptors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11b&amp;dbid=16384&amp;doi=10.1021%2Fjm0611051&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0611051%26sid%3Dliteratum%253Aachs%26aulast%3DHasegawa%26aufirst%3DM.%26aulast%3DNishigaki%26aufirst%3DN.%26aulast%3DWashio%26aufirst%3DY.%26aulast%3DKano%26aufirst%3DK.%26aulast%3DHarris%26aufirst%3DP.%2BA.%26aulast%3DSato%26aufirst%3DH.%26aulast%3DMori%26aufirst%3DI.%26aulast%3DWest%26aufirst%3DR.%2BI.%26aulast%3DShibahara%26aufirst%3DM.%26aulast%3DToyoda%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DNolte%26aufirst%3DR.%2BT.%26aulast%3DVeal%26aufirst%3DJ.%2BM.%26aulast%3DCheung%26aufirst%3DM.%26atitle%3DDiscovery%2520of%2520novel%2520benzimidazoles%2520as%2520potent%2520inhibitors%2520of%2520TIE-2%2520and%2520VEGF-R2%2520tyrosine%2520kinase%2520receptors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D4453%26epage%3D4470" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit11c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Ji, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahmed, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albert, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bouska, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bousquet, P. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cunha, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diaz, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glaser, K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marcotte, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moskey, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oie, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pease, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soni, N. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stewart, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davidsen, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michaelides, M. R.</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">1231</span><span class="NLM_x">â</span> <span class="NLM_lpage">1241</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm701096v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Ji%2C+Z.%3B+Ahmed%2C+A.+A.%3B+Albert%2C+D.+H.%3B+Bouska%2C+J.+J.%3B+Bousquet%2C+P.+F.%3B+Cunha%2C+G.+A.%3B+Diaz%2C+G.%3B+Glaser%2C+K.+B.%3B+Guo%2C+J.%3B+Harris%2C+C.+M.%3B+Li%2C+J.%3B+Marcotte%2C+P.+A.%3B+Moskey%2C+M.+D.%3B+Oie%2C+T.%3B+Pease%2C+L.%3B+Soni%2C+N.+B.%3B+Stewart%2C+K.+D.%3B+Davidsen%2C+S.+K.%3B+Michaelides%2C+M.+R.J.+Med.+Chem.+2008%2C+51%2C+1231%E2%80%931241"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11c&amp;dbid=16384&amp;doi=10.1021%2Fjm701096v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm701096v%26sid%3Dliteratum%253Aachs%26aulast%3DJi%26aufirst%3DZ.%26aulast%3DAhmed%26aufirst%3DA.%2BA.%26aulast%3DAlbert%26aufirst%3DD.%2BH.%26aulast%3DBouska%26aufirst%3DJ.%2BJ.%26aulast%3DBousquet%26aufirst%3DP.%2BF.%26aulast%3DCunha%26aufirst%3DG.%2BA.%26aulast%3DDiaz%26aufirst%3DG.%26aulast%3DGlaser%26aufirst%3DK.%2BB.%26aulast%3DGuo%26aufirst%3DJ.%26aulast%3DHarris%26aufirst%3DC.%2BM.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DMarcotte%26aufirst%3DP.%2BA.%26aulast%3DMoskey%26aufirst%3DM.%2BD.%26aulast%3DOie%26aufirst%3DT.%26aulast%3DPease%26aufirst%3DL.%26aulast%3DSoni%26aufirst%3DN.%2BB.%26aulast%3DStewart%26aufirst%3DK.%2BD.%26aulast%3DDavidsen%26aufirst%3DS.%2BK.%26aulast%3DMichaelides%26aufirst%3DM.%2BR.%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D1231%26epage%3D1241" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit11d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Miyazaki, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maeda, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakano, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nolte, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sato, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sugai, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okamoto, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Truesdale, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hassler, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nartey, E. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patrick, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ozawa, K.</span><span> </span><span class="NLM_article-title">Orally active 4-amino-5-diarylurea-furo[2,3-d]pyrimidine derivatives as anti-angiogenic agent inhibiting VEGF-R2 and TIE-2</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">1773</span><span class="NLM_x">â</span> <span class="NLM_lpage">1778</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=1773-1778&author=Y.+Miyazakiauthor=J.+Tangauthor=Y.+Maedaauthor=M.+Nakanoauthor=L.+Wangauthor=R.+T.+Nolteauthor=H.+Satoauthor=M.+Sugaiauthor=Y.+Okamotoauthor=A.+T.+Truesdaleauthor=D.+F.+Hasslerauthor=E.+N.+Narteyauthor=D.+R.+Patrickauthor=M.+L.+Hoauthor=K.+Ozawa&title=Orally+active+4-amino-5-diarylurea-furo%5B2%2C3-d%5Dpyrimidine+derivatives+as+anti-angiogenic+agent+inhibiting+VEGF-R2+and+TIE-2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMiyazaki%26aufirst%3DY.%26aulast%3DTang%26aufirst%3DJ.%26aulast%3DMaeda%26aufirst%3DY.%26aulast%3DNakano%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DNolte%26aufirst%3DR.%2BT.%26aulast%3DSato%26aufirst%3DH.%26aulast%3DSugai%26aufirst%3DM.%26aulast%3DOkamoto%26aufirst%3DY.%26aulast%3DTruesdale%26aufirst%3DA.%2BT.%26aulast%3DHassler%26aufirst%3DD.%2BF.%26aulast%3DNartey%26aufirst%3DE.%2BN.%26aulast%3DPatrick%26aufirst%3DD.%2BR.%26aulast%3DHo%26aufirst%3DM.%2BL.%26aulast%3DOzawa%26aufirst%3DK.%26atitle%3DOrally%2520active%25204-amino-5-diarylurea-furo%255B2%252C3-d%255Dpyrimidine%2520derivatives%2520as%2520anti-angiogenic%2520agent%2520inhibiting%2520VEGF-R2%2520and%2520TIE-2%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2007%26volume%3D17%26spage%3D1773%26epage%3D1778" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit11e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Miyazakia, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsunagaa, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanga, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maedaa, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakanoa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Philippea, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shibaharaa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liub, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Satoa, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wangb, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nolteb, R. T.</span><span> </span><span class="NLM_article-title">Novel 4-amino-furo[2,3-d]pyrimidines as TIE-2 and VEGF-R2 dual inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">2203</span><span class="NLM_x">â</span> <span class="NLM_lpage">2207</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2005&pages=2203-2207&author=Y.+Miyazakiaauthor=S.+Matsunagaaauthor=J.+Tangaauthor=Y.+Maedaaauthor=M.+Nakanoaauthor=R.+J.+Philippeaauthor=M.+Shibaharaaauthor=W.+Liubauthor=H.+Satoaauthor=L.+Wangbauthor=R.+T.+Nolteb&title=Novel+4-amino-furo%5B2%2C3-d%5Dpyrimidines+as+TIE-2+and+VEGF-R2+dual+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11e&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMiyazakia%26aufirst%3DY.%26aulast%3DMatsunagaa%26aufirst%3DS.%26aulast%3DTanga%26aufirst%3DJ.%26aulast%3DMaedaa%26aufirst%3DY.%26aulast%3DNakanoa%26aufirst%3DM.%26aulast%3DPhilippea%26aufirst%3DR.%2BJ.%26aulast%3DShibaharaa%26aufirst%3DM.%26aulast%3DLiub%26aufirst%3DW.%26aulast%3DSatoa%26aufirst%3DH.%26aulast%3DWangb%26aufirst%3DL.%26aulast%3DNolteb%26aufirst%3DR.%2BT.%26atitle%3DNovel%25204-amino-furo%255B2%252C3-d%255Dpyrimidines%2520as%2520TIE-2%2520and%2520VEGF-R2%2520dual%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2005%26volume%3D15%26spage%3D2203%26epage%3D2207" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Gingrich, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddy, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iqbal, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aimone, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angeles, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albom, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ator, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robinson, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruggeri, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dionne, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaught, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mallamo, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hudkins, R. L.</span><span> </span><span class="NLM_article-title">A new class of potent VEGF receptor tyrosine kinase inhibitors: structure-activity relationships for a series of 9-alkoxymethyl-12-(3-hydroxypropyl)indeno[2,1-a]pyrrolo[3,4-c]carbazole-5-ones and the identification of CEP-5214 and its dimethylglycine ester prodrug clinical candidate CEP-7055</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">5375</span><span class="NLM_x">â</span> <span class="NLM_lpage">5388</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0301641" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=5375-5388&author=D.+E.+Gingrichauthor=D.+R.+Reddyauthor=M.+A.+Iqbalauthor=J.+Singhauthor=L.+D.+Aimoneauthor=T.+S.+Angelesauthor=M.+Albomauthor=S.+Yangauthor=S.+Meyerauthor=M.+Atorauthor=C.+Robinsonauthor=B.+A.+Ruggeriauthor=C.+A.+Dionneauthor=J.+L.+Vaughtauthor=J.+P.+Mallamoauthor=R.+L.+Hudkins&title=A+new+class+of+potent+VEGF+receptor+tyrosine+kinase+inhibitors%3A+structure-activity+relationships+for+a+series+of+9-alkoxymethyl-12-%283-hydroxypropyl%29indeno%5B2%2C1-a%5Dpyrrolo%5B3%2C4-c%5Dcarbazole-5-ones+and+the+identification+of+CEP-5214+and+its+dimethylglycine+ester+prodrug+clinical+candidate+CEP-7055"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12a&amp;dbid=16384&amp;doi=10.1021%2Fjm0301641&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0301641%26sid%3Dliteratum%253Aachs%26aulast%3DGingrich%26aufirst%3DD.%2BE.%26aulast%3DReddy%26aufirst%3DD.%2BR.%26aulast%3DIqbal%26aufirst%3DM.%2BA.%26aulast%3DSingh%26aufirst%3DJ.%26aulast%3DAimone%26aufirst%3DL.%2BD.%26aulast%3DAngeles%26aufirst%3DT.%2BS.%26aulast%3DAlbom%26aufirst%3DM.%26aulast%3DYang%26aufirst%3DS.%26aulast%3DMeyer%26aufirst%3DS.%26aulast%3DAtor%26aufirst%3DM.%26aulast%3DRobinson%26aufirst%3DC.%26aulast%3DRuggeri%26aufirst%3DB.%2BA.%26aulast%3DDionne%26aufirst%3DC.%2BA.%26aulast%3DVaught%26aufirst%3DJ.%2BL.%26aulast%3DMallamo%26aufirst%3DJ.%2BP.%26aulast%3DHudkins%26aufirst%3DR.%2BL.%26atitle%3DA%2520new%2520class%2520of%2520potent%2520VEGF%2520receptor%2520tyrosine%2520kinase%2520inhibitors%253A%2520structure-activity%2520relationships%2520for%2520a%2520series%2520of%25209-alkoxymethyl-12-%25283-hydroxypropyl%2529indeno%255B2%252C1-a%255Dpyrrolo%255B3%252C4-c%255Dcarbazole-5-ones%2520and%2520the%2520identification%2520of%2520CEP-5214%2520and%2520its%2520dimethylglycine%2520ester%2520prodrug%2520clinical%2520candidate%2520CEP-7055%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26spage%3D5375%26epage%3D5388" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit12b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Ruggeri, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gingrich, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angeles, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albom, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robinson, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunter, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dobrzanski, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones-Bolin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aimone, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klein-Szanto, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herbert, J.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bono, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schaeffer, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casellas, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bourie, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pili, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isaacs, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ator, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hudkins, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaught, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mallamo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dionne, C.</span><span> </span><span class="NLM_article-title">CEP-7055: A novel, orally-active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent anti-angiogenic activity and anti-tumor efficacy in pre-clinical models</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">63</span><span class="NLM_x">, </span> <span class="NLM_fpage">5978</span><span class="NLM_x">â</span> <span class="NLM_lpage">5991</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2003&pages=5978-5991&author=B.+Ruggeriauthor=J.+Singhauthor=D.+Gingrichauthor=T.+Angelesauthor=M.+Albomauthor=H.+Changauthor=C.+Robinsonauthor=K.+Hunterauthor=P.+Dobrzanskiauthor=S.+Jones-Bolinauthor=L.+Aimoneauthor=A.+Klein-Szantoauthor=J.-M.+Herbertauthor=F.+Bonoauthor=P.+Schaefferauthor=P.+Casellasauthor=B.+Bourieauthor=R.+Piliauthor=J.+Isaacsauthor=M.+Atorauthor=R.+Hudkinsauthor=J.+Vaughtauthor=J.+Mallamoauthor=C.+Dionne&title=CEP-7055%3A+A+novel%2C+orally-active+pan+inhibitor+of+vascular+endothelial+growth+factor+receptor+tyrosine+kinases+with+potent+anti-angiogenic+activity+and+anti-tumor+efficacy+in+pre-clinical+models"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRuggeri%26aufirst%3DB.%26aulast%3DSingh%26aufirst%3DJ.%26aulast%3DGingrich%26aufirst%3DD.%26aulast%3DAngeles%26aufirst%3DT.%26aulast%3DAlbom%26aufirst%3DM.%26aulast%3DChang%26aufirst%3DH.%26aulast%3DRobinson%26aufirst%3DC.%26aulast%3DHunter%26aufirst%3DK.%26aulast%3DDobrzanski%26aufirst%3DP.%26aulast%3DJones-Bolin%26aufirst%3DS.%26aulast%3DAimone%26aufirst%3DL.%26aulast%3DKlein-Szanto%26aufirst%3DA.%26aulast%3DHerbert%26aufirst%3DJ.-M.%26aulast%3DBono%26aufirst%3DF.%26aulast%3DSchaeffer%26aufirst%3DP.%26aulast%3DCasellas%26aufirst%3DP.%26aulast%3DBourie%26aufirst%3DB.%26aulast%3DPili%26aufirst%3DR.%26aulast%3DIsaacs%26aufirst%3DJ.%26aulast%3DAtor%26aufirst%3DM.%26aulast%3DHudkins%26aufirst%3DR.%26aulast%3DVaught%26aufirst%3DJ.%26aulast%3DMallamo%26aufirst%3DJ.%26aulast%3DDionne%26aufirst%3DC.%26atitle%3DCEP-7055%253A%2520A%2520novel%252C%2520orally-active%2520pan%2520inhibitor%2520of%2520vascular%2520endothelial%2520growth%2520factor%2520receptor%2520tyrosine%2520kinases%2520with%2520potent%2520anti-angiogenic%2520activity%2520and%2520anti-tumor%2520efficacy%2520in%2520pre-clinical%2520models%26jtitle%3DCancer%2520Res.%26date%3D2003%26volume%3D63%26spage%3D5978%26epage%3D5991" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Becknell, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zulli, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angeles, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albom, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aimone, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robinson, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hudkins, R. L.</span><span> </span><span class="NLM_article-title">Novel C-3 N-urea, amide and carbamate dihydroindazolo[5,4-a]pyrrolo[3,4-c]carbazole analogs as potent TIE-2 and VEGF-R2 dual inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">5368</span><span class="NLM_x">â</span> <span class="NLM_lpage">5372</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2006&pages=5368-5372&author=N.+Becknellauthor=A.+L.+Zulliauthor=T.+S.+Angelesauthor=S.+Yangauthor=M.+Albomauthor=L.+D.+Aimoneauthor=C.+Robinsonauthor=H.+Changauthor=R.+L.+Hudkins&title=Novel+C-3+N-urea%2C+amide+and+carbamate+dihydroindazolo%5B5%2C4-a%5Dpyrrolo%5B3%2C4-c%5Dcarbazole+analogs+as+potent+TIE-2+and+VEGF-R2+dual+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBecknell%26aufirst%3DN.%26aulast%3DZulli%26aufirst%3DA.%2BL.%26aulast%3DAngeles%26aufirst%3DT.%2BS.%26aulast%3DYang%26aufirst%3DS.%26aulast%3DAlbom%26aufirst%3DM.%26aulast%3DAimone%26aufirst%3DL.%2BD.%26aulast%3DRobinson%26aufirst%3DC.%26aulast%3DChang%26aufirst%3DH.%26aulast%3DHudkins%26aufirst%3DR.%2BL.%26atitle%3DNovel%2520C-3%2520N-urea%252C%2520amide%2520and%2520carbamate%2520dihydroindazolo%255B5%252C4-a%255Dpyrrolo%255B3%252C4-c%255Dcarbazole%2520analogs%2520as%2520potent%2520TIE-2%2520and%2520VEGF-R2%2520dual%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2006%26volume%3D16%26spage%3D5368%26epage%3D5372" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit13b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Underiner, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruggeri, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aimone, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albom, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angeles, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hudkins, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunter, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Josef, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robinson, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weinberg, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zulli, A.</span><span> </span><span class="NLM_article-title">TIE-2/VEGF-R2 SAR and in vitro activity of C3-acyl and C3-oxo fused pyrrolodihydroindazolo-carbazole analogs</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">2368</span><span class="NLM_x">â</span> <span class="NLM_lpage">2373</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=2368-2373&author=T.+L.+Underinerauthor=B.+Ruggeriauthor=L.+A.+Aimoneauthor=M.+Albomauthor=T.+Angelesauthor=H.+Changauthor=R.+L.+Hudkinsauthor=K.+Hunterauthor=K.+Josefauthor=C.+Robinsonauthor=L.+Weinbergauthor=S.+Yangauthor=A.+Zulli&title=TIE-2%2FVEGF-R2+SAR+and+in+vitro+activity+of+C3-acyl+and+C3-oxo+fused+pyrrolodihydroindazolo-carbazole+analogs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DUnderiner%26aufirst%3DT.%2BL.%26aulast%3DRuggeri%26aufirst%3DB.%26aulast%3DAimone%26aufirst%3DL.%2BA.%26aulast%3DAlbom%26aufirst%3DM.%26aulast%3DAngeles%26aufirst%3DT.%26aulast%3DChang%26aufirst%3DH.%26aulast%3DHudkins%26aufirst%3DR.%2BL.%26aulast%3DHunter%26aufirst%3DK.%26aulast%3DJosef%26aufirst%3DK.%26aulast%3DRobinson%26aufirst%3DC.%26aulast%3DWeinberg%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DS.%26aulast%3DZulli%26aufirst%3DA.%26atitle%3DTIE-2%252FVEGF-R2%2520SAR%2520and%2520in%2520vitro%2520activity%2520of%2520C3-acyl%2520and%2520C3-oxo%2520fused%2520pyrrolodihydroindazolo-carbazole%2520analogs%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D2368%26epage%3D2373" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit13c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Dandu, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zulli, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bacon, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Underiner, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robinson, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miknyoczki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grobelny, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruggeri, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albom, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angeles, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aimone, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hudkins, R. L.</span><span> </span><span class="NLM_article-title">Design and synthesis of dihydroindazolo[5,4-a]pyrrolo[3,4-c]carbazole oximes as potent dual inhibitors of TIE-2 and VEGF-R2 receptor tyrosine kinases</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">1916</span><span class="NLM_x">â</span> <span class="NLM_lpage">1921</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=1916-1921&author=R.+Danduauthor=A.+L.+Zulliauthor=E.+R.+Baconauthor=T.+L.+Underinerauthor=C.+Robinsonauthor=H.+Changauthor=S.+Miknyoczkiauthor=J.+Grobelnyauthor=B.+Ruggeriauthor=S.+Yangauthor=M.+S.+Albomauthor=T.+Angelesauthor=L.+A.+Aimoneauthor=R.+L.+Hudkins&title=Design+and+synthesis+of+dihydroindazolo%5B5%2C4-a%5Dpyrrolo%5B3%2C4-c%5Dcarbazole+oximes+as+potent+dual+inhibitors+of+TIE-2+and+VEGF-R2+receptor+tyrosine+kinases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDandu%26aufirst%3DR.%26aulast%3DZulli%26aufirst%3DA.%2BL.%26aulast%3DBacon%26aufirst%3DE.%2BR.%26aulast%3DUnderiner%26aufirst%3DT.%2BL.%26aulast%3DRobinson%26aufirst%3DC.%26aulast%3DChang%26aufirst%3DH.%26aulast%3DMiknyoczki%26aufirst%3DS.%26aulast%3DGrobelny%26aufirst%3DJ.%26aulast%3DRuggeri%26aufirst%3DB.%26aulast%3DYang%26aufirst%3DS.%26aulast%3DAlbom%26aufirst%3DM.%2BS.%26aulast%3DAngeles%26aufirst%3DT.%26aulast%3DAimone%26aufirst%3DL.%2BA.%26aulast%3DHudkins%26aufirst%3DR.%2BL.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520dihydroindazolo%255B5%252C4-a%255Dpyrrolo%255B3%252C4-c%255Dcarbazole%2520oximes%2520as%2520potent%2520dual%2520inhibitors%2520of%2520TIE-2%2520and%2520VEGF-R2%2520receptor%2520tyrosine%2520kinases%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D1916%26epage%3D1921" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit13d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Hudkins, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zulli, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Underiner, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angeles, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aimone, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pauletti, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fedorov, E. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Almo, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fedorov, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruggeri, B. A.</span><span> </span><span class="NLM_article-title">8-THP-DHI Analogs as Potent Type I Dual TIE-2/VEGF-R2 receptor tyrosine kinase inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">3356</span><span class="NLM_x">â</span> <span class="NLM_lpage">3360</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=3356-3360&author=R.+L.+Hudkinsauthor=A.+L.+Zulliauthor=T.+L.+Underinerauthor=T.+S.+Angelesauthor=L.+D.+Aimoneauthor=S.+L.+Meyerauthor=D.+Paulettiauthor=H.+Changauthor=E.+V.+Fedorovauthor=S.+C.+Almoauthor=A.+A.+Fedorovauthor=B.+A.+Ruggeri&title=8-THP-DHI+Analogs+as+Potent+Type+I+Dual+TIE-2%2FVEGF-R2+receptor+tyrosine+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHudkins%26aufirst%3DR.%2BL.%26aulast%3DZulli%26aufirst%3DA.%2BL.%26aulast%3DUnderiner%26aufirst%3DT.%2BL.%26aulast%3DAngeles%26aufirst%3DT.%2BS.%26aulast%3DAimone%26aufirst%3DL.%2BD.%26aulast%3DMeyer%26aufirst%3DS.%2BL.%26aulast%3DPauletti%26aufirst%3DD.%26aulast%3DChang%26aufirst%3DH.%26aulast%3DFedorov%26aufirst%3DE.%2BV.%26aulast%3DAlmo%26aufirst%3DS.%2BC.%26aulast%3DFedorov%26aufirst%3DA.%2BA.%26aulast%3DRuggeri%26aufirst%3DB.%2BA.%26atitle%3D8-THP-DHI%2520Analogs%2520as%2520Potent%2520Type%2520I%2520Dual%2520TIE-2%252FVEGF-R2%2520receptor%2520tyrosine%2520kinase%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D3356%26epage%3D3360" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Tao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, C-H</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Josef, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hudkins, R. L.</span><span> </span><span class="NLM_article-title">Regiospecific synthesis of 12,13-dihydroindazolo[5,4-a]pyrrolo[3,4-c]carbazole-4-one</span> <span class="citation_source-journal">J. Heterocyclic Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">1185</span><span class="NLM_x">â</span> <span class="NLM_lpage">1189</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14a&amp;dbid=16&amp;doi=10.1021%2Fjm201449n&amp;key=10.1002%2Fjhet.200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14a&amp;dbid=32&amp;doi=10.1021%2Fjm201449n&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFSgsbfE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2009&pages=1185-1189&author=M.+Taoauthor=C-H+Parkauthor=K.+A.+Josefauthor=R.+L.+Hudkins&title=Regiospecific+synthesis+of+12%2C13-dihydroindazolo%5B5%2C4-a%5Dpyrrolo%5B3%2C4-c%5Dcarbazole-4-one"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14aR"><div class="casContent"><span class="casTitleNuber">14a</span><div class="casTitle"><span class="NLM_cas:atitle">Regioselective synthesis of 2-methyl-2,5,6,11,12,13-hexahydro 4H indazolo[5,4-a]pyrrolo[3,4-c]carbazole-4-ones</span></div><div class="casAuthors">Tao, Ming; Park, Chung Ho; Josef, Kurt; Hudkins, Robert L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Heterocyclic Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1185-1189</span>CODEN:
                <span class="NLM_cas:coden">JHTCAD</span>;
        ISSN:<span class="NLM_cas:issn">1943-5193</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">2-Methyl-2,5,6,11,12,13-hexahydro 4H indazolo[5,4-a]pyrrolo[3,4-c]carbazole-4-one was synthesized utilizing a regioselective Diels-Alder reaction with 5-(1H-indol-2-yl)-2-methyl-6,7-dihydro-2H-indazole and Et cis-Î²-cyanoacrylate.  Acetic acid and YtBr3 were the best solvent and catalyst, resp., for the regioselective Diels-Alder reaction.  The chem. was used to synthesize novel 8-pyrimidinyloxy-2,5,6,11,12,13-hexahydro 4H-indazolo[5,4-a]pyrrolo[3,4-c]carbazole-4-ones that were screened and found to be potent inhibitors of DLK.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcz-oWdHXigbVg90H21EOLACvtfcHk0lg8brGYoxNcWg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFSgsbfE&md5=8257f7767c1772a333dcd63c674619ff</span></div><a href="/servlet/linkout?suffix=cit14a&amp;dbid=16384&amp;doi=10.1002%2Fjhet.200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjhet.200%26sid%3Dliteratum%253Aachs%26aulast%3DTao%26aufirst%3DM.%26aulast%3DPark%26aufirst%3DC-H%26aulast%3DJosef%26aufirst%3DK.%2BA.%26aulast%3DHudkins%26aufirst%3DR.%2BL.%26atitle%3DRegiospecific%2520synthesis%2520of%252012%252C13-dihydroindazolo%255B5%252C4-a%255Dpyrrolo%255B3%252C4-c%255Dcarbazole-4-one%26jtitle%3DJ.%2520Heterocyclic%2520Chem.%26date%3D2009%26volume%3D46%26spage%3D1185%26epage%3D1189" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit14b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Reddy, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Josef, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bacon, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hudkins, R. L.</span><span> </span><span class="NLM_article-title">Regiospecific synthesis of 5-(1H-indol-2-yl)-1- and â2-methyl-6,7-dihydro-2H-indazole isomers</span> <span class="citation_source-journal">J. Heterocyclic Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">437</span><span class="NLM_x">â</span> <span class="NLM_lpage">440</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14b&amp;dbid=16&amp;doi=10.1021%2Fjm201449n&amp;key=10.1002%2Fjhet.5570440225" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2007&pages=437-440&author=D.+R.+Reddyauthor=M.+Taoauthor=K.+A.+Josefauthor=E.+R.+Baconauthor=R.+L.+Hudkins&title=Regiospecific+synthesis+of+5-%281H-indol-2-yl%29-1-+and+%E2%88%922-methyl-6%2C7-dihydro-2H-indazole+isomers"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14b&amp;dbid=16384&amp;doi=10.1002%2Fjhet.5570440225&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjhet.5570440225%26sid%3Dliteratum%253Aachs%26aulast%3DReddy%26aufirst%3DD.%2BR.%26aulast%3DTao%26aufirst%3DM.%26aulast%3DJosef%26aufirst%3DK.%2BA.%26aulast%3DBacon%26aufirst%3DE.%2BR.%26aulast%3DHudkins%26aufirst%3DR.%2BL.%26atitle%3DRegiospecific%2520synthesis%2520of%25205-%25281H-indol-2-yl%2529-1-%2520and%2520%25E2%2588%25922-methyl-6%252C7-dihydro-2H-indazole%2520isomers%26jtitle%3DJ.%2520Heterocyclic%2520Chem.%26date%3D2007%26volume%3D44%26spage%3D437%26epage%3D440" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit14c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Josef, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddy, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hudkins, R. L.</span><span> </span><span class="NLM_article-title">Structure determination of N-methyl-1,4,6,7-tetrahydro-5H-indazol-5-one</span> <span class="citation_source-journal">J. Heterocyclic. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">719</span><span class="NLM_x">â</span> <span class="NLM_lpage">722</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14c&amp;dbid=16&amp;doi=10.1021%2Fjm201449n&amp;key=10.1002%2Fjhet.5570430328" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14c&amp;dbid=32&amp;doi=10.1021%2Fjm201449n&amp;key=1%3ACAS%3A528%3ADC%252BD28XlvVaqu7k%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2006&pages=719-722&author=K.+A.+Josefauthor=D.+Reddyauthor=M.+Taoauthor=R.+L.+Hudkins&title=Structure+determination+of+N-methyl-1%2C4%2C6%2C7-tetrahydro-5H-indazol-5-one"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14cR"><div class="casContent"><span class="casTitleNuber">14c</span><div class="casTitle"><span class="NLM_cas:atitle">Structure determination of N-methyl-tetrahydro-5H-indazol-5-ones</span></div><div class="casAuthors">Josef, Kurt A.; Dandu, Reddeppareddy; Tao, Ming; Hudkins, Robert L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Heterocyclic Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">719-722</span>CODEN:
                <span class="NLM_cas:coden">JHTCAD</span>;
        ISSN:<span class="NLM_cas:issn">0022-152X</span>.
    
            (<span class="NLM_cas:orgname">HeteroCorporation</span>)
        </div><div class="casAbstract">This paper communicates the (regio) synthesis and a convenient NMR structural assignment method for N-methyltetrahydro-5H-indazol-5-one isomers.  The cyclization reaction of 7-(hydroxymethylene)-1,4-dioxaspiro[4,5]decan-8-one with methylhydrazine yields, after de-protection predominately the N(2) Me isomer.  Anal. of the product ratio and structural assignments are based on NMR data including NOE difference expts. and were subsequently confirmed with x-ray crystallog. (no data, mol. structure only).  These findings are in sharp contrast with the literature.  The exptl. conditions used to optimize the synthesis of the individual isomers are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYnAFoW0YzR7Vg90H21EOLACvtfcHk0ljXJPTJF0hj5g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XlvVaqu7k%253D&md5=18fd4f7e317b2e8de2b304b6ab6849c1</span></div><a href="/servlet/linkout?suffix=cit14c&amp;dbid=16384&amp;doi=10.1002%2Fjhet.5570430328&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjhet.5570430328%26sid%3Dliteratum%253Aachs%26aulast%3DJosef%26aufirst%3DK.%2BA.%26aulast%3DReddy%26aufirst%3DD.%26aulast%3DTao%26aufirst%3DM.%26aulast%3DHudkins%26aufirst%3DR.%2BL.%26atitle%3DStructure%2520determination%2520of%2520N-methyl-1%252C4%252C6%252C7-tetrahydro-5H-indazol-5-one%26jtitle%3DJ.%2520Heterocyclic.%2520Chem.%26date%3D2006%26volume%3D43%26spage%3D719%26epage%3D722" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit14d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Hudkins, R. L.; Zulli, A. L.; Reddy, D. R.; Gingrich, D. E.; Tao, M.; Becknell, N. C.; Diebold, J. L.; Underiner, T. L.</span><span> </span><span class="NLM_article-title">Preparation of Novel Fusedpyrrolocarbazoles for Treating or Preventing Angiogenesis or Angiogenesis Disorders</span>. US Patent US20050143442.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Hudkins%2C+R.+L.%3B+Zulli%2C+A.+L.%3B+Reddy%2C+D.+R.%3B+Gingrich%2C+D.+E.%3B+Tao%2C+M.%3B+Becknell%2C+N.+C.%3B+Diebold%2C+J.+L.%3B+Underiner%2C+T.+L.+Preparation+of+Novel+Fusedpyrrolocarbazoles+for+Treating+or+Preventing+Angiogenesis+or+Angiogenesis+Disorders.+US+Patent+US20050143442."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHudkins%26aufirst%3DR.%2BL.%26atitle%3DPreparation%2520of%2520Novel%2520Fusedpyrrolocarbazoles%2520for%2520Treating%2520or%2520Preventing%2520Angiogenesis%2520or%2520Angiogenesis%2520Disorders" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit14e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Hudkins, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diebold, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Josef, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angeles, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aimone, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Husten, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ator, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holskin, B. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Durkin, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fedorov, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fedorov, E. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Almo, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathiasen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bozyczko-Coyne, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saporito, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mallamo, J. P.</span><span> </span><span class="NLM_article-title">Mixed lineage kinase 1 (MLK1) and mixed lineage kinase 3 (MLK3) subtype selective dihydronaphthyl[3,4-a]pyrrolo[3,4-c]carbazole-5-ones: Optimization, mixed lineage kinase 1 crystallography and oral in vivo activity in 1-methyl-4-phenyltetrahydropyridine models</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">5680</span><span class="NLM_x">â</span> <span class="NLM_lpage">5689</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm8005838" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=5680-5689&author=R.+L.+Hudkinsauthor=J.+L.+Dieboldauthor=M.+Taoauthor=K.+A.+Josefauthor=C.+H.+Parkauthor=T.+S.+Angelesauthor=L.+D.+Aimoneauthor=J.+Hustenauthor=M.+A.+Atorauthor=S.+L.+Meyerauthor=B.+P.+Holskinauthor=J.+T.+Durkinauthor=A.+A.+Fedorovauthor=E.+V.+Fedorovauthor=S.+C.+Almoauthor=J.+Mathiasenauthor=D.+Bozyczko-Coyneauthor=M.+S.+Saporitoauthor=J.+P.+Mallamo&title=Mixed+lineage+kinase+1+%28MLK1%29+and+mixed+lineage+kinase+3+%28MLK3%29+subtype+selective+dihydronaphthyl%5B3%2C4-a%5Dpyrrolo%5B3%2C4-c%5Dcarbazole-5-ones%3A+Optimization%2C+mixed+lineage+kinase+1+crystallography+and+oral+in+vivo+activity+in+1-methyl-4-phenyltetrahydropyridine+models"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14e&amp;dbid=16384&amp;doi=10.1021%2Fjm8005838&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm8005838%26sid%3Dliteratum%253Aachs%26aulast%3DHudkins%26aufirst%3DR.%2BL.%26aulast%3DDiebold%26aufirst%3DJ.%2BL.%26aulast%3DTao%26aufirst%3DM.%26aulast%3DJosef%26aufirst%3DK.%2BA.%26aulast%3DPark%26aufirst%3DC.%2BH.%26aulast%3DAngeles%26aufirst%3DT.%2BS.%26aulast%3DAimone%26aufirst%3DL.%2BD.%26aulast%3DHusten%26aufirst%3DJ.%26aulast%3DAtor%26aufirst%3DM.%2BA.%26aulast%3DMeyer%26aufirst%3DS.%2BL.%26aulast%3DHolskin%26aufirst%3DB.%2BP.%26aulast%3DDurkin%26aufirst%3DJ.%2BT.%26aulast%3DFedorov%26aufirst%3DA.%2BA.%26aulast%3DFedorov%26aufirst%3DE.%2BV.%26aulast%3DAlmo%26aufirst%3DS.%2BC.%26aulast%3DMathiasen%26aufirst%3DJ.%26aulast%3DBozyczko-Coyne%26aufirst%3DD.%26aulast%3DSaporito%26aufirst%3DM.%2BS.%26aulast%3DMallamo%26aufirst%3DJ.%2BP.%26atitle%3DMixed%2520lineage%2520kinase%25201%2520%2528MLK1%2529%2520and%2520mixed%2520lineage%2520kinase%25203%2520%2528MLK3%2529%2520subtype%2520selective%2520dihydronaphthyl%255B3%252C4-a%255Dpyrrolo%255B3%252C4-c%255Dcarbazole-5-ones%253A%2520Optimization%252C%2520mixed%2520lineage%2520kinase%25201%2520crystallography%2520and%2520oral%2520in%2520vivo%2520activity%2520in%25201-methyl-4-phenyltetrahydropyridine%2520models%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D5680%26epage%3D5689" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">van Erp, N. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gelderblom, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guchelaar, H. J.</span><span> </span><span class="NLM_article-title">Clinical pharmacokinetics of tyrosine kinase inhibitors</span> <span class="citation_source-journal">Cancer Treat. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">692</span><span class="NLM_x">â</span> <span class="NLM_lpage">706</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Fjm201449n&amp;key=10.1016%2Fj.ctrv.2009.08.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Fjm201449n&amp;key=19733976" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Fjm201449n&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsVGlsb3F" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2009&pages=692-706&author=N.+P.+van+Erpauthor=H.+Gelderblomauthor=H.+J.+Guchelaar&title=Clinical+pharmacokinetics+of+tyrosine+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical pharmacokinetics of tyrosine kinase inhibitors</span></div><div class="casAuthors">van Erp, Nielka P.; Gelderblom, Hans; Guchelaar, Henk-Jan</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Treatment Reviews</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">692-706</span>CODEN:
                <span class="NLM_cas:coden">CTREDJ</span>;
        ISSN:<span class="NLM_cas:issn">0305-7372</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Summary: In the recent years, eight tyrosine kinase inhibitors (TKIs) have been approved for cancer treatment and numerous are under investigation.  These drugs are rationally designed to target specific tyrosine kinases that are mutated and/or over-expressed in cancer tissues.  Post marketing study commitments have been made upon (accelerated) approval such as addnl. pharmacokinetic studies in patients with renal- or hepatic impairment, in children, addnl. interactions studies and studies on the relative or abs. bioavailability.  Therefore, much information will emerge on the pharmacokinetic behavior of these drugs after their approval.  In the present manuscript, the pharmacokinetic characteristics; absorption, distribution, metab. and excretion (ADME), of the available TKIs are reviewed.  Results from addnl. studies on the effect of drug transporters and drug-drug interactions have been incorporated.  Overall, the TKIs reach their max. plasma levels relatively fast; have an unknown abs. bioavailability, are extensively distributed and highly protein bound.  The drugs are primarily metabolized by cytochrome P 450 (CYP) 3A4 with other CYP-enzymes playing a secondary role.  They are predominantly excreted with the feces and only a minor fraction is eliminated with the urine.  All TKIs appear to be transported by the efflux ATP binding-cassette transports B1 and G2.  Addnl. these drugs can inhibit some of their own metabolizing enzymes and transporters making steady-state metab. and drug-drug interactions both complex and unpredictable.  By understanding the pharmacokinetic profile of these drugs and their similarities, factors that influence drug exposure will be better recognized and this knowledge may be used to limit sub- or supra-therapeutic drug exposure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGVDDL-swrRLVg90H21EOLACvtfcHk0lj2urtKpWbZQA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsVGlsb3F&md5=12640303503889c3b267a21915fb1ce6</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.ctrv.2009.08.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ctrv.2009.08.004%26sid%3Dliteratum%253Aachs%26aulast%3Dvan%2BErp%26aufirst%3DN.%2BP.%26aulast%3DGelderblom%26aufirst%3DH.%26aulast%3DGuchelaar%26aufirst%3DH.%2BJ.%26atitle%3DClinical%2520pharmacokinetics%2520of%2520tyrosine%2520kinase%2520inhibitors%26jtitle%3DCancer%2520Treat.%2520Rev.%26date%3D2009%26volume%3D35%26spage%3D692%26epage%3D706" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Fedorov, A. A.; Fedorov, E. V.; Pauletti, D.; Meyer, S. L.; Hudkins, R. L.; Almo, S. C.</span><span> </span><span class="NLM_article-title">Crystal structure of cytoplasmic kinase domain of TIE-2 complexed with inhibitor CEP-11207</span>. Protein Data Bank, 3L8P;<span class="NLM_x"> </span><span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=A.+A.+Fedorov&author=E.+V.+Fedorov&author=D.+Pauletti&author=S.+L.+Meyer&author=R.+L.+Hudkins&author=S.+C.+Almo&title=Crystal+structure+of+cytoplasmic+kinase+domain+of+TIE-2+complexed+with+inhibitor+CEP-11207"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DFedorov%26aufirst%3DA.%2BA.%26atitle%3DCrystal%2520structure%2520of%2520cytoplasmic%2520kinase%2520domain%2520of%2520TIE-2%2520complexed%2520with%2520inhibitor%2520CEP-11207%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit16b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Traxler, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furet, P.</span><span> </span><span class="NLM_article-title">Strategies toward the design of novel and selective protein tyrosine kinase inhibitors</span> <span class="citation_source-journal">Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">82</span><span class="NLM_x">, </span> <span class="NLM_fpage">195</span><span class="NLM_x">â</span> <span class="NLM_lpage">206</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16b&amp;dbid=16&amp;doi=10.1021%2Fjm201449n&amp;key=10.1016%2FS0163-7258%2898%2900044-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16b&amp;dbid=8&amp;doi=10.1021%2Fjm201449n&amp;key=10454197" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16b&amp;dbid=32&amp;doi=10.1021%2Fjm201449n&amp;key=1%3ACAS%3A528%3ADyaK1MXjvFOht7Y%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=1999&pages=195-206&author=P.+Traxlerauthor=P.+Furet&title=Strategies+toward+the+design+of+novel+and+selective+protein+tyrosine+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16bR"><div class="casContent"><span class="casTitleNuber">16b</span><div class="casTitle"><span class="NLM_cas:atitle">Strategies toward the design of novel and selective protein tyrosine kinase inhibitors</span></div><div class="casAuthors">Traxler, Peter; Furet, Pascal</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">82</span>
        (<span class="NLM_cas:issue">2-3</span>),
    <span class="NLM_cas:pages">195-206</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">A review with 37 refs.  Protein tyrosine kinases play a fundamental role in signal transduction pathways.  Deregulated tyrosine kinase activity has been obsd. in many proliferative diseases (e.g., cancer, psoriasis, restenosis, etc.).  Tyrosine kinases are, therefore, attractive targets for the design of new therapeutic agents against cancer.  We have built up a pharmacophore model of the ATP-binding site of the epidermal growth factor receptor (EGFR) kinase and used it for the rational design of kinase inhibitors.  Several examples of the successful use of this model are presented in this review.  Amongst these, 4-substituted-pyrrolo[2,3-d]pyrimidines, a new class of highly potent and selective inhibitors of the EGFR kinase, have been identified and further optimized.  The most active derivs. inhibited the EGFR tyrosine kinase with IC50 values between 1 and 5 nM.  In EGF-dependent cellular systems, tyrosine phosphorylation, as well as c-fos mRNA expression, was inhibited with similar IC50 values.  Further successful application of this pharmacophore model led to the identification and optimization of phenylamino-pyrazolo[4,3-d]pyrimidines and substituted isoflavones and quinolones, other classes of potent, selective, and ATP competitive EGFR kinase inhibitors with IC50 values in the low nanomolar range.  Structure-activity relationships of both classes are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzTOVAYLwK77Vg90H21EOLACvtfcHk0lj2urtKpWbZQA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXjvFOht7Y%253D&md5=26e5ed297e37b0cb188a0676e5b27f5b</span></div><a href="/servlet/linkout?suffix=cit16b&amp;dbid=16384&amp;doi=10.1016%2FS0163-7258%2898%2900044-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0163-7258%252898%252900044-8%26sid%3Dliteratum%253Aachs%26aulast%3DTraxler%26aufirst%3DP.%26aulast%3DFuret%26aufirst%3DP.%26atitle%3DStrategies%2520toward%2520the%2520design%2520of%2520novel%2520and%2520selective%2520protein%2520tyrosine%2520kinase%2520inhibitors%26jtitle%3DPharmacol.%2520Ther.%26date%3D1999%26volume%3D82%26spage%3D195%26epage%3D206" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit16c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Backes, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeck, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Felber, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klebl, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MÃ¼ller, G.</span><span> </span><span class="NLM_article-title">Small-molecule inhibitors binding to protein kinases. Part I: exceptions from the traditional pharmacophore approach of type I inhibition</span> <span class="citation_source-journal">Expert Opin. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">1409</span><span class="NLM_x">â</span> <span class="NLM_lpage">1425</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16c&amp;dbid=16&amp;doi=10.1021%2Fjm201449n&amp;key=10.1517%2F17460440802579975" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16c&amp;dbid=8&amp;doi=10.1021%2Fjm201449n&amp;key=23506106" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16c&amp;dbid=32&amp;doi=10.1021%2Fjm201449n&amp;key=1%3ACAS%3A528%3ADC%252BD1MXkvFCmtrk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2008&pages=1409-1425&author=A.+C.+Backesauthor=B.+Zeckauthor=B.+Felberauthor=B.+Kleblauthor=G.+M%C3%BCller&title=Small-molecule+inhibitors+binding+to+protein+kinases.+Part+I%3A+exceptions+from+the+traditional+pharmacophore+approach+of+type+I+inhibition"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16cR"><div class="casContent"><span class="casTitleNuber">16c</span><div class="casTitle"><span class="NLM_cas:atitle">Small-molecule inhibitors binding to protein kinases. Part I: exceptions from the traditional pharmacophore approach of type I inhibition</span></div><div class="casAuthors">Backes, A. C.; Zech, B.; Felber, B.; Klebl, B.; Mueller, G.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Discovery</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1409-1425</span>CODEN:
                <span class="NLM_cas:coden">EODDBX</span>;
        ISSN:<span class="NLM_cas:issn">1746-0441</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Background: Protein kinases are essential enzymes propagating cellular signal transduction processes and consequently have emerged as central targets for drug discovery against a wide range of diseases with a strong historical focus on oncol. disorders.  A large no. of high-resoln. crystal structures of various ATP-competitive inhibitors in complex with their target protein kinases have been detd. and present a wealth of detailed information about binding modes, inhibition mechanisms and assocd. structure-activity relationships of target-bound small mols.  Objective: In this first part of a two-part review, exceptions to the type I binding mode of kinase inhibitors that follow the traditional pharmacophore model are discussed, highlighting unexpected structural features.  Methods: The scope of this review covers published crystal structures of protein kinases in complex with various ligands.  Results: Structural parameters of both inhibitors and kinases contribute to the complexity of designing kinase inhibitors.  The continued study of high-resoln. structures of ligand-enzyme complexes in combination with a more dynamic understanding of accessible conformational states of the target proteins, supported by detailed kinetic studies, will in the long-term help in developing new low-mol. wt. kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgxVqECguWJbVg90H21EOLACvtfcHk0lj2urtKpWbZQA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXkvFCmtrk%253D&md5=705fa7e531ceced90ed86d0d2658766e</span></div><a href="/servlet/linkout?suffix=cit16c&amp;dbid=16384&amp;doi=10.1517%2F17460440802579975&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17460440802579975%26sid%3Dliteratum%253Aachs%26aulast%3DBackes%26aufirst%3DA.%2BC.%26aulast%3DZeck%26aufirst%3DB.%26aulast%3DFelber%26aufirst%3DB.%26aulast%3DKlebl%26aufirst%3DB.%26aulast%3DM%25C3%25BCller%26aufirst%3DG.%26atitle%3DSmall-molecule%2520inhibitors%2520binding%2520to%2520protein%2520kinases.%2520Part%2520I%253A%2520exceptions%2520from%2520the%2520traditional%2520pharmacophore%2520approach%2520of%2520type%2520I%2520inhibition%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2008%26volume%3D3%26spage%3D1409%26epage%3D1425" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Vailhe, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vittet, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feige, J.-J.</span><span> </span><span class="NLM_article-title">In vitro models of vasculogenesis and angiogenesis</span> <span class="citation_source-journal">Lab. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">81</span><span class="NLM_x">, </span> <span class="NLM_fpage">439</span><span class="NLM_x">â</span> <span class="NLM_lpage">452</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=81&publication_year=2001&pages=439-452&author=B.+Vailheauthor=D.+Vittetauthor=J.-J.+Feige&title=In+vitro+models+of+vasculogenesis+and+angiogenesis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVailhe%26aufirst%3DB.%26aulast%3DVittet%26aufirst%3DD.%26aulast%3DFeige%26aufirst%3DJ.-J.%26atitle%3DIn%2520vitro%2520models%2520of%2520vasculogenesis%2520and%2520angiogenesis%26jtitle%3DLab.%2520Invest.%26date%3D2001%26volume%3D81%26spage%3D439%26epage%3D452" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit17b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Ilan, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mahooti, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Madri, J. A.</span><span> </span><span class="NLM_article-title">Distinct signal transduction pathways are utilized during the tube formation and survival phases of <i>in vitro</i> angiogenesis</span> <span class="citation_source-journal">J. Cell Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">111</span><span class="NLM_x">, </span> <span class="NLM_fpage">3621</span><span class="NLM_x">â</span> <span class="NLM_lpage">3631</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=8&amp;doi=10.1021%2Fjm201449n&amp;key=9819353" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=32&amp;doi=10.1021%2Fjm201449n&amp;key=1%3ACAS%3A528%3ADyaK1MXmtlKnsg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=1998&pages=3621-3631&author=N.+Ilanauthor=S.+Mahootiauthor=J.+A.+Madri&title=Distinct+signal+transduction+pathways+are+utilized+during+the+tube+formation+and+survival+phases+of+in+vitro+angiogenesis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17bR"><div class="casContent"><span class="casTitleNuber">17b</span><div class="casTitle"><span class="NLM_cas:atitle">Distinct signal transduction pathways are utilized during the tube formation and survival phases of in vitro angiogenesis</span></div><div class="casAuthors">Ilan, Neta; Mahooti, Sepi; Madri, Joseph A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cell Science</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">3621-3631</span>CODEN:
                <span class="NLM_cas:coden">JNCSAI</span>;
        ISSN:<span class="NLM_cas:issn">0021-9533</span>.
    
            (<span class="NLM_cas:orgname">Company of Biologists Ltd.</span>)
        </div><div class="casAbstract">Angiogenesis, the formation of new blood vessels from preexisting ones, occurs during development, wound healing and cancer and involves stages that orchestrate a network of cooperative interactions.  Peptide growth factors and extracellular matrix (ECM) components are two major groups of angiogenesis mediators.  Among the different ECM proteins, collagens have been well-assocd. with in vivo angiogenesis.  Using human umbilical vein endothelial cells (HUVEC) grown in 3-D collagen gels the authors show that: (1) HUVEC do not survive well in 3-D collagen gels due to rapid induction of apoptosis.  (2) VEGF, a potent in vivo angiogenic factor, fails to induce tube formation.  (3) PMA was effective in inducing tube formation and survival in HUVEC dispersed in 3-D collagen gels, activating MAP kinase, phosphoinositide 3-OH kinase (PI-3-kinase) and Akt/PKB (protein kinase B) pathways.  (4) VEGF was effective in preventing PMA-induced tube-like structure regression after PMA-withdrawal by activating the mitogen activated protein kinase (MAPK), rather than the Akt/PKB, signaling pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqr1l6sVhNXLVg90H21EOLACvtfcHk0lgkKB-83qhtXw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXmtlKnsg%253D%253D&md5=48274561f8df6dfe819caf4c83476a10</span></div><a href="/servlet/linkout?suffix=cit17b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DIlan%26aufirst%3DN.%26aulast%3DMahooti%26aufirst%3DS.%26aulast%3DMadri%26aufirst%3DJ.%2BA.%26atitle%3DDistinct%2520signal%2520transduction%2520pathways%2520are%2520utilized%2520during%2520the%2520tube%2520formation%2520and%2520survival%2520phases%2520of%2520in%2520vitro%2520angiogenesis%26jtitle%3DJ.%2520Cell%2520Sci.%26date%3D1998%26volume%3D111%26spage%3D3621%26epage%3D3631" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit17c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Brown, K.; J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maynes, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bezos, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maguire, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ford, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parish, C. R.</span><span> </span><span class="NLM_article-title">A novel <i>in vitro</i> assay for human angiogenesis</span> <span class="citation_source-journal">Lab. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">75</span><span class="NLM_x">, </span> <span class="NLM_fpage">539</span><span class="NLM_x">â</span> <span class="NLM_lpage">555</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=1996&pages=539-555&author=K.%3B+J.+Brownauthor=S.+F.+Maynesauthor=A.+Bezosauthor=D.+J.+Maguireauthor=M.+D.+Fordauthor=C.+R.+Parish&title=A+novel+in+vitro+assay+for+human+angiogenesis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBrown%26aufirst%3DK.%253B%2BJ.%26aulast%3DMaynes%26aufirst%3DS.%2BF.%26aulast%3DBezos%26aufirst%3DA.%26aulast%3DMaguire%26aufirst%3DD.%2BJ.%26aulast%3DFord%26aufirst%3DM.%2BD.%26aulast%3DParish%26aufirst%3DC.%2BR.%26atitle%3DA%2520novel%2520in%2520vitro%2520assay%2520for%2520human%2520angiogenesis%26jtitle%3DLab.%2520Invest.%26date%3D1996%26volume%3D75%26spage%3D539%26epage%3D555" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit17d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Nicosia, R. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hazelton, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qian, X.</span><span> </span><span class="NLM_article-title">Endogenous regulation of angiogenesis in the rat aorta model. Role of vascular endothelial growth factor</span> <span class="citation_source-journal">Am. J. Pathol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">151</span><span class="NLM_x">, </span> <span class="NLM_fpage">1379</span><span class="NLM_x">â</span> <span class="NLM_lpage">1386</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17d&amp;dbid=8&amp;doi=10.1021%2Fjm201449n&amp;key=9358764" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17d&amp;dbid=32&amp;doi=10.1021%2Fjm201449n&amp;key=1%3ACAS%3A528%3ADyaK2sXntlOktrw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=151&publication_year=1997&pages=1379-1386&author=R.+F.+Nicosiaauthor=Y.+J.+Linauthor=D.+Hazeltonauthor=X.+Qian&title=Endogenous+regulation+of+angiogenesis+in+the+rat+aorta+model.+Role+of+vascular+endothelial+growth+factor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17dR"><div class="casContent"><span class="casTitleNuber">17d</span><div class="casTitle"><span class="NLM_cas:atitle">Endogenous regulation of angiogenesis in the rat aorta model: role of vascular endothelial growth factor</span></div><div class="casAuthors">Nicosia, Roberto F.; Lin, Yuzhong J.; Hazelton, Darcie; Qian, Xiaohua</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Pathology</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">151</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1379-1386</span>CODEN:
                <span class="NLM_cas:coden">AJPAA4</span>;
        ISSN:<span class="NLM_cas:issn">0002-9440</span>.
    
            (<span class="NLM_cas:orgname">American Society for Investigative Pathology</span>)
        </div><div class="casAbstract">The purpose of this study was to investigate the role of vascular endothelial growth factor (VEGF) in the rat aorta model of angiogenesis.  Freshly cut aortic rings generated microvascular outgrowths in serum-free collagen gel culture.  Angiogenesis was reduced to 10% when the explants were embedded in collagen 10 to 14 days after excision from the animal.  Immunochem. studies of conditioned medium demonstrated secretion of VEGF by the aortic cultures.  Levels of VEGF decreased during the second week of culture when the explants became quiescent and microvessels stopped growing.  Treatment of quiescent aortic rings with exogenous VEGF stimulated angiogenesis and restored microvascular growth to values obsd. in cultures of freshly cut explants.  Reverse transcriptase polymerase chain reaction of vasoformative collagen gel cultures of rat aorta demonstrated the expression of the alternatively spliced isoforms VEGF165, VEGF189, and the high-affinity VEGF receptor flk-1.  Reverse transcriptase-polymerase chain reaction of rat aorta-derived cell strains confirmed the presence of VEGF165 and VEGF189 in endothelial cells, smooth muscle cells, and fibroblasts.  The flk-1 receptor was expressed by endothelial cells but not by fibroblasts or smooth muscle cells, which is consistent with the endothelial target specificity of VEGF.  The spontaneous angiogenic response of freshly cut aortic rings was inhibited by 70% with a neutralizing antibody against VEGF, whereas nonimmune IgG had no effect.  These findings provide evidence for a VEGF-mediated autocrine/paracrine regulation of angiogenesis in the rat aorta model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGod6ZyQKv01arVg90H21EOLACvtfcHk0lgkKB-83qhtXw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXntlOktrw%253D&md5=069671e4eaa9e15c67ce312a953c4a26</span></div><a href="/servlet/linkout?suffix=cit17d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNicosia%26aufirst%3DR.%2BF.%26aulast%3DLin%26aufirst%3DY.%2BJ.%26aulast%3DHazelton%26aufirst%3DD.%26aulast%3DQian%26aufirst%3DX.%26atitle%3DEndogenous%2520regulation%2520of%2520angiogenesis%2520in%2520the%2520rat%2520aorta%2520model.%2520Role%2520of%2520vascular%2520endothelial%2520growth%2520factor%26jtitle%3DAm.%2520J.%2520Pathol.%26date%3D1997%26volume%3D151%26spage%3D1379%26epage%3D1386" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1a','cit1b','cit1c','cit1d'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5a','cit5b'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8a','cit8b','cit8c','cit8d','cit8e','cit8f'],'ref9':['cit9a','cit9b','cit9c'],'ref10':['cit10a','cit10b'],'ref11':['cit11a','cit11b','cit11c','cit11d','cit11e'],'ref12':['cit12a','cit12b'],'ref13':['cit13a','cit13b','cit13c','cit13d'],'ref14':['cit14a','cit14b','cit14c','cit14d','cit14e'],'ref15':['cit15'],'ref16':['cit16a','cit16b','cit16c'],'ref17':['cit17a','cit17b','cit17c','cit17d']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 30 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nathanyal J.  Truax</span>, <span class="hlFld-ContribAuthor ">Fernando  Banales Mejia</span>, <span class="hlFld-ContribAuthor ">Deborah O.  Kwansare</span>, <span class="hlFld-ContribAuthor ">Megan M.  Lafferty</span>, <span class="hlFld-ContribAuthor ">Maeve H.  Kean</span>, and <span class="hlFld-ContribAuthor ">Erin T.  Pelkey</span>  . </span><span class="cited-content_cbyCitation_article-title">Synthesis of Benzo[a]carbazoles and an Indolo[2,3-a]carbazole from 3-Aryltetramic Acids. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2016,</strong> <em>81 </em>
                                    (15)
                                     , 6808-6815. <a href="https://doi.org/10.1021/acs.joc.6b01072" title="DOI URL">https://doi.org/10.1021/acs.joc.6b01072</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.6b01072&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.6b01072%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DSynthesis%252Bof%252BBenzo%25255Ba%25255Dcarbazoles%252Band%252Ban%252BIndolo%25255B2%25252C3-a%25255Dcarbazole%252Bfrom%252B3-Aryltetramic%252BAcids%26aulast%3DTruax%26aufirst%3DNathanyal%2BJ.%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D07052016%26date%3D15072016%26date%3D05082016%26date%3D08072016%26volume%3D81%26issue%3D15%26spage%3D6808%26epage%3D6815" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Peichen  Pan</span>, <span class="hlFld-ContribAuthor ">Sheng  Tian</span>, <span class="hlFld-ContribAuthor ">Huiyong  Sun</span>, <span class="hlFld-ContribAuthor ">Xiaotian  Kong</span>, <span class="hlFld-ContribAuthor ">Wenfang  Zhou</span>, <span class="hlFld-ContribAuthor ">Dan  Li</span>, <span class="hlFld-ContribAuthor ">Youyong  Li</span>, and <span class="hlFld-ContribAuthor ">Tingjun  Hou</span>  . </span><span class="cited-content_cbyCitation_article-title">Identification and Preliminary SAR Analysis of Novel Type-I Inhibitors of TIE-2 via Structure-Based Virtual Screening and Biological Evaluation in in vitro Models. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2015,</strong> <em>55 </em>
                                    (12)
                                     , 2693-2704. <a href="https://doi.org/10.1021/acs.jcim.5b00576" title="DOI URL">https://doi.org/10.1021/acs.jcim.5b00576</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jcim.5b00576&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jcim.5b00576%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DIdentification%252Band%252BPreliminary%252BSAR%252BAnalysis%252Bof%252BNovel%252BType-I%252BInhibitors%252Bof%252BTIE-2%252Bvia%252BStructure-Based%252BVirtual%252BScreening%252Band%252BBiological%252BEvaluation%252Bin%252Bin%252Bvitro%252BModels%26aulast%3DPan%26aufirst%3DPeichen%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D18092015%26date%3D15122015%26date%3D28122015%26date%3D30112015%26volume%3D55%26issue%3D12%26spage%3D2693%26epage%3D2704" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Francesca  Musumeci</span>, <span class="hlFld-ContribAuthor ">Marco  Radi</span>, <span class="hlFld-ContribAuthor ">Chiara  Brullo</span>, and <span class="hlFld-ContribAuthor ">Silvia  Schenone</span>  . </span><span class="cited-content_cbyCitation_article-title">Vascular Endothelial Growth Factor (VEGF) Receptors: Drugs and New Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2012,</strong> <em>55 </em>
                                    (24)
                                     , 10797-10822. <a href="https://doi.org/10.1021/jm301085w" title="DOI URL">https://doi.org/10.1021/jm301085w</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm301085w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm301085w%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DVascular%252BEndothelial%252BGrowth%252BFactor%252B%252528VEGF%252529%252BReceptors%25253A%252BDrugs%252Band%252BNew%252BInhibitors%26aulast%3DMusumeci%26aufirst%3DFrancesca%26date%3D2012%26date%3D2012%26date%3D2012%26date%3D25072012%26date%3D06112012%26date%3D27122012%26date%3D25102012%26volume%3D55%26issue%3D24%26spage%3D10797%26epage%3D10822" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yuanyuan  Qiao</span>, <span class="hlFld-ContribAuthor ">Jae Eun  Choi</span>, <span class="hlFld-ContribAuthor ">Jean C.  Tien</span>, <span class="hlFld-ContribAuthor ">Stephanie A.  Simko</span>, <span class="hlFld-ContribAuthor ">Thekkelnaycke  Rajendiran</span>, <span class="hlFld-ContribAuthor ">Josh N.  Vo</span>, <span class="hlFld-ContribAuthor ">Andrew D.  Delekta</span>, <span class="hlFld-ContribAuthor ">Lisha  Wang</span>, <span class="hlFld-ContribAuthor ">Lanbo  Xiao</span>, <span class="hlFld-ContribAuthor ">Nathan B.  Hodge</span>, <span class="hlFld-ContribAuthor ">Parth  Desai</span>, <span class="hlFld-ContribAuthor ">Sergio  Mendoza</span>, <span class="hlFld-ContribAuthor ">Kristin  Juckette</span>, <span class="hlFld-ContribAuthor ">Alice  Xu</span>, <span class="hlFld-ContribAuthor ">Tanu  Soni</span>, <span class="hlFld-ContribAuthor ">Fengyun  Su</span>, <span class="hlFld-ContribAuthor ">Rui  Wang</span>, <span class="hlFld-ContribAuthor ">Xuhong  Cao</span>, <span class="hlFld-ContribAuthor ">Jiali  Yu</span>, <span class="hlFld-ContribAuthor ">Ilona  Kryczek</span>, <span class="hlFld-ContribAuthor ">Xiao-Ming  Wang</span>, <span class="hlFld-ContribAuthor ">Xiaoju  Wang</span>, <span class="hlFld-ContribAuthor ">Javed  Siddiqui</span>, <span class="hlFld-ContribAuthor ">Zhen  Wang</span>, <span class="hlFld-ContribAuthor ">AmÃ©lie  Bernard</span>, <span class="hlFld-ContribAuthor ">Ester  Fernandez-Salas</span>, <span class="hlFld-ContribAuthor ">Nora M.  Navone</span>, <span class="hlFld-ContribAuthor ">Stephanie J.  Ellison</span>, <span class="hlFld-ContribAuthor ">Ke  Ding</span>, <span class="hlFld-ContribAuthor ">Eeva-Liisa  Eskelinen</span>, <span class="hlFld-ContribAuthor ">Elisabeth I.  Heath</span>, <span class="hlFld-ContribAuthor ">Daniel J.  Klionsky</span>, <span class="hlFld-ContribAuthor ">Weiping  Zou</span>, <span class="hlFld-ContribAuthor ">Arul M.  Chinnaiyan</span>. </span><span class="cited-content_cbyCitation_article-title">Autophagy inhibition by targeting PIKfyve potentiates response to immune checkpoint blockade in prostate cancer. </span><span class="cited-content_cbyCitation_journal-name">Nature Cancer</span><span> <strong>2021,</strong> <em>34 </em><a href="https://doi.org/10.1038/s43018-021-00237-1" title="DOI URL">https://doi.org/10.1038/s43018-021-00237-1</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s43018-021-00237-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs43018-021-00237-1%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%2520Cancer%26atitle%3DAutophagy%252Binhibition%252Bby%252Btargeting%252BPIKfyve%252Bpotentiates%252Bresponse%252Bto%252Bimmune%252Bcheckpoint%252Bblockade%252Bin%252Bprostate%252Bcancer%26aulast%3DQiao%26aufirst%3DYuanyuan%26date%3D2021%26date%3D2021%26volume%3D34" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Neha  Upadhyay</span>, <span class="hlFld-ContribAuthor ">Kalpana  Tilekar</span>, <span class="hlFld-ContribAuthor ">Sabreena  Safuan</span>, <span class="hlFld-ContribAuthor ">Alan P.  Kumar</span>, <span class="hlFld-ContribAuthor ">Jimmy  Stalin</span>, <span class="hlFld-ContribAuthor ">Curzio  Ruegg</span>, <span class="hlFld-ContribAuthor ">Ramaa C S</span>. </span><span class="cited-content_cbyCitation_article-title">Recent Antiâangiogenic Drug Discovery Efforts To Combat Cancer. </span><span class="cited-content_cbyCitation_journal-name">ChemistrySelect</span><span> <strong>2021,</strong> <em>6 </em>
                                    (23)
                                     , 5689-5700. <a href="https://doi.org/10.1002/slct.202101792" title="DOI URL">https://doi.org/10.1002/slct.202101792</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/slct.202101792&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fslct.202101792%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistrySelect%26atitle%3DRecent%252BAnti%2525E2%252580%252590angiogenic%252BDrug%252BDiscovery%252BEfforts%252BTo%252BCombat%252BCancer%26aulast%3DUpadhyay%26aufirst%3DNeha%26date%3D2021%26date%3D2021%26volume%3D6%26issue%3D23%26spage%3D5689%26epage%3D5700" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sravani  Sana</span>, <span class="hlFld-ContribAuthor ">Velma Ganga  Reddy</span>, <span class="hlFld-ContribAuthor ">Sonal  Bhandari</span>, <span class="hlFld-ContribAuthor ">T. Srinivasa  Reddy</span>, <span class="hlFld-ContribAuthor ">Ramya  Tokala</span>, <span class="hlFld-ContribAuthor ">Akash P.  Sakla</span>, <span class="hlFld-ContribAuthor ">Suresh K.  Bhargava</span>, <span class="hlFld-ContribAuthor ">Nagula  Shankaraiah</span>. </span><span class="cited-content_cbyCitation_article-title">Exploration of carbamide derived pyrimidine-thioindole conjugates as potential VEGFR-2 inhibitors with anti-angiogenesis effect. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>200 </em>, 112457. <a href="https://doi.org/10.1016/j.ejmech.2020.112457" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112457</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112457&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112457%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DExploration%252Bof%252Bcarbamide%252Bderived%252Bpyrimidine-thioindole%252Bconjugates%252Bas%252Bpotential%252BVEGFR-2%252Binhibitors%252Bwith%252Banti-angiogenesis%252Beffect%26aulast%3DSana%26aufirst%3DSravani%26date%3D2020%26volume%3D200%26spage%3D112457" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wei  Jiang</span>, <span class="hlFld-ContribAuthor ">Meiju  Ji</span>. </span><span class="cited-content_cbyCitation_article-title">Receptor tyrosine kinases in PI3K signaling: The therapeutic targets in cancer. </span><span class="cited-content_cbyCitation_journal-name">Seminars in Cancer Biology</span><span> <strong>2019,</strong> <em>59 </em>, 3-22. <a href="https://doi.org/10.1016/j.semcancer.2019.03.006" title="DOI URL">https://doi.org/10.1016/j.semcancer.2019.03.006</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.semcancer.2019.03.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.semcancer.2019.03.006%26sid%3Dliteratum%253Aachs%26jtitle%3DSeminars%2520in%2520Cancer%2520Biology%26atitle%3DReceptor%252Btyrosine%252Bkinases%252Bin%252BPI3K%252Bsignaling%25253A%252BThe%252Btherapeutic%252Btargets%252Bin%252Bcancer%26aulast%3DJiang%26aufirst%3DWei%26date%3D2019%26volume%3D59%26spage%3D3%26epage%3D22" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mohammad Reza  Javan</span>, <span class="hlFld-ContribAuthor ">Arezou  Khosrojerdi</span>, <span class="hlFld-ContribAuthor ">Seyed Mohammad  Moazzeni</span>. </span><span class="cited-content_cbyCitation_article-title">New Insights Into Implementation of Mesenchymal Stem Cells in Cancer Therapy: Prospects for Anti-angiogenesis Treatment. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Oncology</span><span> <strong>2019,</strong> <em>9 </em><a href="https://doi.org/10.3389/fonc.2019.00840" title="DOI URL">https://doi.org/10.3389/fonc.2019.00840</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fonc.2019.00840&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffonc.2019.00840%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Oncology%26atitle%3DNew%252BInsights%252BInto%252BImplementation%252Bof%252BMesenchymal%252BStem%252BCells%252Bin%252BCancer%252BTherapy%25253A%252BProspects%252Bfor%252BAnti-angiogenesis%252BTreatment%26aulast%3DJavan%26aufirst%3DMohammad%2BReza%26date%3D2019%26date%3D2019%26volume%3D9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yuanyuan  Shan</span>, <span class="hlFld-ContribAuthor ">Binghe  Wang</span>, <span class="hlFld-ContribAuthor ">Jie  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">New strategies in achieving antiangiogenic effect: Multiplex inhibitors suppressing compensatory activations of RTKs. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Research Reviews</span><span> <strong>2018,</strong> <em>38 </em>
                                    (5)
                                     , 1674-1705. <a href="https://doi.org/10.1002/med.21517" title="DOI URL">https://doi.org/10.1002/med.21517</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/med.21517&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fmed.21517%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Research%2520Reviews%26atitle%3DNew%252Bstrategies%252Bin%252Bachieving%252Bantiangiogenic%252Beffect%25253A%252BMultiplex%252Binhibitors%252Bsuppressing%252Bcompensatory%252Bactivations%252Bof%252BRTKs%26aulast%3DShan%26aufirst%3DYuanyuan%26date%3D2018%26date%3D2018%26volume%3D38%26issue%3D5%26spage%3D1674%26epage%3D1705" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">. </span><span class="cited-content_cbyCitation_article-title">2-Aminopyrimidines. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2018,</strong>,, 237-283. <a href="https://doi.org/10.1002/9781118686263.ch7" title="DOI URL">https://doi.org/10.1002/9781118686263.ch7</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/9781118686263.ch7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F9781118686263.ch7%26sid%3Dliteratum%253Aachs%26atitle%3D2-Aminopyrimidines%26date%3D2018%26date%3D2018%26spage%3D237%26epage%3D283%26pub%3DJohn%2520Wiley%2520%2526%2520Sons%252C%2520Inc%26atitle%3DPrivileged%252BStructures%252Bin%252BDrug%252BDiscovery%26aulast%3DYet%26aufirst%3DLarry%26date%3D2018%26volume%3D57" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lin  Zhang</span>, <span class="hlFld-ContribAuthor ">Yuanyuan  Shan</span>, <span class="hlFld-ContribAuthor ">Chuansheng  Li</span>, <span class="hlFld-ContribAuthor ">Ying  Sun</span>, <span class="hlFld-ContribAuthor ">Ping  Su</span>, <span class="hlFld-ContribAuthor ">Jinfeng  Wang</span>, <span class="hlFld-ContribAuthor ">Lisha  Li</span>, <span class="hlFld-ContribAuthor ">Xiaoyan  Pan</span>, <span class="hlFld-ContribAuthor ">Jie  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of novel anti-angiogenesis agents. Part 6: Multi-targeted RTK inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>127 </em>, 275-285. <a href="https://doi.org/10.1016/j.ejmech.2016.12.059" title="DOI URL">https://doi.org/10.1016/j.ejmech.2016.12.059</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2016.12.059&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2016.12.059%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bnovel%252Banti-angiogenesis%252Bagents.%252BPart%252B6%25253A%252BMulti-targeted%252BRTK%252Binhibitors%26aulast%3DZhang%26aufirst%3DLin%26date%3D2017%26volume%3D127%26spage%3D275%26epage%3D285" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Peichen  Pan</span>, <span class="hlFld-ContribAuthor ">Huiyong  Sun</span>, <span class="hlFld-ContribAuthor ">Hui  Liu</span>, <span class="hlFld-ContribAuthor ">Dan  Li</span>, <span class="hlFld-ContribAuthor ">Wenfang  Zhou</span>, <span class="hlFld-ContribAuthor ">Xiaotian  Kong</span>, <span class="hlFld-ContribAuthor ">Youyong  Li</span>, <span class="hlFld-ContribAuthor ">Huidong  Yu</span>, <span class="hlFld-ContribAuthor ">Tingjun  Hou</span>. </span><span class="cited-content_cbyCitation_article-title">In Silico Exploration for Novel Type-I Inhibitors of Tie-2/TEK: The Performance of Different Selection Strategy in Selecting Virtual Screening Candidates. </span><span class="cited-content_cbyCitation_journal-name">Scientific Reports</span><span> <strong>2016,</strong> <em>6 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/srep37628" title="DOI URL">https://doi.org/10.1038/srep37628</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/srep37628&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fsrep37628%26sid%3Dliteratum%253Aachs%26jtitle%3DScientific%2520Reports%26atitle%3DIn%252BSilico%252BExploration%252Bfor%252BNovel%252BType-I%252BInhibitors%252Bof%252BTie-2%25252FTEK%25253A%252BThe%252BPerformance%252Bof%252BDifferent%252BSelection%252BStrategy%252Bin%252BSelecting%252BVirtual%252BScreening%252BCandidates%26aulast%3DPan%26aufirst%3DPeichen%26date%3D2016%26date%3D2016%26volume%3D6%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Afshin  Dowlati</span>, <span class="hlFld-ContribAuthor ">Gordana  Vlahovic</span>, <span class="hlFld-ContribAuthor ">Ronald B.  Natale</span>, <span class="hlFld-ContribAuthor ">Erik  Rasmussen</span>, <span class="hlFld-ContribAuthor ">Indrajeet  Singh</span>, <span class="hlFld-ContribAuthor ">Yuying C.  Hwang</span>, <span class="hlFld-ContribAuthor ">John  Rossi</span>, <span class="hlFld-ContribAuthor ">Michael B.  Bass</span>, <span class="hlFld-ContribAuthor ">Gregory  Friberg</span>, <span class="hlFld-ContribAuthor ">Cheryl A.  Pickett</span>. </span><span class="cited-content_cbyCitation_article-title">A Phase I, First-in-Human Study of AMG 780, an Angiopoietin-1 and -2 Inhibitor, in Patients with Advanced Solid Tumors. </span><span class="cited-content_cbyCitation_journal-name">Clinical Cancer Research</span><span> <strong>2016,</strong> <em>22 </em>
                                    (18)
                                     , 4574-4584. <a href="https://doi.org/10.1158/1078-0432.CCR-15-2145" title="DOI URL">https://doi.org/10.1158/1078-0432.CCR-15-2145</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/1078-0432.CCR-15-2145&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F1078-0432.CCR-15-2145%26sid%3Dliteratum%253Aachs%26jtitle%3DClinical%2520Cancer%2520Research%26atitle%3DA%252BPhase%252BI%25252C%252BFirst-in-Human%252BStudy%252Bof%252BAMG%252B780%25252C%252Ban%252BAngiopoietin-1%252Band%252B-2%252BInhibitor%25252C%252Bin%252BPatients%252Bwith%252BAdvanced%252BSolid%252BTumors%26aulast%3DDowlati%26aufirst%3DAfshin%26date%3D2016%26date%3D2016%26volume%3D22%26issue%3D18%26spage%3D4574%26epage%3D4584" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">George  Jour</span>, <span class="hlFld-ContribAuthor ">Doina  Ivan</span>, <span class="hlFld-ContribAuthor ">Phyu P  Aung</span>. </span><span class="cited-content_cbyCitation_article-title">Angiogenesis in melanoma: an update with a focus on current targeted therapies. </span><span class="cited-content_cbyCitation_journal-name">Journal of Clinical Pathology</span><span> <strong>2016,</strong> <em>69 </em>
                                    (6)
                                     , 472-483. <a href="https://doi.org/10.1136/jclinpath-2015-203482" title="DOI URL">https://doi.org/10.1136/jclinpath-2015-203482</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1136/jclinpath-2015-203482&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1136%2Fjclinpath-2015-203482%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Clinical%2520Pathology%26atitle%3DAngiogenesis%252Bin%252Bmelanoma%25253A%252Ban%252Bupdate%252Bwith%252Ba%252Bfocus%252Bon%252Bcurrent%252Btargeted%252Btherapies%26aulast%3DJour%26aufirst%3DGeorge%26date%3D2016%26date%3D2016%26volume%3D69%26issue%3D6%26spage%3D472%26epage%3D483" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yasuhiro  Yoshimatsu</span>, <span class="hlFld-ContribAuthor ">Hideki  Miyazaki</span>, <span class="hlFld-ContribAuthor ">Tetsuro  Watabe</span>. </span><span class="cited-content_cbyCitation_article-title">Roles of signaling and transcriptional networks in pathological lymphangiogenesis. </span><span class="cited-content_cbyCitation_journal-name">Advanced Drug Delivery Reviews</span><span> <strong>2016,</strong> <em>99 </em>, 161-171. <a href="https://doi.org/10.1016/j.addr.2016.01.020" title="DOI URL">https://doi.org/10.1016/j.addr.2016.01.020</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.addr.2016.01.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.addr.2016.01.020%26sid%3Dliteratum%253Aachs%26jtitle%3DAdvanced%2520Drug%2520Delivery%2520Reviews%26atitle%3DRoles%252Bof%252Bsignaling%252Band%252Btranscriptional%252Bnetworks%252Bin%252Bpathological%252Blymphangiogenesis%26aulast%3DYoshimatsu%26aufirst%3DYasuhiro%26date%3D2016%26volume%3D99%26spage%3D161%26epage%3D171" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">E. V.  Koroleva</span>, <span class="hlFld-ContribAuthor ">Zh. I.  Ignatovich</span>, <span class="hlFld-ContribAuthor ">Yu. V.  Sinyutich</span>, <span class="hlFld-ContribAuthor ">K. N.  Gusak</span>. </span><span class="cited-content_cbyCitation_article-title">Aminopyrimidine derivatives as protein kinases inhibitors. Molecular design, synthesis, and biologic activity. </span><span class="cited-content_cbyCitation_journal-name">Russian Journal of Organic Chemistry</span><span> <strong>2016,</strong> <em>52 </em>
                                    (2)
                                     , 139-177. <a href="https://doi.org/10.1134/S1070428016020019" title="DOI URL">https://doi.org/10.1134/S1070428016020019</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1134/S1070428016020019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1134%2FS1070428016020019%26sid%3Dliteratum%253Aachs%26jtitle%3DRussian%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DAminopyrimidine%252Bderivatives%252Bas%252Bprotein%252Bkinases%252Binhibitors.%252BMolecular%252Bdesign%25252C%252Bsynthesis%25252C%252Band%252Bbiologic%252Bactivity%26aulast%3DKoroleva%26aufirst%3DE.%2BV.%26date%3D2016%26date%3D2016%26volume%3D52%26issue%3D2%26spage%3D139%26epage%3D177" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chris  Sherer</span>, <span class="hlFld-ContribAuthor ">Timothy J.  Snape</span>. </span><span class="cited-content_cbyCitation_article-title">Heterocyclic scaffolds as promising anticancer agents against tumours of the central nervous system: Exploring the scope of indole and carbazole derivatives. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2015,</strong> <em>97 </em>, 552-560. <a href="https://doi.org/10.1016/j.ejmech.2014.11.007" title="DOI URL">https://doi.org/10.1016/j.ejmech.2014.11.007</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2014.11.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2014.11.007%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DHeterocyclic%252Bscaffolds%252Bas%252Bpromising%252Banticancer%252Bagents%252Bagainst%252Btumours%252Bof%252Bthe%252Bcentral%252Bnervous%252Bsystem%25253A%252BExploring%252Bthe%252Bscope%252Bof%252Bindole%252Band%252Bcarbazole%252Bderivatives%26aulast%3DSherer%26aufirst%3DChris%26date%3D2015%26volume%3D97%26spage%3D552%26epage%3D560" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Moritz  Felcht</span>, <span class="hlFld-ContribAuthor ">Markus  Thomas</span>. </span><span class="cited-content_cbyCitation_article-title">Angiogenesis in malignant melanoma. </span><span class="cited-content_cbyCitation_journal-name">JDDG: Journal der Deutschen Dermatologischen Gesellschaft</span><span> <strong>2015,</strong> <em>13 </em>
                                    (2)
                                     , 125-135. <a href="https://doi.org/10.1111/ddg.12580" title="DOI URL">https://doi.org/10.1111/ddg.12580</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/ddg.12580&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fddg.12580%26sid%3Dliteratum%253Aachs%26jtitle%3DJDDG%253A%2520Journal%2520der%2520Deutschen%2520Dermatologischen%2520Gesellschaft%26atitle%3DAngiogenesis%252Bin%252Bmalignant%252Bmelanoma%26aulast%3DFelcht%26aufirst%3DMoritz%26date%3D2015%26date%3D2015%26volume%3D13%26issue%3D2%26spage%3D125%26epage%3D135" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Moritz  Felcht</span>, <span class="hlFld-ContribAuthor ">Markus  Thomas</span>. </span><span class="cited-content_cbyCitation_article-title">Angiogenese beim malignen Melanom. </span><span class="cited-content_cbyCitation_journal-name">JDDG: Journal der Deutschen Dermatologischen Gesellschaft</span><span> <strong>2015,</strong> <em>13 </em>
                                    (2)
                                     , 125-136. <a href="https://doi.org/10.1111/ddg.12580_suppl" title="DOI URL">https://doi.org/10.1111/ddg.12580_suppl</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/ddg.12580_suppl&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fddg.12580_suppl%26sid%3Dliteratum%253Aachs%26jtitle%3DJDDG%253A%2520Journal%2520der%2520Deutschen%2520Dermatologischen%2520Gesellschaft%26atitle%3DAngiogenese%252Bbeim%252Bmalignen%252BMelanom%26aulast%3DFelcht%26aufirst%3DMoritz%26date%3D2015%26date%3D2015%26volume%3D13%26issue%3D2%26spage%3D125%26epage%3D136" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Roberto  Pili</span>, <span class="hlFld-ContribAuthor ">Michael  Carducci</span>, <span class="hlFld-ContribAuthor ">Peter  Brown</span>, <span class="hlFld-ContribAuthor ">Herbert  Hurwitz</span>. </span><span class="cited-content_cbyCitation_article-title">An open-label study to determine the maximum tolerated dose of the multitargeted tyrosine kinase inhibitor CEP-11981 in patients with advanced cancer. </span><span class="cited-content_cbyCitation_journal-name">Investigational New Drugs</span><span> <strong>2014,</strong> <em>32 </em>
                                    (6)
                                     , 1258-1268. <a href="https://doi.org/10.1007/s10637-014-0147-9" title="DOI URL">https://doi.org/10.1007/s10637-014-0147-9</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s10637-014-0147-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs10637-014-0147-9%26sid%3Dliteratum%253Aachs%26jtitle%3DInvestigational%2520New%2520Drugs%26atitle%3DAn%252Bopen-label%252Bstudy%252Bto%252Bdetermine%252Bthe%252Bmaximum%252Btolerated%252Bdose%252Bof%252Bthe%252Bmultitargeted%252Btyrosine%252Bkinase%252Binhibitor%252BCEP-11981%252Bin%252Bpatients%252Bwith%252Badvanced%252Bcancer%26aulast%3DPili%26aufirst%3DRoberto%26date%3D2014%26date%3D2014%26volume%3D32%26issue%3D6%26spage%3D1258%26epage%3D1268" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ji Yoon  Lee</span>, <span class="hlFld-ContribAuthor ">Hee-Je  Kim</span>. </span><span class="cited-content_cbyCitation_article-title">(Lymph)angiogenic influences on hematopoietic cells in acute myeloid leukemia. </span><span class="cited-content_cbyCitation_journal-name">Experimental & Molecular Medicine</span><span> <strong>2014,</strong> <em>46 </em>
                                    (11)
                                     , e122-e122. <a href="https://doi.org/10.1038/emm.2014.72" title="DOI URL">https://doi.org/10.1038/emm.2014.72</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/emm.2014.72&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Femm.2014.72%26sid%3Dliteratum%253Aachs%26jtitle%3DExperimental%2520%2526%2520Molecular%2520Medicine%26atitle%3D%252528Lymph%252529angiogenic%252Binfluences%252Bon%252Bhematopoietic%252Bcells%252Bin%252Bacute%252Bmyeloid%252Bleukemia%26aulast%3DLee%26aufirst%3DJi%2BYoon%26date%3D2014%26date%3D2014%26volume%3D46%26issue%3D11%26spage%3De122%26epage%3De122" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Steven A.  Stacker</span>, <span class="hlFld-ContribAuthor ">Steven P.  Williams</span>, <span class="hlFld-ContribAuthor ">Tara  Karnezis</span>, <span class="hlFld-ContribAuthor ">Ramin  Shayan</span>, <span class="hlFld-ContribAuthor ">Stephen B.  Fox</span>, <span class="hlFld-ContribAuthor ">Marc G.  Achen</span>. </span><span class="cited-content_cbyCitation_article-title">Lymphangiogenesis and lymphatic vessel remodelling in cancer. </span><span class="cited-content_cbyCitation_journal-name">Nature Reviews Cancer</span><span> <strong>2014,</strong> <em>14 </em>
                                    (3)
                                     , 159-172. <a href="https://doi.org/10.1038/nrc3677" title="DOI URL">https://doi.org/10.1038/nrc3677</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/nrc3677&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fnrc3677%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%2520Reviews%2520Cancer%26atitle%3DLymphangiogenesis%252Band%252Blymphatic%252Bvessel%252Bremodelling%252Bin%252Bcancer%26aulast%3DStacker%26aufirst%3DSteven%2BA.%26date%3D2014%26date%3D2014%26volume%3D14%26issue%3D3%26spage%3D159%26epage%3D172" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">A.  Mortlock</span>, <span class="hlFld-ContribAuthor ">K.  Foote</span>, <span class="hlFld-ContribAuthor ">J.  Kettle</span>, <span class="hlFld-ContribAuthor ">B.  Aquila</span>. </span><span class="cited-content_cbyCitation_article-title">Kinase Inhibitors in Cancer. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2014,</strong>,<a href="https://doi.org/10.1016/B978-0-12-409547-2.11033-9" title="DOI URL">https://doi.org/10.1016/B978-0-12-409547-2.11033-9</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-409547-2.11033-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-409547-2.11033-9%26sid%3Dliteratum%253Aachs%26atitle%3DKinase%252BInhibitors%252Bin%252BCancer%26aulast%3DMortlock%26aufirst%3DA.%26date%3D2014%26pub%3DElsevier%26atitle%3DReference%252BModule%252Bin%252BChemistry%25252C%252BMolecular%252BSciences%252Band%252BChemical%252BEngineering%26date%3D2014%26volume%3D409" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ana Marta  Matos</span>, <span class="hlFld-ContribAuthor ">Ana Paula  Francisco</span>. </span><span class="cited-content_cbyCitation_article-title">Targets, Structures, and Recent Approaches in Malignant Melanoma Chemotherapy. </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2013,</strong> <em>8 </em>
                                    (11)
                                     , 1751-1765. <a href="https://doi.org/10.1002/cmdc.201300248" title="DOI URL">https://doi.org/10.1002/cmdc.201300248</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.201300248&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.201300248%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DTargets%25252C%252BStructures%25252C%252Band%252BRecent%252BApproaches%252Bin%252BMalignant%252BMelanoma%252BChemotherapy%26aulast%3DMatos%26aufirst%3DAna%2BMarta%26date%3D2013%26date%3D2013%26volume%3D8%26issue%3D11%26spage%3D1751%26epage%3D1765" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zeynep  Eroglu</span>, <span class="hlFld-ContribAuthor ">Cy A  Stein</span>, <span class="hlFld-ContribAuthor ">Sumanta K  Pal</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting angiopoietin-2 signaling in cancer therapy. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Investigational Drugs</span><span> <strong>2013,</strong> <em>22 </em>
                                    (7)
                                     , 813-825. <a href="https://doi.org/10.1517/13543784.2013.793306" title="DOI URL">https://doi.org/10.1517/13543784.2013.793306</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1517/13543784.2013.793306&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1517%2F13543784.2013.793306%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Investigational%2520Drugs%26atitle%3DTargeting%252Bangiopoietin-2%252Bsignaling%252Bin%252Bcancer%252Btherapy%26aulast%3DEroglu%26aufirst%3DZeynep%26date%3D2013%26date%3D2013%26volume%3D22%26issue%3D7%26spage%3D813%26epage%3D825" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shivaputra A  Patil</span>, <span class="hlFld-ContribAuthor ">Amira  Hosni-Ahmed</span>, <span class="hlFld-ContribAuthor ">Terreia S  Jones</span>, <span class="hlFld-ContribAuthor ">Renukadevi  Patil</span>, <span class="hlFld-ContribAuthor ">Lawrence M  Pfeffer</span>, <span class="hlFld-ContribAuthor ">Duane D  Miller</span>. </span><span class="cited-content_cbyCitation_article-title">Novel approaches to glioma drug design and drug screening. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Drug Discovery</span><span> <strong>2013,</strong> <em>8 </em>
                                    (9)
                                     , 1135-1151. <a href="https://doi.org/10.1517/17460441.2013.807248" title="DOI URL">https://doi.org/10.1517/17460441.2013.807248</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1517/17460441.2013.807248&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1517%2F17460441.2013.807248%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Drug%2520Discovery%26atitle%3DNovel%252Bapproaches%252Bto%252Bglioma%252Bdrug%252Bdesign%252Band%252Bdrug%252Bscreening%26aulast%3DPatil%26aufirst%3DShivaputra%2BA%26date%3D2013%26date%3D2013%26volume%3D8%26issue%3D9%26spage%3D1135%26epage%3D1151" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Joel T.  Arcari</span>, <span class="hlFld-ContribAuthor ">Jean S.  Beebe</span>, <span class="hlFld-ContribAuthor ">Martin A.  Berliner</span>, <span class="hlFld-ContribAuthor ">Vincent  Bernardo</span>, <span class="hlFld-ContribAuthor ">Merin  Boehm</span>, <span class="hlFld-ContribAuthor ">Gary V.  Borzillo</span>, <span class="hlFld-ContribAuthor ">Tracey  Clark</span>, <span class="hlFld-ContribAuthor ">Bruce D.  Cohen</span>, <span class="hlFld-ContribAuthor ">Richard D.  Connell</span>, <span class="hlFld-ContribAuthor ">Heather N.  Frost</span>, <span class="hlFld-ContribAuthor ">Deborah A.  Gordon</span>, <span class="hlFld-ContribAuthor ">William M.  Hungerford</span>, <span class="hlFld-ContribAuthor ">Shefali M.  Kakar</span>, <span class="hlFld-ContribAuthor ">Aaron  Kanter</span>, <span class="hlFld-ContribAuthor ">Nandell F.  Keene</span>, <span class="hlFld-ContribAuthor ">Elizabeth A.  Knauth</span>, <span class="hlFld-ContribAuthor ">Susan D.  LaGreca</span>, <span class="hlFld-ContribAuthor ">Yong  Lu</span>, <span class="hlFld-ContribAuthor ">Louis  Martinez-Alsina</span>, <span class="hlFld-ContribAuthor ">Matthew A.  Marx</span>, <span class="hlFld-ContribAuthor ">Joel  Morris</span>, <span class="hlFld-ContribAuthor ">Nandini C.  Patel</span>, <span class="hlFld-ContribAuthor ">Doug  Savage</span>, <span class="hlFld-ContribAuthor ">Cathy I.  Soderstrom</span>, <span class="hlFld-ContribAuthor ">Carl  Thompson</span>, <span class="hlFld-ContribAuthor ">George  Tkalcevic</span>, <span class="hlFld-ContribAuthor ">Norma J.  Tom</span>, <span class="hlFld-ContribAuthor ">Felix F.  Vajdos</span>, <span class="hlFld-ContribAuthor ">James J.  Valentine</span>, <span class="hlFld-ContribAuthor ">Patrick W.  Vincent</span>, <span class="hlFld-ContribAuthor ">Matthew D.  Wessel</span>, <span class="hlFld-ContribAuthor ">Jinshan M.  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery and synthesis of novel 4-aminopyrrolopyrimidine Tie-2 kinase inhibitors for the treatment of solid tumors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2013,</strong> <em>23 </em>
                                    (10)
                                     , 3059-3063. <a href="https://doi.org/10.1016/j.bmcl.2013.03.012" title="DOI URL">https://doi.org/10.1016/j.bmcl.2013.03.012</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2013.03.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2013.03.012%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Band%252Bsynthesis%252Bof%252Bnovel%252B4-aminopyrrolopyrimidine%252BTie-2%252Bkinase%252Binhibitors%252Bfor%252Bthe%252Btreatment%252Bof%252Bsolid%252Btumors%26aulast%3DArcari%26aufirst%3DJoel%2BT.%26date%3D2013%26volume%3D23%26issue%3D10%26spage%3D3059%26epage%3D3063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Damien  Gerald</span>, <span class="hlFld-ContribAuthor ">Sudhakar  Chintharlapalli</span>, <span class="hlFld-ContribAuthor ">Hellmut G.  Augustin</span>, <span class="hlFld-ContribAuthor ">Laura E.  Benjamin</span>. </span><span class="cited-content_cbyCitation_article-title">Angiopoietin-2: An Attractive Target for Improved Antiangiogenic Tumor Therapy. </span><span class="cited-content_cbyCitation_journal-name">Cancer Research</span><span> <strong>2013,</strong> <em>73 </em>
                                    (6)
                                     , 1649-1657. <a href="https://doi.org/10.1158/0008-5472.CAN-12-4697" title="DOI URL">https://doi.org/10.1158/0008-5472.CAN-12-4697</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/0008-5472.CAN-12-4697&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F0008-5472.CAN-12-4697%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Research%26atitle%3DAngiopoietin-2%25253A%252BAn%252BAttractive%252BTarget%252Bfor%252BImproved%252BAntiangiogenic%252BTumor%252BTherapy%26aulast%3DGerald%26aufirst%3DDamien%26date%3D2013%26date%3D2013%26volume%3D73%26issue%3D6%26spage%3D1649%26epage%3D1657" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jun  Cai</span>, <span class="hlFld-ContribAuthor ">Qing  Ruan</span>, <span class="hlFld-ContribAuthor ">Zhi J  Chen</span>, <span class="hlFld-ContribAuthor ">Song  Han</span>. </span><span class="cited-content_cbyCitation_article-title">Connection of pericyteâangiopoietin-Tie-2 system in diabetic retinopathy: friend or foe?. </span><span class="cited-content_cbyCitation_journal-name">Future Medicinal Chemistry</span><span> <strong>2012,</strong> <em>4 </em>
                                    (17)
                                     , 2163-2176. <a href="https://doi.org/10.4155/fmc.12.170" title="DOI URL">https://doi.org/10.4155/fmc.12.170</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4155/fmc.12.170&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4155%2Ffmc.12.170%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Medicinal%2520Chemistry%26atitle%3DConnection%252Bof%252Bpericyte%2525E2%252580%252593angiopoietin-Tie-2%252Bsystem%252Bin%252Bdiabetic%252Bretinopathy%25253A%252Bfriend%252Bor%252Bfoe%25253F%26aulast%3DCai%26aufirst%3DJun%26date%3D2012%26volume%3D4%26issue%3D17%26spage%3D2163%26epage%3D2176" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lingyi  Huang</span>, <span class="hlFld-ContribAuthor ">Zhengui  Huang</span>, <span class="hlFld-ContribAuthor ">Zhiqiang  Bai</span>, <span class="hlFld-ContribAuthor ">Rui  Xie</span>, <span class="hlFld-ContribAuthor ">Liping  Sun</span>, <span class="hlFld-ContribAuthor ">Kejiang  Lin</span>. </span><span class="cited-content_cbyCitation_article-title">Development and strategies of VEGFR-2/KDR inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Future Medicinal Chemistry</span><span> <strong>2012,</strong> <em>4 </em>
                                    (14)
                                     , 1839-1852. <a href="https://doi.org/10.4155/fmc.12.121" title="DOI URL">https://doi.org/10.4155/fmc.12.121</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4155/fmc.12.121&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4155%2Ffmc.12.121%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Medicinal%2520Chemistry%26atitle%3DDevelopment%252Band%252Bstrategies%252Bof%252BVEGFR-2%25252FKDR%252Binhibitors%26aulast%3DHuang%26aufirst%3DLingyi%26date%3D2012%26volume%3D4%26issue%3D14%26spage%3D1839%26epage%3D1852" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-2/jm201449n/production/images/medium/jm-2011-01449n_0006.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-2/jm201449n/production/images/large/jm-2011-01449n_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201449n&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-2/jm201449n/production/images/medium/jm-2011-01449n_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-2/jm201449n/production/images/large/jm-2011-01449n_0008.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of angiogenesis inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-2/jm201449n/production/images/large/jm-2011-01449n_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201449n&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-2/jm201449n/production/images/medium/jm-2011-01449n_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-2/jm201449n/production/images/large/jm-2011-01449n_0009.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. First and second generation angiogenesis inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-2/jm201449n/production/images/large/jm-2011-01449n_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201449n&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-2/jm201449n/production/images/medium/jm-2011-01449n_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-2/jm201449n/production/images/large/jm-2011-01449n_0002.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. <sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-2/jm201449n/production/images/large/jm-2011-01449n_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201449n&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) alkyl iodide, NaOH, acetone, reflux, 18 h, 87â93% ; (b) HNO<sub>3</sub>, AcOH, 80 Â°C, 1 h 70â87%; (c) H<sub>2</sub>, Raney-Ni, DMF-MeOH, 81â97%; (d) heteroaryl-chloride, 1-butanol, reflux, 40â65%.</p></p></figure><figure data-id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-2/jm201449n/production/images/medium/jm-2011-01449n_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-2/jm201449n/production/images/large/jm-2011-01449n_0003.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. <sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-2/jm201449n/production/images/large/jm-2011-01449n_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201449n&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) 1-iodo-2-methyl-propane, NaOH, acetone, reflux, 18 h, 90%; (b) HNO<sub>3</sub>, AcOH, 80 Â°C, 1 h, 85%; (c) H<sub>2</sub>, Raney-Ni, DMF-MeOH, 80% ; (d) 2-chloropyrimidine, 1-butanol, reflux, 45%.</p></p></figure><figure data-id="fig3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-2/jm201449n/production/images/medium/jm-2011-01449n_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-2/jm201449n/production/images/large/jm-2011-01449n_0010.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Predicted binding mode of <b>11b</b> with TIE-2.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-2/jm201449n/production/images/large/jm-2011-01449n_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201449n&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-2/jm201449n/production/images/medium/jm-2011-01449n_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-2/jm201449n/production/images/large/jm-2011-01449n_0011.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Antiangiogenic activity of <b>11b</b> ex vivo rat aortic ring explant cultures and in vitro HUVEC capillary-tube formation bioassays. Ex vivo rat aortic ring explant cultures and target-directed in vitro HUVEC capillary-tube formation to assess their antiangiogenic activities and potential cytotoxic profiles in primary cell and organ cultures. Compound <b>11b</b> exhibited dose-related inhibitory effects on peak phase microvessel growth (day 8â10 in culture) in rat aortic ring explants in 3D-collagen gels under serum-free conditions with an EC<sub>50</sub> of approximately 4 nM, and inhibition of complete capillary-tube formation by HUVECs on Matrigel with an EC<sub>50</sub> of approximately 2 nM. <i>P</i> < 0.05**, <i>p</i> < 0.01* relative to control cultures.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-2/jm201449n/production/images/large/jm-2011-01449n_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201449n&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-2/jm201449n/production/images/medium/jm-2011-01449n_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-2/jm201449n/production/images/large/jm-2011-01449n_0012.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Oral antitumor activity of <b>11b</b> in the U251 MG human glioblastoma xenograft. Tumor cells were injected subcutaneously in serum-free media into the right flank of athymic female nude mice. Twelve days post-implantation, mice with established tumors were randomized into treatment groups (<i>n</i> = 10 mice/group) and administered <b>11b</b> orally (100 Î¼L/dose) at the doses indicated and tumor volumes measured as defined in the <a class="ref internalNav" href="#sec5" aria-label="Experimental Section">Experimental Section</a>. Statistical analyses for efficacy of <b>11b</b> are detailed in Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-2/jm201449n/production/images/large/jm-2011-01449n_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201449n&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-2/jm201449n/production/images/medium/jm-2011-01449n_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-2/jm201449n/production/images/large/jm-2011-01449n_0013.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Oral antitumor activity of <b>11b</b> in the A375 human melanoma xenograft model. Tumor cells were injected subcutaneously in serum-free media into the right flank of athymic female nude mice. Ten days post-implantation, mice with established tumors were randomized into treatment groups (<i>n</i> = 10 mice/group) and administered <b>11b</b> orally (100 Î¼L/dose) at the doses indicated and relative tumor volume to those at day 1 of treatment with <b>11b</b> measured as defined in the <a class="ref internalNav" href="#sec5" aria-label="Experimental Section">Experimental Section</a>. Statistical analyses for efficacy of <b>11b</b> are detailed in Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-2/jm201449n/production/images/large/jm-2011-01449n_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201449n&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-2/jm201449n/production/images/medium/jm-2011-01449n_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-2/jm201449n/production/images/large/jm-2011-01449n_0001.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Survival benefit of continuous and intermittent oral administration of <b>11b</b> in the P388 systemic murine leukemia model in mice. KaplanâMeier survival plot of continuous versus intermittent once and twice daily oral dosing regimens of <b>11b</b> (30 mg/kg po) on median survival of DBA/2 mice implanted with murine P388 leukemia cells. Details of analyses are defined in the <a class="ref internalNav" href="#sec5" aria-label="Experimental Section">Experimental Section</a> and the text.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-2/jm201449n/production/images/large/jm-2011-01449n_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201449n&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i48">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_34626" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_34626" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 17 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Folkman, J.</span><span> </span><span class="NLM_article-title">Tumor angiogenesis: therapeutic implications</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1971</span><span class="NLM_x">, </span> <span class="NLM_volume">285</span><span class="NLM_x">, </span> <span class="NLM_fpage">1182</span><span class="NLM_x">â</span> <span class="NLM_lpage">1186</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=16&amp;doi=10.1021%2Fjm201449n&amp;key=10.1056%2FNEJM197111182852108" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=8&amp;doi=10.1021%2Fjm201449n&amp;key=4938153" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=32&amp;doi=10.1021%2Fjm201449n&amp;key=1%3ACAS%3A280%3ADyaE38%252FgvVCqsQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=285&publication_year=1971&pages=1182-1186&author=J.+Folkman&title=Tumor+angiogenesis%3A+therapeutic+implications"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1aR"><div class="casContent"><span class="casTitleNuber">1a</span><div class="casTitle"><span class="NLM_cas:atitle">Tumor angiogenesis: therapeutic implications</span></div><div class="casAuthors">Folkman J</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">1971</span>),
    <span class="NLM_cas:volume">285</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">1182-6</span>
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRA0C6odtE1LPxQvRxYU81tfW6udTcc2eaLaoQoO8CH2rntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaE38%252FgvVCqsQ%253D%253D&md5=efdddcba0c04be542edd51fef2ef27b9</span></div><a href="/servlet/linkout?suffix=cit1a&amp;dbid=16384&amp;doi=10.1056%2FNEJM197111182852108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJM197111182852108%26sid%3Dliteratum%253Aachs%26aulast%3DFolkman%26aufirst%3DJ.%26atitle%3DTumor%2520angiogenesis%253A%2520therapeutic%2520implications%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D1971%26volume%3D285%26spage%3D1182%26epage%3D1186" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit1b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Folkman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shing, Y.</span><span> </span><span class="NLM_article-title">Angiogenesis</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1992</span><span class="NLM_x">, </span> <span class="NLM_volume">267</span><span class="NLM_x">, </span> <span class="NLM_fpage">10931</span><span class="NLM_x">â</span> <span class="NLM_lpage">10934</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=267&publication_year=1992&pages=10931-10934&author=J.+Folkmanauthor=Y.+Shing&title=Angiogenesis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFolkman%26aufirst%3DJ.%26aulast%3DShing%26aufirst%3DY.%26atitle%3DAngiogenesis%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1992%26volume%3D267%26spage%3D10931%26epage%3D10934" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit1c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Carmeliet, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jain, R. K.</span><span> </span><span class="NLM_article-title">Angiogenesis in cancer and other diseases</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">407</span><span class="NLM_x">, </span> <span class="NLM_fpage">249</span><span class="NLM_x">â</span> <span class="NLM_lpage">257</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1c&amp;dbid=16&amp;doi=10.1021%2Fjm201449n&amp;key=10.1038%2F35025220" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1c&amp;dbid=8&amp;doi=10.1021%2Fjm201449n&amp;key=11001068" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1c&amp;dbid=32&amp;doi=10.1021%2Fjm201449n&amp;key=1%3ACAS%3A528%3ADC%252BD3cXmvVSls74%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=407&publication_year=2000&pages=249-257&author=P.+Carmelietauthor=R.+K.+Jain&title=Angiogenesis+in+cancer+and+other+diseases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1cR"><div class="casContent"><span class="casTitleNuber">1c</span><div class="casTitle"><span class="NLM_cas:atitle">Angiogenesis in cancer and other diseases</span></div><div class="casAuthors">Carmeliet, Peter; Jain, Rakesh K.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">407</span>
        (<span class="NLM_cas:issue">6801</span>),
    <span class="NLM_cas:pages">249-257</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review with 75 refs.  Pathol. angiogenesis is a hallmark of cancer and various ischemic and inflammatory diseases.  Concd. efforts in this area of research are leading to the discovery of a growing no. of pro- and anti-angiogenic mols., some of which are already in clin. trials.  The complex interactions among these mols. and how they affect vascular structure and function in different environments are now beginning to be elucidated.  This integrated understanding is leading to the development of a no. of exciting and bold approaches to treat cancer and other diseases.  But owing to several unanswered questions, caution is needed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPQMelW0OMYbVg90H21EOLACvtfcHk0liVVO7zxeMWww"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXmvVSls74%253D&md5=703cbcdbd32292a9238f0394220c853c</span></div><a href="/servlet/linkout?suffix=cit1c&amp;dbid=16384&amp;doi=10.1038%2F35025220&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F35025220%26sid%3Dliteratum%253Aachs%26aulast%3DCarmeliet%26aufirst%3DP.%26aulast%3DJain%26aufirst%3DR.%2BK.%26atitle%3DAngiogenesis%2520in%2520cancer%2520and%2520other%2520diseases%26jtitle%3DNature%26date%3D2000%26volume%3D407%26spage%3D249%26epage%3D257" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit1d"><span><span class="NLM_label">(d) </span><span> </span><span class="NLM_article-title">Folkman, Angiogenesis in cancer, vascular, rheumatoid and other disease</span>. J. Nat. Med.<span class="NLM_x"> </span><span class="NLM_year">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">27</span><span class="NLM_x">â</span> <span class="NLM_lpage">31</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1d&amp;dbid=16&amp;doi=10.1021%2Fjm201449n&amp;key=10.1038%2Fnm0195-27" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1d&amp;dbid=8&amp;doi=10.1021%2Fjm201449n&amp;key=7584949" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1d&amp;dbid=32&amp;doi=10.1021%2Fjm201449n&amp;key=1%3ACAS%3A528%3ADyaK2MXjs1KnsLk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Folkman%2C+Angiogenesis+in+cancer%2C+vascular%2C+rheumatoid+and+other+disease.+J.+Nat.+Med.+1995%2C+1%2C+27%E2%80%9331."target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1dR"><div class="casContent"><span class="casTitleNuber">1d</span><div class="casTitle"><span class="NLM_cas:atitle">Angiogenesis in cancer, vascular, rheumatoid and other disease</span></div><div class="casAuthors">Folkman, Judah</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York)</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">27-31</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Co.</span>)
        </div><div class="casAbstract">A review with â¼72 refs.  Recent discoveries of endogenous neg. regulators of angiogenesis, thrombospondin, angiostatin and glioma-derived angiogenesis inhibitory factor, all assocd. with neovascularized tumors, suggest a new paradigm of tumorigenesis.  It is now helpful to think of the switch to the angiogenic phenotype as a net balance of pos. and neg. regulators of blood vessel growth.  The extent to which the neg. regulators are decreased during this switch may dictate whether a primary tumor grows rapidly or slowly and whether metastases grow at all.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpF2nWHt2eJbVg90H21EOLACvtfcHk0liVVO7zxeMWww"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXjs1KnsLk%253D&md5=849f4f3828ac5d78886d666787f72d4f</span></div><a href="/servlet/linkout?suffix=cit1d&amp;dbid=16384&amp;doi=10.1038%2Fnm0195-27&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26id%3Ddoi%3A10.1038%252Fnm0195-27%26sid%3Dliteratum%253Aachs%26atitle%3DFolkman%252C%2520Angiogenesis%2520in%2520cancer%252C%2520vascular%252C%2520rheumatoid%2520and%2520other%2520disease%26jtitle%3DJ.%2520Nat.%2520Med.%26date%3D1995%26volume%3D1%26spage%3D27%26epage%3D31" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Hurwitz, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fehrenbacher, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Novotny, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cartwright, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hainsworth, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heim, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berlin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baron, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffing, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holmgren, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferrara, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fyfe, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rogers, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ross, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kabbinavar, F.</span><span> </span><span class="NLM_article-title">Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer</span> <span class="citation_source-journal">N. Engl J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">350</span><span class="NLM_x">, </span> <span class="NLM_fpage">2335</span><span class="NLM_x">â</span> <span class="NLM_lpage">2342</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Fjm201449n&amp;key=10.1056%2FNEJMoa032691" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Fjm201449n&amp;key=15175435" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Fjm201449n&amp;key=1%3ACAS%3A528%3ADC%252BD2cXks1Gjt74%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=350&publication_year=2004&pages=2335-2342&author=H.+Hurwitzauthor=L.+Fehrenbacherauthor=W.+Novotnyauthor=T.+Cartwrightauthor=J.+Hainsworthauthor=W.+Heimauthor=J.+Berlinauthor=A.+Baronauthor=S.+Griffingauthor=E.+Holmgrenauthor=N.+Ferraraauthor=G.+Fyfeauthor=B.+Rogersauthor=R.+Rossauthor=F.+Kabbinavar&title=Bevacizumab+plus+irinotecan%2C+fluorouracil%2C+and+leucovorin+for+metastatic+colorectal+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer</span></div><div class="casAuthors">Hurwitz, Herbert; Fehrenbacher, Louis; Novotny, William; Cartwright, Thomas; Hainsworth, John; Heim, William; Berlin, Jordan; Baron, Ari; Griffing, Susan; Holmgren, Eric; Ferrara, Napoleone; Fyfe, Gwen; Rogers, Beth; Ross, Robert; Kabbinavar, Fairooz</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">350</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">2335-2342</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, has shown promising preclin. and clin. activity against metastatic colorectal cancer, particularly in combination with chemotherapy.  Of 813 patients with previously untreated metastatic colorectal cancer, we randomly assigned 402 to receive irinotecan, bolus fluorouracil, and leucovorin (IFL) plus bevacizumab (5 mg per kg of body wt. every two weeks) and 411 to receive IFL plus placebo.  The primary end point was overall survival.  Secondary end points were progression-free survival, the response rate, the duration of the response, safety, and the quality of life.  The median duration of survival was 20.3 mo in the group given IFL plus bevacizumab, as compared with 15.6 mo in the group given IFL plus placebo, corresponding to a hazard ratio for death of 0.66 (P<0.001).  The median duration of progression-free survival was 10.6 mo in the group given IFL plus bevacizumab, as compared with 6.2 mo in the group given IFL plus placebo (hazard ratio for disease progression, 0.54; P<0.001); the corresponding rates of response were 44.8 % and 34.8 % (P = 0.004).  The median duration of the response was 10.4 mo in the group given IFL plus bevacizumab, as compared with 7.1 mo in the group given IFL plus placebo (hazard ratio for progression, 0.62; P = 0.001).  Grade 3 hypertension was more common during treatment with IFL plus bevacizumab than with IFL plus placebo (11.0 % vs. 2.3 %) but was easily managed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5r6uP5oxZU7Vg90H21EOLACvtfcHk0liVVO7zxeMWww"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXks1Gjt74%253D&md5=6a1289cdbf1501f121eb0482e5a1f536</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa032691&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa032691%26sid%3Dliteratum%253Aachs%26aulast%3DHurwitz%26aufirst%3DH.%26aulast%3DFehrenbacher%26aufirst%3DL.%26aulast%3DNovotny%26aufirst%3DW.%26aulast%3DCartwright%26aufirst%3DT.%26aulast%3DHainsworth%26aufirst%3DJ.%26aulast%3DHeim%26aufirst%3DW.%26aulast%3DBerlin%26aufirst%3DJ.%26aulast%3DBaron%26aufirst%3DA.%26aulast%3DGriffing%26aufirst%3DS.%26aulast%3DHolmgren%26aufirst%3DE.%26aulast%3DFerrara%26aufirst%3DN.%26aulast%3DFyfe%26aufirst%3DG.%26aulast%3DRogers%26aufirst%3DB.%26aulast%3DRoss%26aufirst%3DR.%26aulast%3DKabbinavar%26aufirst%3DF.%26atitle%3DBevacizumab%2520plus%2520irinotecan%252C%2520fluorouracil%252C%2520and%2520leucovorin%2520for%2520metastatic%2520colorectal%2520cancer%26jtitle%3DN.%2520Engl%2520J.%2520Med.%26date%3D2004%26volume%3D350%26spage%3D2335%26epage%3D2342" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Escudier, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eisen, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stadler, W. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szczylik, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oudard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Staehler, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Negrier, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chevreau, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Desai, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rolland, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demkow, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hutson, T. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gore, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hofilena, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pena, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lathia, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bukowski, R. M.</span><span> </span><span class="NLM_article-title">Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">3312</span><span class="NLM_x">â</span> <span class="NLM_lpage">3318</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Fjm201449n&amp;key=10.1200%2FJCO.2008.19.5511" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Fjm201449n&amp;key=19451442" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm201449n&amp;key=1%3ACAS%3A528%3ADC%252BD1MXpvFejt7w%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2009&pages=3312-3318&author=B.+Escudierauthor=T.+Eisenauthor=W.+M.+Stadlerauthor=C.+Szczylikauthor=S.+Oudardauthor=M.+Staehlerauthor=S.+Negrierauthor=C.+Chevreauauthor=A.+A.+Desaiauthor=F.+Rollandauthor=T.+Demkowauthor=T.+E.+Hutsonauthor=M.+Goreauthor=S.+Andersonauthor=G.+Hofilenaauthor=M.+Shanauthor=C.+Penaauthor=C.+Lathiaauthor=R.+M.+Bukowski&title=Sorafenib+for+treatment+of+renal+cell+carcinoma%3A+Final+efficacy+and+safety+results+of+the+phase+III+treatment+approaches+in+renal+cancer+global+evaluation+trial"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in Renal Cancer Global Evaluation Trial</span></div><div class="casAuthors">Escudier, Bernard; Eisen, Tim; Stadler, Walter M.; Szczylik, Cezary; Oudard, Stephane; Staehler, Michael; Negrier, Sylvie; Chevreau, Christine; Desai, Apurva A.; Rolland, Frederic; Demkow, Tomasz; Hutson, Thomas E.; Gore, Martin; Anderson, Sibyl; Hofilena, Gloria; Shan, Minghua; Pena, Carol; Lathia, Chetan; Bukowski, Ronald M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">3312-3318</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Mature survival data and evaluation of vascular endothelial growth factor (VEGF) as a prognostic biomarker from the Treatment Approaches in Renal Cancer Global Evaluation Trial (TARGET) study in patients with renal cell carcinoma (RCC) are reported.  Nine hundred three previously treated patients were randomly assigned to receive sorafenib vs. placebo.  On demonstration of progression-free survival (PFS) benefit with sorafenib, patients assigned to placebo were offered sorafenib.  Overall survival (OS) was detd. at two planned interim analyses and one final anal., with a secondary OS anal. conducted by censoring placebo patients who crossed over to sorafenib.  The relationships between baseline VEGF level and prognosis and efficacy were evaluated.  The final OS of patients receiving sorafenib was comparable with that of patients receiving placebo (17.8 v 15.2 mo, resp.; hazard ratio [HR] = 0.88; P = .146); however, when post-cross-over placebo survival data were censored, the difference became significant (17.8 v 14.3 mo, resp.; HR = 0.78; P = .029).  Adverse events at 16 mo after cross over were similar to those previously reported.  Baseline VEGF levels correlated with Eastern Cooperative Oncol. Group performance status (P < .0001), Memorial Sloan-Kettering Cancer Center score (P < .0001), and PFS and OS in univariate (PFS, P = .0013; OS, P = .0009) and multivariate (PFS, P = .0231; OS, P = .0416) analyses of placebo patients and with short OS by multivariate anal. of patients receiving sorafenib (P = .0145).  Both high-VEGF (P < .01) and low-VEGF (P < .01) groups benefited from sorafenib.  Although an OS benefit was not seen on a primary intent-to-treat anal., results of a secondary OS anal. censoring placebo patients demonstrated a survival advantage for those receiving sorafenib, suggesting an important cross-over effect.  VEGF levels are prognostic for PFS and OS in RCC.  The results of TARGET establish the efficacy and safety of sorafenib in advanced RCC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5GZeSGUwB9rVg90H21EOLACvtfcHk0lg0pnWsJyP1rA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXpvFejt7w%253D&md5=aee6dc30eca5a92d6e225f5bd22d9a38</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1200%2FJCO.2008.19.5511&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2008.19.5511%26sid%3Dliteratum%253Aachs%26aulast%3DEscudier%26aufirst%3DB.%26aulast%3DEisen%26aufirst%3DT.%26aulast%3DStadler%26aufirst%3DW.%2BM.%26aulast%3DSzczylik%26aufirst%3DC.%26aulast%3DOudard%26aufirst%3DS.%26aulast%3DStaehler%26aufirst%3DM.%26aulast%3DNegrier%26aufirst%3DS.%26aulast%3DChevreau%26aufirst%3DC.%26aulast%3DDesai%26aufirst%3DA.%2BA.%26aulast%3DRolland%26aufirst%3DF.%26aulast%3DDemkow%26aufirst%3DT.%26aulast%3DHutson%26aufirst%3DT.%2BE.%26aulast%3DGore%26aufirst%3DM.%26aulast%3DAnderson%26aufirst%3DS.%26aulast%3DHofilena%26aufirst%3DG.%26aulast%3DShan%26aufirst%3DM.%26aulast%3DPena%26aufirst%3DC.%26aulast%3DLathia%26aufirst%3DC.%26aulast%3DBukowski%26aufirst%3DR.%2BM.%26atitle%3DSorafenib%2520for%2520treatment%2520of%2520renal%2520cell%2520carcinoma%253A%2520Final%2520efficacy%2520and%2520safety%2520results%2520of%2520the%2520phase%2520III%2520treatment%2520approaches%2520in%2520renal%2520cancer%2520global%2520evaluation%2520trial%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2009%26volume%3D27%26spage%3D3312%26epage%3D3318" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Demetri, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Oosterom, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garrett, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blackstein, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verweij, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McArthur, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Judson, I. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heinrich, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morgan, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Desai, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">George, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bello, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baum, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casali, P. G.</span><span> </span><span class="NLM_article-title">Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">368</span><span class="NLM_x">, </span> <span class="NLM_fpage">1329</span><span class="NLM_x">â</span> <span class="NLM_lpage">1338</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=368&publication_year=2006&pages=1329-1338&author=G.+D.+Demetriauthor=A.+T.+van+Oosteromauthor=C.+R.+Garrettauthor=M.+E.+Blacksteinauthor=M.+H.+Shahauthor=J.+Verweijauthor=G.+McArthurauthor=I.+R.+Judsonauthor=M.+C.+Heinrichauthor=J.+A.+Morganauthor=J.+Desaiauthor=C.+D.+Fletcherauthor=S.+Georgeauthor=C.+L.+Belloauthor=X.+Huangauthor=C.+M.+Baumauthor=P.+G.+Casali&title=Efficacy+and+safety+of+sunitinib+in+patients+with+advanced+gastrointestinal+stromal+tumour+after+failure+of+imatinib%3A+a+randomised+controlled+trial"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDemetri%26aufirst%3DG.%2BD.%26aulast%3Dvan%2BOosterom%26aufirst%3DA.%2BT.%26aulast%3DGarrett%26aufirst%3DC.%2BR.%26aulast%3DBlackstein%26aufirst%3DM.%2BE.%26aulast%3DShah%26aufirst%3DM.%2BH.%26aulast%3DVerweij%26aufirst%3DJ.%26aulast%3DMcArthur%26aufirst%3DG.%26aulast%3DJudson%26aufirst%3DI.%2BR.%26aulast%3DHeinrich%26aufirst%3DM.%2BC.%26aulast%3DMorgan%26aufirst%3DJ.%2BA.%26aulast%3DDesai%26aufirst%3DJ.%26aulast%3DFletcher%26aufirst%3DC.%2BD.%26aulast%3DGeorge%26aufirst%3DS.%26aulast%3DBello%26aufirst%3DC.%2BL.%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DBaum%26aufirst%3DC.%2BM.%26aulast%3DCasali%26aufirst%3DP.%2BG.%26atitle%3DEfficacy%2520and%2520safety%2520of%2520sunitinib%2520in%2520patients%2520with%2520advanced%2520gastrointestinal%2520stromal%2520tumour%2520after%2520failure%2520of%2520imatinib%253A%2520a%2520randomised%2520controlled%2520trial%26jtitle%3DLancet%26date%3D2006%26volume%3D368%26spage%3D1329%26epage%3D1338" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Xu, C. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bing, N. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ball, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rajagopalan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sternberg, C. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hutson, T. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Souza, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xue, Z. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCann, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">King, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ragone, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whittaker, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spraggs, C. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cardon, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mooser, V. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pandite, L. N.</span><span> </span><span class="NLM_article-title">Pazopanib efficacy in renal cell carcinoma: Evidence for predictive genetic markers in angiogenesis-related and exposure-related genes</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">2557</span><span class="NLM_x">â</span> <span class="NLM_lpage">2564</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=16&amp;doi=10.1021%2Fjm201449n&amp;key=10.1200%2FJCO.2010.32.9110" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=8&amp;doi=10.1021%2Fjm201449n&amp;key=21576632" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=32&amp;doi=10.1021%2Fjm201449n&amp;key=1%3ACAS%3A528%3ADC%252BC3MXpsVyqtrs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2011&pages=2557-2564&author=C.+F.+Xuauthor=N.+X.+Bingauthor=H.+A.+Ballauthor=D.+Rajagopalanauthor=C.+N.+Sternbergauthor=T.+E.+Hutsonauthor=P.+de+Souzaauthor=Z.+G.+Xueauthor=L.+McCannauthor=K.+S.+Kingauthor=L.+J.+Ragoneauthor=J.+C.+Whittakerauthor=C.+F.+Spraggsauthor=L.+R.+Cardonauthor=V.+E.+Mooserauthor=L.+N.+Pandite&title=Pazopanib+efficacy+in+renal+cell+carcinoma%3A+Evidence+for+predictive+genetic+markers+in+angiogenesis-related+and+exposure-related+genes"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5aR"><div class="casContent"><span class="casTitleNuber">5a</span><div class="casTitle"><span class="NLM_cas:atitle">Pazopanib efficacy in renal cell carcinoma: Evidence for predictive genetic markers in angiogenesis-related and exposure-related genes</span></div><div class="casAuthors">Xu, Chun-Fang; Bing, Nan X.; Ball, Howard A.; Rajagopalan, Dilip; Sternberg, Cora N.; Hutson, Thomas E.; de Souza, Paul; Xue, Zhengyu G.; McCann, Lauren; King, Karen S.; Ragone, Leigh J.; Whittaker, John C.; Spraggs, Colin F.; Cardon, Lon R.; Mooser, Vincent E.; Pandite, Lini N.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">2557-2564</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Pazopanib, an oral angiogenesis inhibitor, is approved for the treatment of advanced renal cell carcinoma (RCC).  Response to pazopanib monotherapy varies between patients, and no validated biomarkers predictive of treatment outcome have been identified.  We tested the hypothesis that this variability is partially dependent on germline genetic variants that may affect pazopanib exposure or angiogenesis pathways.  27 Functional polymorphisms within 13 genes were evaluated in 397 patients with RCC.  Genetic assocn. with progression-free survival (PFS) and objective response rate (RR) was analyzed using the Cox proportional hazards model and proportional odds model, resp.  3 Polymorphisms in IL8 and HIF1A and five polymorphisms in HIF1A, NR1I2, and VEGFA showed nominally significant assocn. (P â¤ .05) with PFS and RR, resp.  Compared with the wild-type AA genotype (median PFS, 48 wk), the IL8 2767TT variant genotype showed inferior PFS (27 wk, P = .009).  The HIF1A 1790AG genotype was assocd. with inferior PFS and reduced RR, compared with the wild-type GG genotype (median PFS, 20 v 44 wk; P = .03; RR, 30% v 43%, P = .02).  Redns. in RR were detected for the NR1I2-25385TT genotype, compared with the wild-type CC genotype (37% v 50%, P = .03), and for the VEGFA - 1498CC genotype compared with the TT genotypes (33% v 51%).  Germline variants in angiogenesis- and exposure-related genes may predict treatment response to pazopanib monotherapy in patients with RCC.  If validated, these markers may explain why certain patients fail antiangiogenesis therapy and they may support the use of alternative strategies to circumvent this issue.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYP-HZufZfhrVg90H21EOLACvtfcHk0lj7OdVV5cu8mg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXpsVyqtrs%253D&md5=434ae6fdf2b7ed6561d59eaefd32a92c</span></div><a href="/servlet/linkout?suffix=cit5a&amp;dbid=16384&amp;doi=10.1200%2FJCO.2010.32.9110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2010.32.9110%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DC.%2BF.%26aulast%3DBing%26aufirst%3DN.%2BX.%26aulast%3DBall%26aufirst%3DH.%2BA.%26aulast%3DRajagopalan%26aufirst%3DD.%26aulast%3DSternberg%26aufirst%3DC.%2BN.%26aulast%3DHutson%26aufirst%3DT.%2BE.%26aulast%3Dde%2BSouza%26aufirst%3DP.%26aulast%3DXue%26aufirst%3DZ.%2BG.%26aulast%3DMcCann%26aufirst%3DL.%26aulast%3DKing%26aufirst%3DK.%2BS.%26aulast%3DRagone%26aufirst%3DL.%2BJ.%26aulast%3DWhittaker%26aufirst%3DJ.%2BC.%26aulast%3DSpraggs%26aufirst%3DC.%2BF.%26aulast%3DCardon%26aufirst%3DL.%2BR.%26aulast%3DMooser%26aufirst%3DV.%2BE.%26aulast%3DPandite%26aufirst%3DL.%2BN.%26atitle%3DPazopanib%2520efficacy%2520in%2520renal%2520cell%2520carcinoma%253A%2520Evidence%2520for%2520predictive%2520genetic%2520markers%2520in%2520angiogenesis-related%2520and%2520exposure-related%2520genes%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2011%26volume%3D29%26spage%3D2557%26epage%3D2564" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit5b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Harris, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boloor, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheung, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumar, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crosby, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis-Ward, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Epperly, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hinkle, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunter, R. N.,  III</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knick, V. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laudeman, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luttrell, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mook, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nolte, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rudolph, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szewczyk, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Truesdale, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Veal, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stafford, J. A.</span><span> </span><span class="NLM_article-title">Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">4632</span><span class="NLM_x">â</span> <span class="NLM_lpage">4640</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm800566m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=4632-4640&author=P.+A.+Harrisauthor=A.+Boloorauthor=M.+Cheungauthor=R.+Kumarauthor=R.+M.+Crosbyauthor=R.+G.+Davis-Wardauthor=A.+H.+Epperlyauthor=K.+W.+Hinkleauthor=R.+N.+Hunterauthor=J.+H.+Johnsonauthor=V.+B.+Knickauthor=C.+P.+Laudemanauthor=D.+K.+Luttrellauthor=R.+A.+Mookauthor=R.+T.+Nolteauthor=S.+K.+Rudolphauthor=J.+R.+Szewczykauthor=A.+T.+Truesdaleauthor=J.+M.+Vealauthor=L.+Wangauthor=J.+A.+Stafford&title=Discovery+of+5-%5B%5B4-%5B%282%2C3-dimethyl-2H-indazol-6-yl%29methylamino%5D-2-pyrimidinyl%5Damino%5D-2-methyl-benzenesulfonamide+%28Pazopanib%29%2C+a+novel+and+potent+vascular+endothelial+growth+factor+receptor+inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5b&amp;dbid=16384&amp;doi=10.1021%2Fjm800566m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800566m%26sid%3Dliteratum%253Aachs%26aulast%3DHarris%26aufirst%3DP.%2BA.%26aulast%3DBoloor%26aufirst%3DA.%26aulast%3DCheung%26aufirst%3DM.%26aulast%3DKumar%26aufirst%3DR.%26aulast%3DCrosby%26aufirst%3DR.%2BM.%26aulast%3DDavis-Ward%26aufirst%3DR.%2BG.%26aulast%3DEpperly%26aufirst%3DA.%2BH.%26aulast%3DHinkle%26aufirst%3DK.%2BW.%26aulast%3DHunter%26aufirst%3DR.%2BN.%26aulast%3DJohnson%26aufirst%3DJ.%2BH.%26aulast%3DKnick%26aufirst%3DV.%2BB.%26aulast%3DLaudeman%26aufirst%3DC.%2BP.%26aulast%3DLuttrell%26aufirst%3DD.%2BK.%26aulast%3DMook%26aufirst%3DR.%2BA.%26aulast%3DNolte%26aufirst%3DR.%2BT.%26aulast%3DRudolph%26aufirst%3DS.%2BK.%26aulast%3DSzewczyk%26aufirst%3DJ.%2BR.%26aulast%3DTruesdale%26aufirst%3DA.%2BT.%26aulast%3DVeal%26aufirst%3DJ.%2BM.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DStafford%26aufirst%3DJ.%2BA.%26atitle%3DDiscovery%2520of%25205-%255B%255B4-%255B%25282%252C3-dimethyl-2H-indazol-6-yl%2529methylamino%255D-2-pyrimidinyl%255Damino%255D-2-methyl-benzenesulfonamide%2520%2528Pazopanib%2529%252C%2520a%2520novel%2520and%2520potent%2520vascular%2520endothelial%2520growth%2520factor%2520receptor%2520inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D4632%26epage%3D4640" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Cai, Z. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borzilleri, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qian, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbosa, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wautlet, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mortillo, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeyaseelan, R.,  Sr</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kukral, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamath, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marathe, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DâArienzo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Derbin, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrish, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robl, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunt, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lombardo, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fargnoli, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhide, R. S.</span><span> </span><span class="NLM_article-title">Discovery of brivanib alaninate ((S)-((R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-yl)2-aminopropanoate), a novel prodrug of dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinase inhibitor (BMS-540215)</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">1976</span><span class="NLM_x">â</span> <span class="NLM_lpage">1980</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm7013309" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=1976-1980&author=Z.+W.+Caiauthor=Y.+Zhangauthor=R.+M.+Borzilleriauthor=L.+Qianauthor=S.+Barbosaauthor=D.+Weiauthor=X.+Zhengauthor=L.+Wuauthor=J.+Fanauthor=Z.+Shiauthor=B.+S.+Wautletauthor=S.+Mortilloauthor=R.+Jeyaseelanauthor=D.+W.+Kukralauthor=A.+Kamathauthor=P.+Maratheauthor=C.+D%E2%80%99Arienzoauthor=G.+Derbinauthor=J.+C.+Barrishauthor=J.+A.+Roblauthor=J.+T.+Huntauthor=L.+J.+Lombardoauthor=J.+Fargnoliauthor=R.+S.+Bhide&title=Discovery+of+brivanib+alaninate+%28%28S%29-%28%28R%29-1-%284-%284-fluoro-2-methyl-1H-indol-5-yloxy%29-5-methylpyrrolo%5B2%2C1-f%5D%5B1%2C2%2C4%5Dtriazin-6-yloxy%29propan-2-yl%292-aminopropanoate%29%2C+a+novel+prodrug+of+dual+vascular+endothelial+growth+factor+receptor-2+and+fibroblast+growth+factor+receptor-1+kinase+inhibitor+%28BMS-540215%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1021%2Fjm7013309&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm7013309%26sid%3Dliteratum%253Aachs%26aulast%3DCai%26aufirst%3DZ.%2BW.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DBorzilleri%26aufirst%3DR.%2BM.%26aulast%3DQian%26aufirst%3DL.%26aulast%3DBarbosa%26aufirst%3DS.%26aulast%3DWei%26aufirst%3DD.%26aulast%3DZheng%26aufirst%3DX.%26aulast%3DWu%26aufirst%3DL.%26aulast%3DFan%26aufirst%3DJ.%26aulast%3DShi%26aufirst%3DZ.%26aulast%3DWautlet%26aufirst%3DB.%2BS.%26aulast%3DMortillo%26aufirst%3DS.%26aulast%3DJeyaseelan%26aufirst%3DR.%26aulast%3DKukral%26aufirst%3DD.%2BW.%26aulast%3DKamath%26aufirst%3DA.%26aulast%3DMarathe%26aufirst%3DP.%26aulast%3DD%25E2%2580%2599Arienzo%26aufirst%3DC.%26aulast%3DDerbin%26aufirst%3DG.%26aulast%3DBarrish%26aufirst%3DJ.%2BC.%26aulast%3DRobl%26aufirst%3DJ.%2BA.%26aulast%3DHunt%26aufirst%3DJ.%2BT.%26aulast%3DLombardo%26aufirst%3DL.%2BJ.%26aulast%3DFargnoli%26aufirst%3DJ.%26aulast%3DBhide%26aufirst%3DR.%2BS.%26atitle%3DDiscovery%2520of%2520brivanib%2520alaninate%2520%2528%2528S%2529-%2528%2528R%2529-1-%25284-%25284-fluoro-2-methyl-1H-indol-5-yloxy%2529-5-methylpyrrolo%255B2%252C1-f%255D%255B1%252C2%252C4%255Dtriazin-6-yloxy%2529propan-2-yl%25292-aminopropanoate%2529%252C%2520a%2520novel%2520prodrug%2520of%2520dual%2520vascular%2520endothelial%2520growth%2520factor%2520receptor-2%2520and%2520fibroblast%2520growth%2520factor%2520receptor-1%2520kinase%2520inhibitor%2520%2528BMS-540215%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D1976%26epage%3D1980" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Bergers, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benjamin, L. E.</span><span> </span><span class="NLM_article-title">Tumorigenesis and the angiogenic switch</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">401</span><span class="NLM_x">â</span> <span class="NLM_lpage">410</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Fjm201449n&amp;key=10.1038%2Fnrc1093" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Fjm201449n&amp;key=12778130" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Fjm201449n&amp;key=1%3ACAS%3A528%3ADC%252BD3sXktFOnsb8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2003&pages=401-410&author=G.+Bergersauthor=L.+E.+Benjamin&title=Tumorigenesis+and+the+angiogenic+switch"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Angiogenesis: Tumorigenesis and the angiogenic switch</span></div><div class="casAuthors">Bergers, Gabriele; Benjamin, Laura E.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">401-410</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  It has become evident that the authors cannot understand tumor growth without considering components of the stromal microenvironment, such as the vasculature.  At the same time, the tumor phenotype dets. the nature of the tumor vasculature.  Much research is now devoted to detg. the impact of angiogenesis on tumor development and progression, and the reciprocal influences of tumor products on the microvasculature.  A more detailed understanding of the complex parameters that govern the interactions between the tumor and vascular compartments will help to improve anti-angiogenic strategies - not only for cancer treatment, but also for preventing recurrence.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZSf-pIdliV7Vg90H21EOLACvtfcHk0lhri320GgoXNw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXktFOnsb8%253D&md5=1c2717ab1374694b7d9edc420d29583a</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fnrc1093&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1093%26sid%3Dliteratum%253Aachs%26aulast%3DBergers%26aufirst%3DG.%26aulast%3DBenjamin%26aufirst%3DL.%2BE.%26atitle%3DTumorigenesis%2520and%2520the%2520angiogenic%2520switch%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2003%26volume%3D3%26spage%3D401%26epage%3D410" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Lin, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buxton, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Acheson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Radziejewski, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maisonpierre, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yancopoulos, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Channon, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hale, L. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dewhirst, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">George, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peters, K. G.</span><span> </span><span class="NLM_article-title">Antiangiogenic gene therapy targeting the endothelium-specific receptor tyrosine kinase TIE-2</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">95</span><span class="NLM_x">, </span> <span class="NLM_fpage">8829</span><span class="NLM_x">â</span> <span class="NLM_lpage">8834</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=1998&pages=8829-8834&author=P.+Linauthor=J.+A.+Buxtonauthor=A.+Achesonauthor=C.+Radziejewskiauthor=P.+C.+Maisonpierreauthor=G.+D.+Yancopoulosauthor=K.+M.+Channonauthor=L.+P.+Haleauthor=M.+W.+Dewhirstauthor=S.+E.+Georgeauthor=K.+G.+Peters&title=Antiangiogenic+gene+therapy+targeting+the+endothelium-specific+receptor+tyrosine+kinase+TIE-2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DP.%26aulast%3DBuxton%26aufirst%3DJ.%2BA.%26aulast%3DAcheson%26aufirst%3DA.%26aulast%3DRadziejewski%26aufirst%3DC.%26aulast%3DMaisonpierre%26aufirst%3DP.%2BC.%26aulast%3DYancopoulos%26aufirst%3DG.%2BD.%26aulast%3DChannon%26aufirst%3DK.%2BM.%26aulast%3DHale%26aufirst%3DL.%2BP.%26aulast%3DDewhirst%26aufirst%3DM.%2BW.%26aulast%3DGeorge%26aufirst%3DS.%2BE.%26aulast%3DPeters%26aufirst%3DK.%2BG.%26atitle%3DAntiangiogenic%2520gene%2520therapy%2520targeting%2520the%2520endothelium-specific%2520receptor%2520tyrosine%2520kinase%2520TIE-2%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D1998%26volume%3D95%26spage%3D8829%26epage%3D8834" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit8b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Cristofanilli, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Charnsangavej, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hortobagyi, G. N.</span><span> </span><span class="NLM_article-title">Angiogenesis modulation in cancer research: novel clinical approaches</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">415</span><span class="NLM_x">â</span> <span class="NLM_lpage">426</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2002&pages=415-426&author=M.+Cristofanilliauthor=C.+Charnsangavejauthor=G.+N.+Hortobagyi&title=Angiogenesis+modulation+in+cancer+research%3A+novel+clinical+approaches"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCristofanilli%26aufirst%3DM.%26aulast%3DCharnsangavej%26aufirst%3DC.%26aulast%3DHortobagyi%26aufirst%3DG.%2BN.%26atitle%3DAngiogenesis%2520modulation%2520in%2520cancer%2520research%253A%2520novel%2520clinical%2520approaches%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2002%26volume%3D1%26spage%3D415%26epage%3D426" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit8c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Jones, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LLjin, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dumount, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alitalo, K.</span><span> </span><span class="NLM_article-title">TIE receptors: new modulators of angiogenic and lymphangiogenic responses</span> <span class="citation_source-journal">Nat. Rev. Mol. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">257</span><span class="NLM_x">â</span> <span class="NLM_lpage">267</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8c&amp;dbid=16&amp;doi=10.1021%2Fjm201449n&amp;key=10.1038%2F35067005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8c&amp;dbid=8&amp;doi=10.1021%2Fjm201449n&amp;key=11283723" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8c&amp;dbid=32&amp;doi=10.1021%2Fjm201449n&amp;key=1%3ACAS%3A528%3ADC%252BD3MXis12jtL4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2001&pages=257-267&author=N.+Jonesauthor=K.+LLjinauthor=D.+Dumountauthor=K.+Alitalo&title=TIE+receptors%3A+new+modulators+of+angiogenic+and+lymphangiogenic+responses"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8cR"><div class="casContent"><span class="casTitleNuber">8c</span><div class="casTitle"><span class="NLM_cas:atitle">Tie receptors: new modulators of angiogenic and lymphangiogenic responses</span></div><div class="casAuthors">Jones, Nina; Iljin, Kristiina; Dumont, Daniel J.; Alitalo, Kari</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">257-267</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review, with 107 refs.  Angiogenesis is required for normal embryonic vascular development and aberrant angiogenesis contributes to several diseases, including cancer, diabetes, and tissue ischemia.  What are the mol. mechanisms that regulate this important process.  The Tie family of receptors and their ligands, the angiopoietins, are beginning to provide insight into how vessels make decisions such as whether to grow or regress - processes that are important not only during development but throughout an organism's life.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq132ywhxGgW7Vg90H21EOLACvtfcHk0lhri320GgoXNw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXis12jtL4%253D&md5=60dfebc8d6a9e61625addbd67d1487d0</span></div><a href="/servlet/linkout?suffix=cit8c&amp;dbid=16384&amp;doi=10.1038%2F35067005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F35067005%26sid%3Dliteratum%253Aachs%26aulast%3DJones%26aufirst%3DN.%26aulast%3DLLjin%26aufirst%3DK.%26aulast%3DDumount%26aufirst%3DD.%26aulast%3DAlitalo%26aufirst%3DK.%26atitle%3DTIE%2520receptors%253A%2520new%2520modulators%2520of%2520angiogenic%2520and%2520lymphangiogenic%2520responses%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2001%26volume%3D2%26spage%3D257%26epage%3D267" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit8d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Uemura, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogawa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirashima, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujiwara, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koyama, S</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takagi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Honda, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiegand, S, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yancopoulos, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishikawa, S.</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">110</span><span class="NLM_x">, </span> <span class="NLM_fpage">1619</span><span class="NLM_x">â</span> <span class="NLM_lpage">1628</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Uemura%2C+A.%3B+Ogawa%2C+M.%3B+Hirashima%2C+M.%3B+Fujiwara%2C+T.%3B+Koyama%2C+S%3B+Takagi%2C+H.%3B+Honda%2C+Y.%3B+Wiegand%2C+S%2C+J.%3B+Yancopoulos%2C+G.+D.%3B+Nishikawa%2C+S.J.+Clin.+Invest.+2002%2C+110%2C+1619%E2%80%931628"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DUemura%26aufirst%3DA.%26aulast%3DOgawa%26aufirst%3DM.%26aulast%3DHirashima%26aufirst%3DM.%26aulast%3DFujiwara%26aufirst%3DT.%26aulast%3DKoyama%26aufirst%3DS%26aulast%3DTakagi%26aufirst%3DH.%26aulast%3DHonda%26aufirst%3DY.%26aulast%3DWiegand%26aufirst%3DS%252C%2BJ.%26aulast%3DYancopoulos%26aufirst%3DG.%2BD.%26aulast%3DNishikawa%26aufirst%3DS.%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2002%26volume%3D110%26spage%3D1619%26epage%3D1628" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit8e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Visconti, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richardson, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sato, T. N.</span><span> </span><span class="NLM_article-title">Orchestration of angiogenesis and arteriovenous contribution by angiopoietins and vascular endothelial growth factor (VEGF)</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">99</span><span class="NLM_x">, </span> <span class="NLM_fpage">8219</span><span class="NLM_x">â</span> <span class="NLM_lpage">8224</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2002&pages=8219-8224&author=R.+P.+Viscontiauthor=C.+D.+Richardsonauthor=T.+N.+Sato&title=Orchestration+of+angiogenesis+and+arteriovenous+contribution+by+angiopoietins+and+vascular+endothelial+growth+factor+%28VEGF%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8e&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVisconti%26aufirst%3DR.%2BP.%26aulast%3DRichardson%26aufirst%3DC.%2BD.%26aulast%3DSato%26aufirst%3DT.%2BN.%26atitle%3DOrchestration%2520of%2520angiogenesis%2520and%2520arteriovenous%2520contribution%2520by%2520angiopoietins%2520and%2520vascular%2520endothelial%2520growth%2520factor%2520%2528VEGF%2529%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2002%26volume%3D99%26spage%3D8219%26epage%3D8224" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit8f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group">Jain, R. K.</span><span> </span><span class="NLM_article-title">Molecular regulation of vessel maturation</span> <span class="citation_source-journal">Nature Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">685</span><span class="NLM_x">â</span> <span class="NLM_lpage">693</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2003&pages=685-693&author=R.+K.+Jain&title=Molecular+regulation+of+vessel+maturation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8f&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJain%26aufirst%3DR.%2BK.%26atitle%3DMolecular%2520regulation%2520of%2520vessel%2520maturation%26jtitle%3DNature%2520Med.%26date%3D2003%26volume%3D9%26spage%3D685%26epage%3D693" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Lin, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polverini, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dewhirst, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rao, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peters, K. G.</span><span> </span><span class="NLM_article-title">Inhibition of tumor angiogenesis using a soluble receptor establishes a role for TIE-2 in pathologic vascular growth</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">100</span><span class="NLM_x">, </span> <span class="NLM_fpage">2072</span><span class="NLM_x">â</span> <span class="NLM_lpage">2078</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=1997&pages=2072-2078&author=P.+Linauthor=P.+Polveriniauthor=M.+Dewhirstauthor=S.+Shanauthor=P.+S.+Raoauthor=K.+G.+Peters&title=Inhibition+of+tumor+angiogenesis+using+a+soluble+receptor+establishes+a+role+for+TIE-2+in+pathologic+vascular+growth"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DP.%26aulast%3DPolverini%26aufirst%3DP.%26aulast%3DDewhirst%26aufirst%3DM.%26aulast%3DShan%26aufirst%3DS.%26aulast%3DRao%26aufirst%3DP.%2BS.%26aulast%3DPeters%26aufirst%3DK.%2BG.%26atitle%3DInhibition%2520of%2520tumor%2520angiogenesis%2520using%2520a%2520soluble%2520receptor%2520establishes%2520a%2520role%2520for%2520TIE-2%2520in%2520pathologic%2520vascular%2520growth%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D1997%26volume%3D100%26spage%3D2072%26epage%3D2078" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit9b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Shim, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teh, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mack, P. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ge, R.</span><span> </span><span class="NLM_article-title">Inhibition of angiopoietin-1 expression in tumor cells by an antisense RNA approach inhibited xenograft tumor growth in immunodeficient mice</span> <span class="citation_source-journal">Int. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">94</span><span class="NLM_x">, </span> <span class="NLM_fpage">6</span><span class="NLM_x">â</span> <span class="NLM_lpage">15</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=16&amp;doi=10.1021%2Fjm201449n&amp;key=10.1002%2Fijc.1428" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=8&amp;doi=10.1021%2Fjm201449n&amp;key=11668472" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=32&amp;doi=10.1021%2Fjm201449n&amp;key=1%3ACAS%3A528%3ADC%252BD3MXms1Kgs7Y%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=2001&pages=6-15&author=W.+S.+Shimauthor=M.+Tehauthor=P.+O.+Mackauthor=R.+Ge&title=Inhibition+of+angiopoietin-1+expression+in+tumor+cells+by+an+antisense+RNA+approach+inhibited+xenograft+tumor+growth+in+immunodeficient+mice"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9bR"><div class="casContent"><span class="casTitleNuber">9b</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of angiopoietin-1 expression in tumor cells by an antisense RNA approach inhibited xenograft tumor growth in immunodeficient mice</span></div><div class="casAuthors">Shim, Winston S. N.; Teh, Ming; Mack, Peter O. P.; Ge, Ruowen</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">6-15</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Angiopoietin-1 (Ang1) is an angiogenic growth factor that functions through activation of its endothelium-specific tyrosine kinase receptor Tie2; it mediates the interaction between endothelial and surrounding cells to promote the remodeling, maturation and stabilization of blood vessels.  Although Ang1 is expressed constitutively in many adult tissues, its role in tumor growth and metastasis is not clear.  Here we describe expts. in which Ang1 expression was inhibited in HeLa cells by an antisense RNA approach.  The modified HeLa cells produced significantly less Ang1 protein both in cultured cells and in tumors formed when these cells were injected into immunodeficient mice.  The Ang1 antisense tumors grew much more slowly, with significantly reduced tumor angiogenesis compared with control tumors.  Furthermore, they also had substantially increased tumor cell apoptosis and decreased tumor necrosis.  Our results indicate that the perturbation of Ang1 expression in tumors could be an effective method to control tumor growth by inhibiting tumor angiogenesis and that antisense RNA is an efficient way to inhibit Ang1 protein prodn. in tumor cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGryNwUaCFxQ8bVg90H21EOLACvtfcHk0ljCxnRP3myY0g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXms1Kgs7Y%253D&md5=a4d376df7f7f035c18523e4804851283</span></div><a href="/servlet/linkout?suffix=cit9b&amp;dbid=16384&amp;doi=10.1002%2Fijc.1428&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.1428%26sid%3Dliteratum%253Aachs%26aulast%3DShim%26aufirst%3DW.%2BS.%26aulast%3DTeh%26aufirst%3DM.%26aulast%3DMack%26aufirst%3DP.%2BO.%26aulast%3DGe%26aufirst%3DR.%26atitle%3DInhibition%2520of%2520angiopoietin-1%2520expression%2520in%2520tumor%2520cells%2520by%2520an%2520antisense%2520RNA%2520approach%2520inhibited%2520xenograft%2520tumor%2520growth%2520in%2520immunodeficient%2520mice%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2001%26volume%3D94%26spage%3D6%26epage%3D15" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit9c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Stratmann, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Acker, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burger, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amann, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Risau, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plate, K. H.</span><span> </span><span class="NLM_article-title">Differential inhibition of tumor angiogenesis by TIE-2 and vascular endothelial growth factor receptor-2 dominant-negative receptor mutants</span> <span class="citation_source-journal">Int. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">91</span><span class="NLM_x">, </span> <span class="NLM_fpage">273</span><span class="NLM_x">â</span> <span class="NLM_lpage">282</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9c&amp;dbid=16&amp;doi=10.1021%2Fjm201449n&amp;key=10.1002%2F1097-0215%28200002%299999%3A9999%3C%3A%3AAID-IJC1054%3E3.0.CO%3B2-Q" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9c&amp;dbid=8&amp;doi=10.1021%2Fjm201449n&amp;key=11169947" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9c&amp;dbid=32&amp;doi=10.1021%2Fjm201449n&amp;key=1%3ACAS%3A528%3ADC%252BD3MXmsFOktQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=2001&pages=273-282&author=A.+Stratmannauthor=T.+Ackerauthor=A.+M.+Burgerauthor=K.+Amannauthor=W.+Risauauthor=K.+H.+Plate&title=Differential+inhibition+of+tumor+angiogenesis+by+TIE-2+and+vascular+endothelial+growth+factor+receptor-2+dominant-negative+receptor+mutants"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9cR"><div class="casContent"><span class="casTitleNuber">9c</span><div class="casTitle"><span class="NLM_cas:atitle">Differential inhibition of tumor angiogenesis by TIE2 and vascular endothelial growth factor receptor-2 dominant-negative receptor mutants</span></div><div class="casAuthors">Stratmann, Astrid; Acker, Till; Burger, Angelika M.; Amann, Kerstin; Risau, Werner; Plate, Karl H.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">91</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">273-282</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Tumor growth is angiogenesis-dependent.  Current evidence suggests that vascular endothelial growth factor (VEGF), a major regulator of embryonic and hypoxia-mediated angiogenesis, is necessary for tumor angiogenesis.  VEGF is expressed in tumor cells in vivo, and its Tyr kinase receptors VEGFR-1 and VEGFR-2 are up-regulated in the tumor endothelium.  A second endothelial cell-specific ligand/receptor Tyr kinase system, consisting of the tie2 receptor, its activating ligand angiopoietin-1 and the inhibitory ligand angiopoietin-2, was characterized.  The authors have examd. 6 human primary breast-cancer samples and 4 murine breast-cancer cell lines (M6363, M6378, M6444, M6468), transplanted into nude mice, by in situ hybridization and/or Northern anal.  Expression of angiopoietin-1, angiopoietin-2 and tie2 was compared to VEGF and VEGFR-2 expression.  Human tumors expressed VEGFR-2 and tie2 but varied considerably in VEGF and angiopoietin-1/-2 expression.  In the murine tumor models, the authors obsd. high heterogeneity of receptor and ligand expression.  M6363 and M6378 tumors were analyzed in detail because they showed different expression of components of the tie2/angiopoietin signaling system.  M6363 tumors expressed VEGF, VEGFR-2 and angiopoietin-2 but not tie2 or angiopoietin-1, suggesting activation of VEGFR-2 and inhibition of tie2 signaling pathways, whereas M6378 tumors expressed VEGF, VEGFR-2, tie2 and angiopoietin-1 but little angiopoietin-2, suggesting activation of both VEGFR-2 and tie2 signaling pathways.  In vivo studies using truncated dominant-neg. tie2 and VEGFR-2 mutants revealed inhibition of M6363 tumor growth by 15% (truncated tie2) and 36% (truncated VEGFR-2), resp.  In contrast, M6378 tumor growth was inhibited by 57% (truncated tie2) and 47% (truncated VEGFR-2), resp.  These findings support the hypothesis that tumor angiogenesis is dependent on VEGFR-2 but suggest that, in addn., tie2-dependent pathways of tumor angiogenesis may exist.  For adequate application of angiogenesis inhibitors in tumor patients, anal. of prevailing angiogenesis pathways may be a prerequisite.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDdiCPRxhiV7Vg90H21EOLACvtfcHk0ljCxnRP3myY0g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXmsFOktQ%253D%253D&md5=dcafe52efa95848d38d3381097ab6fc8</span></div><a href="/servlet/linkout?suffix=cit9c&amp;dbid=16384&amp;doi=10.1002%2F1097-0215%28200002%299999%3A9999%3C%3A%3AAID-IJC1054%3E3.0.CO%3B2-Q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F1097-0215%2528200002%25299999%253A9999%253C%253A%253AAID-IJC1054%253E3.0.CO%253B2-Q%26sid%3Dliteratum%253Aachs%26aulast%3DStratmann%26aufirst%3DA.%26aulast%3DAcker%26aufirst%3DT.%26aulast%3DBurger%26aufirst%3DA.%2BM.%26aulast%3DAmann%26aufirst%3DK.%26aulast%3DRisau%26aufirst%3DW.%26aulast%3DPlate%26aufirst%3DK.%2BH.%26atitle%3DDifferential%2520inhibition%2520of%2520tumor%2520angiogenesis%2520by%2520TIE-2%2520and%2520vascular%2520endothelial%2520growth%2520factor%2520receptor-2%2520dominant-negative%2520receptor%2520mutants%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2001%26volume%3D91%26spage%3D273%26epage%3D282" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Jendreyko, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Popkov, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rader, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbas, C. F.</span><span> </span><span class="NLM_article-title">Phenotypic knockout of VEGF-R2 and TIE-2 with an intradiabody reduces tumor growth and angiogenesis in vivo</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">102</span><span class="NLM_x">, </span> <span class="NLM_fpage">8293</span><span class="NLM_x">â</span> <span class="NLM_lpage">8298</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=16&amp;doi=10.1021%2Fjm201449n&amp;key=10.1073%2Fpnas.0503168102" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=8&amp;doi=10.1021%2Fjm201449n&amp;key=15928093" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=32&amp;doi=10.1021%2Fjm201449n&amp;key=1%3ACAS%3A528%3ADC%252BD2MXlsV2mtLs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2005&pages=8293-8298&author=N.+Jendreykoauthor=M.+Popkovauthor=C.+Raderauthor=C.+F.+Barbas&title=Phenotypic+knockout+of+VEGF-R2+and+TIE-2+with+an+intradiabody+reduces+tumor+growth+and+angiogenesis+in+vivo"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10aR"><div class="casContent"><span class="casTitleNuber">10a</span><div class="casTitle"><span class="NLM_cas:atitle">Phenotypic knockout of VEGF-R2 and Tie-2 with an intradiabody reduces tumor growth and angiogenesis in vivo</span></div><div class="casAuthors">Jendreyko, Nina; Popkov, Mikhail; Rader, Christoph; Barbas, Carlos F., III</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">8293-8298</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The endothelial cell receptor-tyrosine kinases, VEGF receptor 2 (VEGF-R2) and Tie-2, and their ligands, vascular endothelial growth factor (VEGF) and angiopoietins 1 and 2, resp., play key roles in tumor angiogenesis.  Several studies suggest that the VEGF receptor pathway and the Tie-2 pathway are independent and essential mediators of angiogenesis, leading to the hypothesis that simultaneous interference with both pathways should result in additive effects on tumor growth.  In this study, a human melanoma xenograft model (M21) was used to analyze the effects of simultaneous intradiabody depletion of vascular endothelial growth receptor-R2 and Tie-2 on tumor angiogenesis and tumor xenograft growth.  The intradiabodies were expressed from recombinant adenovirus delivered through subtumoral injection.  Blockade of both VEGF-R2 and Tie-2 pathways simultaneously or the VEGF receptor pathway alone resulted in a significant inhibition of tumor growth and tumor angiogenesis (92.2% and 74.4%, resp.).  In addn., immunohistochem. staining of intradiabody-treated tumors demonstrated a decreased no. of tumor-assocd. blood vessels vs. control treatment.  Previous studies with intrabodies had demonstrated that the Tie-2 receptor pathway was essential for tumor growth.  The simultaneous blockade of the VEGF and Tie-2 pathways resulted in effective inhibition of tumor growth and demonstrated the potential of simultaneous targeting of multiple pathways as a therapeutic strategy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZ9MF0zdW6YLVg90H21EOLACvtfcHk0lhcNqhYED3Mpw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXlsV2mtLs%253D&md5=62c03cfdc0e2ba959b52f38c17b18631</span></div><a href="/servlet/linkout?suffix=cit10a&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0503168102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0503168102%26sid%3Dliteratum%253Aachs%26aulast%3DJendreyko%26aufirst%3DN.%26aulast%3DPopkov%26aufirst%3DM.%26aulast%3DRader%26aufirst%3DC.%26aulast%3DBarbas%26aufirst%3DC.%2BF.%26atitle%3DPhenotypic%2520knockout%2520of%2520VEGF-R2%2520and%2520TIE-2%2520with%2520an%2520intradiabody%2520reduces%2520tumor%2520growth%2520and%2520angiogenesis%2520in%2520vivo%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2005%26volume%3D102%26spage%3D8293%26epage%3D8298" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit10b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Popkov, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jendreyko, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGavern, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rader, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbas, C. F.</span><span> </span><span class="NLM_article-title">Targeting tumor angiogenesis with adenovirus-delivered anti-TIE-2 intrabody</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">65</span><span class="NLM_x">, </span> <span class="NLM_fpage">972</span><span class="NLM_x">â</span> <span class="NLM_lpage">991</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=8&amp;doi=10.1021%2Fjm201449n&amp;key=15705898" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=32&amp;doi=10.1021%2Fjm201449n&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVWntb0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2005&pages=972-991&author=M.+Popkovauthor=N.+Jendreykoauthor=D.+B.+McGavernauthor=C.+Raderauthor=C.+F.+Barbas&title=Targeting+tumor+angiogenesis+with+adenovirus-delivered+anti-TIE-2+intrabody"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10bR"><div class="casContent"><span class="casTitleNuber">10b</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting tumor angiogenesis with adenovirus-delivered anti-Tie-2 intrabody</span></div><div class="casAuthors">Popkov, Mikhail; Jendreyko, Nina; McGavern, Dorian B.; Rader, Christoph; Barbas, Carlos F., III</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">972-981</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Inhibition of tumor angiogenesis is a promising approach for cancer therapy.  As an endothelial cell-specific receptor kinase expressed almost exclusively on the surface of vascular endothelium, Tie-2 has an important role in tumor angiogenesis.  To explore the therapeutic potential of blocking Tie-2 receptor-interaction pathway, an adenoviral vector was used to deliver a recombinant single-chain antibody fragment rabbit intrabody (pAd-2S03) capable of inhibition of both mouse and human Tie-2 surface expression.  PAd-2S03 was given to mice with well-established primary tumors, either a human Kaposi's sarcoma (SLK) or a human colon carcinoma (SW1222).  The intrabody significantly inhibited growth of both tumors (75% and 63%, resp.) when compared with pAd-GFP control-treated tumors (P < 0.01).  Histopathol. anal. of cryosections taken from mice treated with pAd-2S03 revealed a marked decrease in vessel d., which was reduced by >87% in both tumor models when compared with control-treated tumors (P < 0.01).  In contrast, human Tie-2-monospecific pAd-1S05 intrabody did not affect the growth of tumors, indicating that the antitumor effect of pAd-2S03 was due to the inhibition of tumor angiogenesis in these murine models.  Our results show that the Tie-2 receptor pathway is essential for both SLK sarcoma and SW1222 colon carcinoma xenograft growth.  The present study shows the potential utility of antiangiogenic agents that target the endothelium-specific receptor Tie-2 for down-regulation or genetic deletion.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotTuWwaEkK6LVg90H21EOLACvtfcHk0lhcNqhYED3Mpw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVWntb0%253D&md5=8f91fd95654011fff049197d333dc43c</span></div><a href="/servlet/linkout?suffix=cit10b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPopkov%26aufirst%3DM.%26aulast%3DJendreyko%26aufirst%3DN.%26aulast%3DMcGavern%26aufirst%3DD.%2BB.%26aulast%3DRader%26aufirst%3DC.%26aulast%3DBarbas%26aufirst%3DC.%2BF.%26atitle%3DTargeting%2520tumor%2520angiogenesis%2520with%2520adenovirus-delivered%2520anti-TIE-2%2520intrabody%26jtitle%3DCancer%2520Res.%26date%3D2005%26volume%3D65%26spage%3D972%26epage%3D991" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Beebe, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jani, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knauth, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goodwin, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Higdon, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rossi, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emerson, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finkelstein, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harriman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atherton, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hillerman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soderstrom, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kou, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gant, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noe, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foster, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rastinejad, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marx, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schaeffer, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whalen, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, W. G.</span><span> </span><span class="NLM_article-title">Pharmacological characterization of CP-547,632, a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for cancer therapy</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">63</span><span class="NLM_x">, </span> <span class="NLM_fpage">7301</span><span class="NLM_x">â</span> <span class="NLM_lpage">7309</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2003&pages=7301-7309&author=J.+S.+Beebeauthor=J.+P.+Janiauthor=E.+Knauthauthor=P.+Goodwinauthor=C.+Higdonauthor=A.+M.+Rossiauthor=E.+Emersonauthor=M.+Finkelsteinauthor=E.+Floydauthor=S.+Harrimanauthor=J.+Athertonauthor=S.+Hillermanauthor=C.+Soderstromauthor=K.+Kouauthor=T.+Gantauthor=M.+C.+Noeauthor=B.+Fosterauthor=F.+Rastinejadauthor=M.+A.+Marxauthor=T.+Schaefferauthor=P.+M.+Whalenauthor=W.+G.+Roberts&title=Pharmacological+characterization+of+CP-547%2C632%2C+a+novel+vascular+endothelial+growth+factor+receptor-2+tyrosine+kinase+inhibitor+for+cancer+therapy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBeebe%26aufirst%3DJ.%2BS.%26aulast%3DJani%26aufirst%3DJ.%2BP.%26aulast%3DKnauth%26aufirst%3DE.%26aulast%3DGoodwin%26aufirst%3DP.%26aulast%3DHigdon%26aufirst%3DC.%26aulast%3DRossi%26aufirst%3DA.%2BM.%26aulast%3DEmerson%26aufirst%3DE.%26aulast%3DFinkelstein%26aufirst%3DM.%26aulast%3DFloyd%26aufirst%3DE.%26aulast%3DHarriman%26aufirst%3DS.%26aulast%3DAtherton%26aufirst%3DJ.%26aulast%3DHillerman%26aufirst%3DS.%26aulast%3DSoderstrom%26aufirst%3DC.%26aulast%3DKou%26aufirst%3DK.%26aulast%3DGant%26aufirst%3DT.%26aulast%3DNoe%26aufirst%3DM.%2BC.%26aulast%3DFoster%26aufirst%3DB.%26aulast%3DRastinejad%26aufirst%3DF.%26aulast%3DMarx%26aufirst%3DM.%2BA.%26aulast%3DSchaeffer%26aufirst%3DT.%26aulast%3DWhalen%26aufirst%3DP.%2BM.%26aulast%3DRoberts%26aufirst%3DW.%2BG.%26atitle%3DPharmacological%2520characterization%2520of%2520CP-547%252C632%252C%2520a%2520novel%2520vascular%2520endothelial%2520growth%2520factor%2520receptor-2%2520tyrosine%2520kinase%2520inhibitor%2520for%2520cancer%2520therapy%26jtitle%3DCancer%2520Res.%26date%3D2003%26volume%3D63%26spage%3D7301%26epage%3D7309" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit11b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Hasegawa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishigaki, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Washio, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kano, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sato, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mori, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">West, R. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shibahara, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toyoda, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nolte, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Veal, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheung, M.</span><span> </span><span class="NLM_article-title">Discovery of novel benzimidazoles as potent inhibitors of TIE-2 and VEGF-R2 tyrosine kinase receptors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">4453</span><span class="NLM_x">â</span> <span class="NLM_lpage">4470</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0611051" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=4453-4470&author=M.+Hasegawaauthor=N.+Nishigakiauthor=Y.+Washioauthor=K.+Kanoauthor=P.+A.+Harrisauthor=H.+Satoauthor=I.+Moriauthor=R.+I.+Westauthor=M.+Shibaharaauthor=H.+Toyodaauthor=L.+Wangauthor=R.+T.+Nolteauthor=J.+M.+Vealauthor=M.+Cheung&title=Discovery+of+novel+benzimidazoles+as+potent+inhibitors+of+TIE-2+and+VEGF-R2+tyrosine+kinase+receptors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11b&amp;dbid=16384&amp;doi=10.1021%2Fjm0611051&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0611051%26sid%3Dliteratum%253Aachs%26aulast%3DHasegawa%26aufirst%3DM.%26aulast%3DNishigaki%26aufirst%3DN.%26aulast%3DWashio%26aufirst%3DY.%26aulast%3DKano%26aufirst%3DK.%26aulast%3DHarris%26aufirst%3DP.%2BA.%26aulast%3DSato%26aufirst%3DH.%26aulast%3DMori%26aufirst%3DI.%26aulast%3DWest%26aufirst%3DR.%2BI.%26aulast%3DShibahara%26aufirst%3DM.%26aulast%3DToyoda%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DNolte%26aufirst%3DR.%2BT.%26aulast%3DVeal%26aufirst%3DJ.%2BM.%26aulast%3DCheung%26aufirst%3DM.%26atitle%3DDiscovery%2520of%2520novel%2520benzimidazoles%2520as%2520potent%2520inhibitors%2520of%2520TIE-2%2520and%2520VEGF-R2%2520tyrosine%2520kinase%2520receptors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D4453%26epage%3D4470" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit11c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Ji, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahmed, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albert, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bouska, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bousquet, P. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cunha, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diaz, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glaser, K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marcotte, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moskey, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oie, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pease, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soni, N. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stewart, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davidsen, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michaelides, M. R.</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">1231</span><span class="NLM_x">â</span> <span class="NLM_lpage">1241</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm701096v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Ji%2C+Z.%3B+Ahmed%2C+A.+A.%3B+Albert%2C+D.+H.%3B+Bouska%2C+J.+J.%3B+Bousquet%2C+P.+F.%3B+Cunha%2C+G.+A.%3B+Diaz%2C+G.%3B+Glaser%2C+K.+B.%3B+Guo%2C+J.%3B+Harris%2C+C.+M.%3B+Li%2C+J.%3B+Marcotte%2C+P.+A.%3B+Moskey%2C+M.+D.%3B+Oie%2C+T.%3B+Pease%2C+L.%3B+Soni%2C+N.+B.%3B+Stewart%2C+K.+D.%3B+Davidsen%2C+S.+K.%3B+Michaelides%2C+M.+R.J.+Med.+Chem.+2008%2C+51%2C+1231%E2%80%931241"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11c&amp;dbid=16384&amp;doi=10.1021%2Fjm701096v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm701096v%26sid%3Dliteratum%253Aachs%26aulast%3DJi%26aufirst%3DZ.%26aulast%3DAhmed%26aufirst%3DA.%2BA.%26aulast%3DAlbert%26aufirst%3DD.%2BH.%26aulast%3DBouska%26aufirst%3DJ.%2BJ.%26aulast%3DBousquet%26aufirst%3DP.%2BF.%26aulast%3DCunha%26aufirst%3DG.%2BA.%26aulast%3DDiaz%26aufirst%3DG.%26aulast%3DGlaser%26aufirst%3DK.%2BB.%26aulast%3DGuo%26aufirst%3DJ.%26aulast%3DHarris%26aufirst%3DC.%2BM.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DMarcotte%26aufirst%3DP.%2BA.%26aulast%3DMoskey%26aufirst%3DM.%2BD.%26aulast%3DOie%26aufirst%3DT.%26aulast%3DPease%26aufirst%3DL.%26aulast%3DSoni%26aufirst%3DN.%2BB.%26aulast%3DStewart%26aufirst%3DK.%2BD.%26aulast%3DDavidsen%26aufirst%3DS.%2BK.%26aulast%3DMichaelides%26aufirst%3DM.%2BR.%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D1231%26epage%3D1241" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit11d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Miyazaki, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maeda, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakano, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nolte, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sato, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sugai, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okamoto, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Truesdale, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hassler, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nartey, E. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patrick, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ozawa, K.</span><span> </span><span class="NLM_article-title">Orally active 4-amino-5-diarylurea-furo[2,3-d]pyrimidine derivatives as anti-angiogenic agent inhibiting VEGF-R2 and TIE-2</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">1773</span><span class="NLM_x">â</span> <span class="NLM_lpage">1778</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=1773-1778&author=Y.+Miyazakiauthor=J.+Tangauthor=Y.+Maedaauthor=M.+Nakanoauthor=L.+Wangauthor=R.+T.+Nolteauthor=H.+Satoauthor=M.+Sugaiauthor=Y.+Okamotoauthor=A.+T.+Truesdaleauthor=D.+F.+Hasslerauthor=E.+N.+Narteyauthor=D.+R.+Patrickauthor=M.+L.+Hoauthor=K.+Ozawa&title=Orally+active+4-amino-5-diarylurea-furo%5B2%2C3-d%5Dpyrimidine+derivatives+as+anti-angiogenic+agent+inhibiting+VEGF-R2+and+TIE-2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMiyazaki%26aufirst%3DY.%26aulast%3DTang%26aufirst%3DJ.%26aulast%3DMaeda%26aufirst%3DY.%26aulast%3DNakano%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DNolte%26aufirst%3DR.%2BT.%26aulast%3DSato%26aufirst%3DH.%26aulast%3DSugai%26aufirst%3DM.%26aulast%3DOkamoto%26aufirst%3DY.%26aulast%3DTruesdale%26aufirst%3DA.%2BT.%26aulast%3DHassler%26aufirst%3DD.%2BF.%26aulast%3DNartey%26aufirst%3DE.%2BN.%26aulast%3DPatrick%26aufirst%3DD.%2BR.%26aulast%3DHo%26aufirst%3DM.%2BL.%26aulast%3DOzawa%26aufirst%3DK.%26atitle%3DOrally%2520active%25204-amino-5-diarylurea-furo%255B2%252C3-d%255Dpyrimidine%2520derivatives%2520as%2520anti-angiogenic%2520agent%2520inhibiting%2520VEGF-R2%2520and%2520TIE-2%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2007%26volume%3D17%26spage%3D1773%26epage%3D1778" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit11e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Miyazakia, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsunagaa, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanga, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maedaa, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakanoa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Philippea, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shibaharaa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liub, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Satoa, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wangb, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nolteb, R. T.</span><span> </span><span class="NLM_article-title">Novel 4-amino-furo[2,3-d]pyrimidines as TIE-2 and VEGF-R2 dual inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">2203</span><span class="NLM_x">â</span> <span class="NLM_lpage">2207</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2005&pages=2203-2207&author=Y.+Miyazakiaauthor=S.+Matsunagaaauthor=J.+Tangaauthor=Y.+Maedaaauthor=M.+Nakanoaauthor=R.+J.+Philippeaauthor=M.+Shibaharaaauthor=W.+Liubauthor=H.+Satoaauthor=L.+Wangbauthor=R.+T.+Nolteb&title=Novel+4-amino-furo%5B2%2C3-d%5Dpyrimidines+as+TIE-2+and+VEGF-R2+dual+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11e&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMiyazakia%26aufirst%3DY.%26aulast%3DMatsunagaa%26aufirst%3DS.%26aulast%3DTanga%26aufirst%3DJ.%26aulast%3DMaedaa%26aufirst%3DY.%26aulast%3DNakanoa%26aufirst%3DM.%26aulast%3DPhilippea%26aufirst%3DR.%2BJ.%26aulast%3DShibaharaa%26aufirst%3DM.%26aulast%3DLiub%26aufirst%3DW.%26aulast%3DSatoa%26aufirst%3DH.%26aulast%3DWangb%26aufirst%3DL.%26aulast%3DNolteb%26aufirst%3DR.%2BT.%26atitle%3DNovel%25204-amino-furo%255B2%252C3-d%255Dpyrimidines%2520as%2520TIE-2%2520and%2520VEGF-R2%2520dual%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2005%26volume%3D15%26spage%3D2203%26epage%3D2207" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Gingrich, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddy, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iqbal, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aimone, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angeles, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albom, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ator, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robinson, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruggeri, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dionne, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaught, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mallamo, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hudkins, R. L.</span><span> </span><span class="NLM_article-title">A new class of potent VEGF receptor tyrosine kinase inhibitors: structure-activity relationships for a series of 9-alkoxymethyl-12-(3-hydroxypropyl)indeno[2,1-a]pyrrolo[3,4-c]carbazole-5-ones and the identification of CEP-5214 and its dimethylglycine ester prodrug clinical candidate CEP-7055</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">5375</span><span class="NLM_x">â</span> <span class="NLM_lpage">5388</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0301641" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=5375-5388&author=D.+E.+Gingrichauthor=D.+R.+Reddyauthor=M.+A.+Iqbalauthor=J.+Singhauthor=L.+D.+Aimoneauthor=T.+S.+Angelesauthor=M.+Albomauthor=S.+Yangauthor=S.+Meyerauthor=M.+Atorauthor=C.+Robinsonauthor=B.+A.+Ruggeriauthor=C.+A.+Dionneauthor=J.+L.+Vaughtauthor=J.+P.+Mallamoauthor=R.+L.+Hudkins&title=A+new+class+of+potent+VEGF+receptor+tyrosine+kinase+inhibitors%3A+structure-activity+relationships+for+a+series+of+9-alkoxymethyl-12-%283-hydroxypropyl%29indeno%5B2%2C1-a%5Dpyrrolo%5B3%2C4-c%5Dcarbazole-5-ones+and+the+identification+of+CEP-5214+and+its+dimethylglycine+ester+prodrug+clinical+candidate+CEP-7055"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12a&amp;dbid=16384&amp;doi=10.1021%2Fjm0301641&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0301641%26sid%3Dliteratum%253Aachs%26aulast%3DGingrich%26aufirst%3DD.%2BE.%26aulast%3DReddy%26aufirst%3DD.%2BR.%26aulast%3DIqbal%26aufirst%3DM.%2BA.%26aulast%3DSingh%26aufirst%3DJ.%26aulast%3DAimone%26aufirst%3DL.%2BD.%26aulast%3DAngeles%26aufirst%3DT.%2BS.%26aulast%3DAlbom%26aufirst%3DM.%26aulast%3DYang%26aufirst%3DS.%26aulast%3DMeyer%26aufirst%3DS.%26aulast%3DAtor%26aufirst%3DM.%26aulast%3DRobinson%26aufirst%3DC.%26aulast%3DRuggeri%26aufirst%3DB.%2BA.%26aulast%3DDionne%26aufirst%3DC.%2BA.%26aulast%3DVaught%26aufirst%3DJ.%2BL.%26aulast%3DMallamo%26aufirst%3DJ.%2BP.%26aulast%3DHudkins%26aufirst%3DR.%2BL.%26atitle%3DA%2520new%2520class%2520of%2520potent%2520VEGF%2520receptor%2520tyrosine%2520kinase%2520inhibitors%253A%2520structure-activity%2520relationships%2520for%2520a%2520series%2520of%25209-alkoxymethyl-12-%25283-hydroxypropyl%2529indeno%255B2%252C1-a%255Dpyrrolo%255B3%252C4-c%255Dcarbazole-5-ones%2520and%2520the%2520identification%2520of%2520CEP-5214%2520and%2520its%2520dimethylglycine%2520ester%2520prodrug%2520clinical%2520candidate%2520CEP-7055%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26spage%3D5375%26epage%3D5388" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit12b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Ruggeri, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gingrich, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angeles, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albom, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robinson, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunter, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dobrzanski, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones-Bolin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aimone, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klein-Szanto, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herbert, J.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bono, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schaeffer, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casellas, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bourie, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pili, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isaacs, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ator, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hudkins, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaught, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mallamo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dionne, C.</span><span> </span><span class="NLM_article-title">CEP-7055: A novel, orally-active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent anti-angiogenic activity and anti-tumor efficacy in pre-clinical models</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">63</span><span class="NLM_x">, </span> <span class="NLM_fpage">5978</span><span class="NLM_x">â</span> <span class="NLM_lpage">5991</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2003&pages=5978-5991&author=B.+Ruggeriauthor=J.+Singhauthor=D.+Gingrichauthor=T.+Angelesauthor=M.+Albomauthor=H.+Changauthor=C.+Robinsonauthor=K.+Hunterauthor=P.+Dobrzanskiauthor=S.+Jones-Bolinauthor=L.+Aimoneauthor=A.+Klein-Szantoauthor=J.-M.+Herbertauthor=F.+Bonoauthor=P.+Schaefferauthor=P.+Casellasauthor=B.+Bourieauthor=R.+Piliauthor=J.+Isaacsauthor=M.+Atorauthor=R.+Hudkinsauthor=J.+Vaughtauthor=J.+Mallamoauthor=C.+Dionne&title=CEP-7055%3A+A+novel%2C+orally-active+pan+inhibitor+of+vascular+endothelial+growth+factor+receptor+tyrosine+kinases+with+potent+anti-angiogenic+activity+and+anti-tumor+efficacy+in+pre-clinical+models"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRuggeri%26aufirst%3DB.%26aulast%3DSingh%26aufirst%3DJ.%26aulast%3DGingrich%26aufirst%3DD.%26aulast%3DAngeles%26aufirst%3DT.%26aulast%3DAlbom%26aufirst%3DM.%26aulast%3DChang%26aufirst%3DH.%26aulast%3DRobinson%26aufirst%3DC.%26aulast%3DHunter%26aufirst%3DK.%26aulast%3DDobrzanski%26aufirst%3DP.%26aulast%3DJones-Bolin%26aufirst%3DS.%26aulast%3DAimone%26aufirst%3DL.%26aulast%3DKlein-Szanto%26aufirst%3DA.%26aulast%3DHerbert%26aufirst%3DJ.-M.%26aulast%3DBono%26aufirst%3DF.%26aulast%3DSchaeffer%26aufirst%3DP.%26aulast%3DCasellas%26aufirst%3DP.%26aulast%3DBourie%26aufirst%3DB.%26aulast%3DPili%26aufirst%3DR.%26aulast%3DIsaacs%26aufirst%3DJ.%26aulast%3DAtor%26aufirst%3DM.%26aulast%3DHudkins%26aufirst%3DR.%26aulast%3DVaught%26aufirst%3DJ.%26aulast%3DMallamo%26aufirst%3DJ.%26aulast%3DDionne%26aufirst%3DC.%26atitle%3DCEP-7055%253A%2520A%2520novel%252C%2520orally-active%2520pan%2520inhibitor%2520of%2520vascular%2520endothelial%2520growth%2520factor%2520receptor%2520tyrosine%2520kinases%2520with%2520potent%2520anti-angiogenic%2520activity%2520and%2520anti-tumor%2520efficacy%2520in%2520pre-clinical%2520models%26jtitle%3DCancer%2520Res.%26date%3D2003%26volume%3D63%26spage%3D5978%26epage%3D5991" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Becknell, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zulli, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angeles, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albom, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aimone, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robinson, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hudkins, R. L.</span><span> </span><span class="NLM_article-title">Novel C-3 N-urea, amide and carbamate dihydroindazolo[5,4-a]pyrrolo[3,4-c]carbazole analogs as potent TIE-2 and VEGF-R2 dual inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">5368</span><span class="NLM_x">â</span> <span class="NLM_lpage">5372</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2006&pages=5368-5372&author=N.+Becknellauthor=A.+L.+Zulliauthor=T.+S.+Angelesauthor=S.+Yangauthor=M.+Albomauthor=L.+D.+Aimoneauthor=C.+Robinsonauthor=H.+Changauthor=R.+L.+Hudkins&title=Novel+C-3+N-urea%2C+amide+and+carbamate+dihydroindazolo%5B5%2C4-a%5Dpyrrolo%5B3%2C4-c%5Dcarbazole+analogs+as+potent+TIE-2+and+VEGF-R2+dual+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBecknell%26aufirst%3DN.%26aulast%3DZulli%26aufirst%3DA.%2BL.%26aulast%3DAngeles%26aufirst%3DT.%2BS.%26aulast%3DYang%26aufirst%3DS.%26aulast%3DAlbom%26aufirst%3DM.%26aulast%3DAimone%26aufirst%3DL.%2BD.%26aulast%3DRobinson%26aufirst%3DC.%26aulast%3DChang%26aufirst%3DH.%26aulast%3DHudkins%26aufirst%3DR.%2BL.%26atitle%3DNovel%2520C-3%2520N-urea%252C%2520amide%2520and%2520carbamate%2520dihydroindazolo%255B5%252C4-a%255Dpyrrolo%255B3%252C4-c%255Dcarbazole%2520analogs%2520as%2520potent%2520TIE-2%2520and%2520VEGF-R2%2520dual%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2006%26volume%3D16%26spage%3D5368%26epage%3D5372" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit13b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Underiner, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruggeri, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aimone, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albom, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angeles, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hudkins, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunter, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Josef, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robinson, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weinberg, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zulli, A.</span><span> </span><span class="NLM_article-title">TIE-2/VEGF-R2 SAR and in vitro activity of C3-acyl and C3-oxo fused pyrrolodihydroindazolo-carbazole analogs</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">2368</span><span class="NLM_x">â</span> <span class="NLM_lpage">2373</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=2368-2373&author=T.+L.+Underinerauthor=B.+Ruggeriauthor=L.+A.+Aimoneauthor=M.+Albomauthor=T.+Angelesauthor=H.+Changauthor=R.+L.+Hudkinsauthor=K.+Hunterauthor=K.+Josefauthor=C.+Robinsonauthor=L.+Weinbergauthor=S.+Yangauthor=A.+Zulli&title=TIE-2%2FVEGF-R2+SAR+and+in+vitro+activity+of+C3-acyl+and+C3-oxo+fused+pyrrolodihydroindazolo-carbazole+analogs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DUnderiner%26aufirst%3DT.%2BL.%26aulast%3DRuggeri%26aufirst%3DB.%26aulast%3DAimone%26aufirst%3DL.%2BA.%26aulast%3DAlbom%26aufirst%3DM.%26aulast%3DAngeles%26aufirst%3DT.%26aulast%3DChang%26aufirst%3DH.%26aulast%3DHudkins%26aufirst%3DR.%2BL.%26aulast%3DHunter%26aufirst%3DK.%26aulast%3DJosef%26aufirst%3DK.%26aulast%3DRobinson%26aufirst%3DC.%26aulast%3DWeinberg%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DS.%26aulast%3DZulli%26aufirst%3DA.%26atitle%3DTIE-2%252FVEGF-R2%2520SAR%2520and%2520in%2520vitro%2520activity%2520of%2520C3-acyl%2520and%2520C3-oxo%2520fused%2520pyrrolodihydroindazolo-carbazole%2520analogs%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D2368%26epage%3D2373" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit13c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Dandu, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zulli, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bacon, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Underiner, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robinson, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miknyoczki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grobelny, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruggeri, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albom, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angeles, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aimone, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hudkins, R. L.</span><span> </span><span class="NLM_article-title">Design and synthesis of dihydroindazolo[5,4-a]pyrrolo[3,4-c]carbazole oximes as potent dual inhibitors of TIE-2 and VEGF-R2 receptor tyrosine kinases</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">1916</span><span class="NLM_x">â</span> <span class="NLM_lpage">1921</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=1916-1921&author=R.+Danduauthor=A.+L.+Zulliauthor=E.+R.+Baconauthor=T.+L.+Underinerauthor=C.+Robinsonauthor=H.+Changauthor=S.+Miknyoczkiauthor=J.+Grobelnyauthor=B.+Ruggeriauthor=S.+Yangauthor=M.+S.+Albomauthor=T.+Angelesauthor=L.+A.+Aimoneauthor=R.+L.+Hudkins&title=Design+and+synthesis+of+dihydroindazolo%5B5%2C4-a%5Dpyrrolo%5B3%2C4-c%5Dcarbazole+oximes+as+potent+dual+inhibitors+of+TIE-2+and+VEGF-R2+receptor+tyrosine+kinases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDandu%26aufirst%3DR.%26aulast%3DZulli%26aufirst%3DA.%2BL.%26aulast%3DBacon%26aufirst%3DE.%2BR.%26aulast%3DUnderiner%26aufirst%3DT.%2BL.%26aulast%3DRobinson%26aufirst%3DC.%26aulast%3DChang%26aufirst%3DH.%26aulast%3DMiknyoczki%26aufirst%3DS.%26aulast%3DGrobelny%26aufirst%3DJ.%26aulast%3DRuggeri%26aufirst%3DB.%26aulast%3DYang%26aufirst%3DS.%26aulast%3DAlbom%26aufirst%3DM.%2BS.%26aulast%3DAngeles%26aufirst%3DT.%26aulast%3DAimone%26aufirst%3DL.%2BA.%26aulast%3DHudkins%26aufirst%3DR.%2BL.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520dihydroindazolo%255B5%252C4-a%255Dpyrrolo%255B3%252C4-c%255Dcarbazole%2520oximes%2520as%2520potent%2520dual%2520inhibitors%2520of%2520TIE-2%2520and%2520VEGF-R2%2520receptor%2520tyrosine%2520kinases%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D1916%26epage%3D1921" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit13d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Hudkins, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zulli, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Underiner, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angeles, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aimone, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pauletti, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fedorov, E. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Almo, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fedorov, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruggeri, B. A.</span><span> </span><span class="NLM_article-title">8-THP-DHI Analogs as Potent Type I Dual TIE-2/VEGF-R2 receptor tyrosine kinase inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">3356</span><span class="NLM_x">â</span> <span class="NLM_lpage">3360</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=3356-3360&author=R.+L.+Hudkinsauthor=A.+L.+Zulliauthor=T.+L.+Underinerauthor=T.+S.+Angelesauthor=L.+D.+Aimoneauthor=S.+L.+Meyerauthor=D.+Paulettiauthor=H.+Changauthor=E.+V.+Fedorovauthor=S.+C.+Almoauthor=A.+A.+Fedorovauthor=B.+A.+Ruggeri&title=8-THP-DHI+Analogs+as+Potent+Type+I+Dual+TIE-2%2FVEGF-R2+receptor+tyrosine+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHudkins%26aufirst%3DR.%2BL.%26aulast%3DZulli%26aufirst%3DA.%2BL.%26aulast%3DUnderiner%26aufirst%3DT.%2BL.%26aulast%3DAngeles%26aufirst%3DT.%2BS.%26aulast%3DAimone%26aufirst%3DL.%2BD.%26aulast%3DMeyer%26aufirst%3DS.%2BL.%26aulast%3DPauletti%26aufirst%3DD.%26aulast%3DChang%26aufirst%3DH.%26aulast%3DFedorov%26aufirst%3DE.%2BV.%26aulast%3DAlmo%26aufirst%3DS.%2BC.%26aulast%3DFedorov%26aufirst%3DA.%2BA.%26aulast%3DRuggeri%26aufirst%3DB.%2BA.%26atitle%3D8-THP-DHI%2520Analogs%2520as%2520Potent%2520Type%2520I%2520Dual%2520TIE-2%252FVEGF-R2%2520receptor%2520tyrosine%2520kinase%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D3356%26epage%3D3360" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Tao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, C-H</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Josef, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hudkins, R. L.</span><span> </span><span class="NLM_article-title">Regiospecific synthesis of 12,13-dihydroindazolo[5,4-a]pyrrolo[3,4-c]carbazole-4-one</span> <span class="citation_source-journal">J. Heterocyclic Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">1185</span><span class="NLM_x">â</span> <span class="NLM_lpage">1189</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14a&amp;dbid=16&amp;doi=10.1021%2Fjm201449n&amp;key=10.1002%2Fjhet.200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14a&amp;dbid=32&amp;doi=10.1021%2Fjm201449n&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFSgsbfE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2009&pages=1185-1189&author=M.+Taoauthor=C-H+Parkauthor=K.+A.+Josefauthor=R.+L.+Hudkins&title=Regiospecific+synthesis+of+12%2C13-dihydroindazolo%5B5%2C4-a%5Dpyrrolo%5B3%2C4-c%5Dcarbazole-4-one"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14aR"><div class="casContent"><span class="casTitleNuber">14a</span><div class="casTitle"><span class="NLM_cas:atitle">Regioselective synthesis of 2-methyl-2,5,6,11,12,13-hexahydro 4H indazolo[5,4-a]pyrrolo[3,4-c]carbazole-4-ones</span></div><div class="casAuthors">Tao, Ming; Park, Chung Ho; Josef, Kurt; Hudkins, Robert L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Heterocyclic Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1185-1189</span>CODEN:
                <span class="NLM_cas:coden">JHTCAD</span>;
        ISSN:<span class="NLM_cas:issn">1943-5193</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">2-Methyl-2,5,6,11,12,13-hexahydro 4H indazolo[5,4-a]pyrrolo[3,4-c]carbazole-4-one was synthesized utilizing a regioselective Diels-Alder reaction with 5-(1H-indol-2-yl)-2-methyl-6,7-dihydro-2H-indazole and Et cis-Î²-cyanoacrylate.  Acetic acid and YtBr3 were the best solvent and catalyst, resp., for the regioselective Diels-Alder reaction.  The chem. was used to synthesize novel 8-pyrimidinyloxy-2,5,6,11,12,13-hexahydro 4H-indazolo[5,4-a]pyrrolo[3,4-c]carbazole-4-ones that were screened and found to be potent inhibitors of DLK.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcz-oWdHXigbVg90H21EOLACvtfcHk0ljrTof9zmJ53Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFSgsbfE&md5=8257f7767c1772a333dcd63c674619ff</span></div><a href="/servlet/linkout?suffix=cit14a&amp;dbid=16384&amp;doi=10.1002%2Fjhet.200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjhet.200%26sid%3Dliteratum%253Aachs%26aulast%3DTao%26aufirst%3DM.%26aulast%3DPark%26aufirst%3DC-H%26aulast%3DJosef%26aufirst%3DK.%2BA.%26aulast%3DHudkins%26aufirst%3DR.%2BL.%26atitle%3DRegiospecific%2520synthesis%2520of%252012%252C13-dihydroindazolo%255B5%252C4-a%255Dpyrrolo%255B3%252C4-c%255Dcarbazole-4-one%26jtitle%3DJ.%2520Heterocyclic%2520Chem.%26date%3D2009%26volume%3D46%26spage%3D1185%26epage%3D1189" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit14b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Reddy, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Josef, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bacon, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hudkins, R. L.</span><span> </span><span class="NLM_article-title">Regiospecific synthesis of 5-(1H-indol-2-yl)-1- and â2-methyl-6,7-dihydro-2H-indazole isomers</span> <span class="citation_source-journal">J. Heterocyclic Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">437</span><span class="NLM_x">â</span> <span class="NLM_lpage">440</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14b&amp;dbid=16&amp;doi=10.1021%2Fjm201449n&amp;key=10.1002%2Fjhet.5570440225" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2007&pages=437-440&author=D.+R.+Reddyauthor=M.+Taoauthor=K.+A.+Josefauthor=E.+R.+Baconauthor=R.+L.+Hudkins&title=Regiospecific+synthesis+of+5-%281H-indol-2-yl%29-1-+and+%E2%88%922-methyl-6%2C7-dihydro-2H-indazole+isomers"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14b&amp;dbid=16384&amp;doi=10.1002%2Fjhet.5570440225&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjhet.5570440225%26sid%3Dliteratum%253Aachs%26aulast%3DReddy%26aufirst%3DD.%2BR.%26aulast%3DTao%26aufirst%3DM.%26aulast%3DJosef%26aufirst%3DK.%2BA.%26aulast%3DBacon%26aufirst%3DE.%2BR.%26aulast%3DHudkins%26aufirst%3DR.%2BL.%26atitle%3DRegiospecific%2520synthesis%2520of%25205-%25281H-indol-2-yl%2529-1-%2520and%2520%25E2%2588%25922-methyl-6%252C7-dihydro-2H-indazole%2520isomers%26jtitle%3DJ.%2520Heterocyclic%2520Chem.%26date%3D2007%26volume%3D44%26spage%3D437%26epage%3D440" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit14c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Josef, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddy, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hudkins, R. L.</span><span> </span><span class="NLM_article-title">Structure determination of N-methyl-1,4,6,7-tetrahydro-5H-indazol-5-one</span> <span class="citation_source-journal">J. Heterocyclic. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">719</span><span class="NLM_x">â</span> <span class="NLM_lpage">722</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14c&amp;dbid=16&amp;doi=10.1021%2Fjm201449n&amp;key=10.1002%2Fjhet.5570430328" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14c&amp;dbid=32&amp;doi=10.1021%2Fjm201449n&amp;key=1%3ACAS%3A528%3ADC%252BD28XlvVaqu7k%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2006&pages=719-722&author=K.+A.+Josefauthor=D.+Reddyauthor=M.+Taoauthor=R.+L.+Hudkins&title=Structure+determination+of+N-methyl-1%2C4%2C6%2C7-tetrahydro-5H-indazol-5-one"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14cR"><div class="casContent"><span class="casTitleNuber">14c</span><div class="casTitle"><span class="NLM_cas:atitle">Structure determination of N-methyl-tetrahydro-5H-indazol-5-ones</span></div><div class="casAuthors">Josef, Kurt A.; Dandu, Reddeppareddy; Tao, Ming; Hudkins, Robert L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Heterocyclic Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">719-722</span>CODEN:
                <span class="NLM_cas:coden">JHTCAD</span>;
        ISSN:<span class="NLM_cas:issn">0022-152X</span>.
    
            (<span class="NLM_cas:orgname">HeteroCorporation</span>)
        </div><div class="casAbstract">This paper communicates the (regio) synthesis and a convenient NMR structural assignment method for N-methyltetrahydro-5H-indazol-5-one isomers.  The cyclization reaction of 7-(hydroxymethylene)-1,4-dioxaspiro[4,5]decan-8-one with methylhydrazine yields, after de-protection predominately the N(2) Me isomer.  Anal. of the product ratio and structural assignments are based on NMR data including NOE difference expts. and were subsequently confirmed with x-ray crystallog. (no data, mol. structure only).  These findings are in sharp contrast with the literature.  The exptl. conditions used to optimize the synthesis of the individual isomers are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYnAFoW0YzR7Vg90H21EOLACvtfcHk0liiPveAr77RSg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XlvVaqu7k%253D&md5=18fd4f7e317b2e8de2b304b6ab6849c1</span></div><a href="/servlet/linkout?suffix=cit14c&amp;dbid=16384&amp;doi=10.1002%2Fjhet.5570430328&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjhet.5570430328%26sid%3Dliteratum%253Aachs%26aulast%3DJosef%26aufirst%3DK.%2BA.%26aulast%3DReddy%26aufirst%3DD.%26aulast%3DTao%26aufirst%3DM.%26aulast%3DHudkins%26aufirst%3DR.%2BL.%26atitle%3DStructure%2520determination%2520of%2520N-methyl-1%252C4%252C6%252C7-tetrahydro-5H-indazol-5-one%26jtitle%3DJ.%2520Heterocyclic.%2520Chem.%26date%3D2006%26volume%3D43%26spage%3D719%26epage%3D722" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit14d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Hudkins, R. L.; Zulli, A. L.; Reddy, D. R.; Gingrich, D. E.; Tao, M.; Becknell, N. C.; Diebold, J. L.; Underiner, T. L.</span><span> </span><span class="NLM_article-title">Preparation of Novel Fusedpyrrolocarbazoles for Treating or Preventing Angiogenesis or Angiogenesis Disorders</span>. US Patent US20050143442.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Hudkins%2C+R.+L.%3B+Zulli%2C+A.+L.%3B+Reddy%2C+D.+R.%3B+Gingrich%2C+D.+E.%3B+Tao%2C+M.%3B+Becknell%2C+N.+C.%3B+Diebold%2C+J.+L.%3B+Underiner%2C+T.+L.+Preparation+of+Novel+Fusedpyrrolocarbazoles+for+Treating+or+Preventing+Angiogenesis+or+Angiogenesis+Disorders.+US+Patent+US20050143442."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHudkins%26aufirst%3DR.%2BL.%26atitle%3DPreparation%2520of%2520Novel%2520Fusedpyrrolocarbazoles%2520for%2520Treating%2520or%2520Preventing%2520Angiogenesis%2520or%2520Angiogenesis%2520Disorders" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit14e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Hudkins, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diebold, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Josef, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angeles, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aimone, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Husten, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ator, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holskin, B. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Durkin, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fedorov, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fedorov, E. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Almo, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathiasen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bozyczko-Coyne, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saporito, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mallamo, J. P.</span><span> </span><span class="NLM_article-title">Mixed lineage kinase 1 (MLK1) and mixed lineage kinase 3 (MLK3) subtype selective dihydronaphthyl[3,4-a]pyrrolo[3,4-c]carbazole-5-ones: Optimization, mixed lineage kinase 1 crystallography and oral in vivo activity in 1-methyl-4-phenyltetrahydropyridine models</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">5680</span><span class="NLM_x">â</span> <span class="NLM_lpage">5689</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm8005838" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=5680-5689&author=R.+L.+Hudkinsauthor=J.+L.+Dieboldauthor=M.+Taoauthor=K.+A.+Josefauthor=C.+H.+Parkauthor=T.+S.+Angelesauthor=L.+D.+Aimoneauthor=J.+Hustenauthor=M.+A.+Atorauthor=S.+L.+Meyerauthor=B.+P.+Holskinauthor=J.+T.+Durkinauthor=A.+A.+Fedorovauthor=E.+V.+Fedorovauthor=S.+C.+Almoauthor=J.+Mathiasenauthor=D.+Bozyczko-Coyneauthor=M.+S.+Saporitoauthor=J.+P.+Mallamo&title=Mixed+lineage+kinase+1+%28MLK1%29+and+mixed+lineage+kinase+3+%28MLK3%29+subtype+selective+dihydronaphthyl%5B3%2C4-a%5Dpyrrolo%5B3%2C4-c%5Dcarbazole-5-ones%3A+Optimization%2C+mixed+lineage+kinase+1+crystallography+and+oral+in+vivo+activity+in+1-methyl-4-phenyltetrahydropyridine+models"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14e&amp;dbid=16384&amp;doi=10.1021%2Fjm8005838&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm8005838%26sid%3Dliteratum%253Aachs%26aulast%3DHudkins%26aufirst%3DR.%2BL.%26aulast%3DDiebold%26aufirst%3DJ.%2BL.%26aulast%3DTao%26aufirst%3DM.%26aulast%3DJosef%26aufirst%3DK.%2BA.%26aulast%3DPark%26aufirst%3DC.%2BH.%26aulast%3DAngeles%26aufirst%3DT.%2BS.%26aulast%3DAimone%26aufirst%3DL.%2BD.%26aulast%3DHusten%26aufirst%3DJ.%26aulast%3DAtor%26aufirst%3DM.%2BA.%26aulast%3DMeyer%26aufirst%3DS.%2BL.%26aulast%3DHolskin%26aufirst%3DB.%2BP.%26aulast%3DDurkin%26aufirst%3DJ.%2BT.%26aulast%3DFedorov%26aufirst%3DA.%2BA.%26aulast%3DFedorov%26aufirst%3DE.%2BV.%26aulast%3DAlmo%26aufirst%3DS.%2BC.%26aulast%3DMathiasen%26aufirst%3DJ.%26aulast%3DBozyczko-Coyne%26aufirst%3DD.%26aulast%3DSaporito%26aufirst%3DM.%2BS.%26aulast%3DMallamo%26aufirst%3DJ.%2BP.%26atitle%3DMixed%2520lineage%2520kinase%25201%2520%2528MLK1%2529%2520and%2520mixed%2520lineage%2520kinase%25203%2520%2528MLK3%2529%2520subtype%2520selective%2520dihydronaphthyl%255B3%252C4-a%255Dpyrrolo%255B3%252C4-c%255Dcarbazole-5-ones%253A%2520Optimization%252C%2520mixed%2520lineage%2520kinase%25201%2520crystallography%2520and%2520oral%2520in%2520vivo%2520activity%2520in%25201-methyl-4-phenyltetrahydropyridine%2520models%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D5680%26epage%3D5689" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">van Erp, N. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gelderblom, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guchelaar, H. J.</span><span> </span><span class="NLM_article-title">Clinical pharmacokinetics of tyrosine kinase inhibitors</span> <span class="citation_source-journal">Cancer Treat. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">692</span><span class="NLM_x">â</span> <span class="NLM_lpage">706</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Fjm201449n&amp;key=10.1016%2Fj.ctrv.2009.08.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Fjm201449n&amp;key=19733976" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Fjm201449n&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsVGlsb3F" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2009&pages=692-706&author=N.+P.+van+Erpauthor=H.+Gelderblomauthor=H.+J.+Guchelaar&title=Clinical+pharmacokinetics+of+tyrosine+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical pharmacokinetics of tyrosine kinase inhibitors</span></div><div class="casAuthors">van Erp, Nielka P.; Gelderblom, Hans; Guchelaar, Henk-Jan</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Treatment Reviews</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">692-706</span>CODEN:
                <span class="NLM_cas:coden">CTREDJ</span>;
        ISSN:<span class="NLM_cas:issn">0305-7372</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Summary: In the recent years, eight tyrosine kinase inhibitors (TKIs) have been approved for cancer treatment and numerous are under investigation.  These drugs are rationally designed to target specific tyrosine kinases that are mutated and/or over-expressed in cancer tissues.  Post marketing study commitments have been made upon (accelerated) approval such as addnl. pharmacokinetic studies in patients with renal- or hepatic impairment, in children, addnl. interactions studies and studies on the relative or abs. bioavailability.  Therefore, much information will emerge on the pharmacokinetic behavior of these drugs after their approval.  In the present manuscript, the pharmacokinetic characteristics; absorption, distribution, metab. and excretion (ADME), of the available TKIs are reviewed.  Results from addnl. studies on the effect of drug transporters and drug-drug interactions have been incorporated.  Overall, the TKIs reach their max. plasma levels relatively fast; have an unknown abs. bioavailability, are extensively distributed and highly protein bound.  The drugs are primarily metabolized by cytochrome P 450 (CYP) 3A4 with other CYP-enzymes playing a secondary role.  They are predominantly excreted with the feces and only a minor fraction is eliminated with the urine.  All TKIs appear to be transported by the efflux ATP binding-cassette transports B1 and G2.  Addnl. these drugs can inhibit some of their own metabolizing enzymes and transporters making steady-state metab. and drug-drug interactions both complex and unpredictable.  By understanding the pharmacokinetic profile of these drugs and their similarities, factors that influence drug exposure will be better recognized and this knowledge may be used to limit sub- or supra-therapeutic drug exposure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGVDDL-swrRLVg90H21EOLACvtfcHk0liiPveAr77RSg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsVGlsb3F&md5=12640303503889c3b267a21915fb1ce6</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.ctrv.2009.08.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ctrv.2009.08.004%26sid%3Dliteratum%253Aachs%26aulast%3Dvan%2BErp%26aufirst%3DN.%2BP.%26aulast%3DGelderblom%26aufirst%3DH.%26aulast%3DGuchelaar%26aufirst%3DH.%2BJ.%26atitle%3DClinical%2520pharmacokinetics%2520of%2520tyrosine%2520kinase%2520inhibitors%26jtitle%3DCancer%2520Treat.%2520Rev.%26date%3D2009%26volume%3D35%26spage%3D692%26epage%3D706" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Fedorov, A. A.; Fedorov, E. V.; Pauletti, D.; Meyer, S. L.; Hudkins, R. L.; Almo, S. C.</span><span> </span><span class="NLM_article-title">Crystal structure of cytoplasmic kinase domain of TIE-2 complexed with inhibitor CEP-11207</span>. Protein Data Bank, 3L8P;<span class="NLM_x"> </span><span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=A.+A.+Fedorov&author=E.+V.+Fedorov&author=D.+Pauletti&author=S.+L.+Meyer&author=R.+L.+Hudkins&author=S.+C.+Almo&title=Crystal+structure+of+cytoplasmic+kinase+domain+of+TIE-2+complexed+with+inhibitor+CEP-11207"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DFedorov%26aufirst%3DA.%2BA.%26atitle%3DCrystal%2520structure%2520of%2520cytoplasmic%2520kinase%2520domain%2520of%2520TIE-2%2520complexed%2520with%2520inhibitor%2520CEP-11207%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit16b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Traxler, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furet, P.</span><span> </span><span class="NLM_article-title">Strategies toward the design of novel and selective protein tyrosine kinase inhibitors</span> <span class="citation_source-journal">Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">82</span><span class="NLM_x">, </span> <span class="NLM_fpage">195</span><span class="NLM_x">â</span> <span class="NLM_lpage">206</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16b&amp;dbid=16&amp;doi=10.1021%2Fjm201449n&amp;key=10.1016%2FS0163-7258%2898%2900044-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16b&amp;dbid=8&amp;doi=10.1021%2Fjm201449n&amp;key=10454197" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16b&amp;dbid=32&amp;doi=10.1021%2Fjm201449n&amp;key=1%3ACAS%3A528%3ADyaK1MXjvFOht7Y%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=1999&pages=195-206&author=P.+Traxlerauthor=P.+Furet&title=Strategies+toward+the+design+of+novel+and+selective+protein+tyrosine+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16bR"><div class="casContent"><span class="casTitleNuber">16b</span><div class="casTitle"><span class="NLM_cas:atitle">Strategies toward the design of novel and selective protein tyrosine kinase inhibitors</span></div><div class="casAuthors">Traxler, Peter; Furet, Pascal</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">82</span>
        (<span class="NLM_cas:issue">2-3</span>),
    <span class="NLM_cas:pages">195-206</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">A review with 37 refs.  Protein tyrosine kinases play a fundamental role in signal transduction pathways.  Deregulated tyrosine kinase activity has been obsd. in many proliferative diseases (e.g., cancer, psoriasis, restenosis, etc.).  Tyrosine kinases are, therefore, attractive targets for the design of new therapeutic agents against cancer.  We have built up a pharmacophore model of the ATP-binding site of the epidermal growth factor receptor (EGFR) kinase and used it for the rational design of kinase inhibitors.  Several examples of the successful use of this model are presented in this review.  Amongst these, 4-substituted-pyrrolo[2,3-d]pyrimidines, a new class of highly potent and selective inhibitors of the EGFR kinase, have been identified and further optimized.  The most active derivs. inhibited the EGFR tyrosine kinase with IC50 values between 1 and 5 nM.  In EGF-dependent cellular systems, tyrosine phosphorylation, as well as c-fos mRNA expression, was inhibited with similar IC50 values.  Further successful application of this pharmacophore model led to the identification and optimization of phenylamino-pyrazolo[4,3-d]pyrimidines and substituted isoflavones and quinolones, other classes of potent, selective, and ATP competitive EGFR kinase inhibitors with IC50 values in the low nanomolar range.  Structure-activity relationships of both classes are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzTOVAYLwK77Vg90H21EOLACvtfcHk0lhsyvIqzjYyYw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXjvFOht7Y%253D&md5=26e5ed297e37b0cb188a0676e5b27f5b</span></div><a href="/servlet/linkout?suffix=cit16b&amp;dbid=16384&amp;doi=10.1016%2FS0163-7258%2898%2900044-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0163-7258%252898%252900044-8%26sid%3Dliteratum%253Aachs%26aulast%3DTraxler%26aufirst%3DP.%26aulast%3DFuret%26aufirst%3DP.%26atitle%3DStrategies%2520toward%2520the%2520design%2520of%2520novel%2520and%2520selective%2520protein%2520tyrosine%2520kinase%2520inhibitors%26jtitle%3DPharmacol.%2520Ther.%26date%3D1999%26volume%3D82%26spage%3D195%26epage%3D206" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit16c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Backes, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeck, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Felber, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klebl, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MÃ¼ller, G.</span><span> </span><span class="NLM_article-title">Small-molecule inhibitors binding to protein kinases. Part I: exceptions from the traditional pharmacophore approach of type I inhibition</span> <span class="citation_source-journal">Expert Opin. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">1409</span><span class="NLM_x">â</span> <span class="NLM_lpage">1425</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16c&amp;dbid=16&amp;doi=10.1021%2Fjm201449n&amp;key=10.1517%2F17460440802579975" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16c&amp;dbid=8&amp;doi=10.1021%2Fjm201449n&amp;key=23506106" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16c&amp;dbid=32&amp;doi=10.1021%2Fjm201449n&amp;key=1%3ACAS%3A528%3ADC%252BD1MXkvFCmtrk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2008&pages=1409-1425&author=A.+C.+Backesauthor=B.+Zeckauthor=B.+Felberauthor=B.+Kleblauthor=G.+M%C3%BCller&title=Small-molecule+inhibitors+binding+to+protein+kinases.+Part+I%3A+exceptions+from+the+traditional+pharmacophore+approach+of+type+I+inhibition"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16cR"><div class="casContent"><span class="casTitleNuber">16c</span><div class="casTitle"><span class="NLM_cas:atitle">Small-molecule inhibitors binding to protein kinases. Part I: exceptions from the traditional pharmacophore approach of type I inhibition</span></div><div class="casAuthors">Backes, A. C.; Zech, B.; Felber, B.; Klebl, B.; Mueller, G.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Discovery</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1409-1425</span>CODEN:
                <span class="NLM_cas:coden">EODDBX</span>;
        ISSN:<span class="NLM_cas:issn">1746-0441</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Background: Protein kinases are essential enzymes propagating cellular signal transduction processes and consequently have emerged as central targets for drug discovery against a wide range of diseases with a strong historical focus on oncol. disorders.  A large no. of high-resoln. crystal structures of various ATP-competitive inhibitors in complex with their target protein kinases have been detd. and present a wealth of detailed information about binding modes, inhibition mechanisms and assocd. structure-activity relationships of target-bound small mols.  Objective: In this first part of a two-part review, exceptions to the type I binding mode of kinase inhibitors that follow the traditional pharmacophore model are discussed, highlighting unexpected structural features.  Methods: The scope of this review covers published crystal structures of protein kinases in complex with various ligands.  Results: Structural parameters of both inhibitors and kinases contribute to the complexity of designing kinase inhibitors.  The continued study of high-resoln. structures of ligand-enzyme complexes in combination with a more dynamic understanding of accessible conformational states of the target proteins, supported by detailed kinetic studies, will in the long-term help in developing new low-mol. wt. kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgxVqECguWJbVg90H21EOLACvtfcHk0lhsyvIqzjYyYw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXkvFCmtrk%253D&md5=705fa7e531ceced90ed86d0d2658766e</span></div><a href="/servlet/linkout?suffix=cit16c&amp;dbid=16384&amp;doi=10.1517%2F17460440802579975&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17460440802579975%26sid%3Dliteratum%253Aachs%26aulast%3DBackes%26aufirst%3DA.%2BC.%26aulast%3DZeck%26aufirst%3DB.%26aulast%3DFelber%26aufirst%3DB.%26aulast%3DKlebl%26aufirst%3DB.%26aulast%3DM%25C3%25BCller%26aufirst%3DG.%26atitle%3DSmall-molecule%2520inhibitors%2520binding%2520to%2520protein%2520kinases.%2520Part%2520I%253A%2520exceptions%2520from%2520the%2520traditional%2520pharmacophore%2520approach%2520of%2520type%2520I%2520inhibition%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2008%26volume%3D3%26spage%3D1409%26epage%3D1425" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Vailhe, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vittet, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feige, J.-J.</span><span> </span><span class="NLM_article-title">In vitro models of vasculogenesis and angiogenesis</span> <span class="citation_source-journal">Lab. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">81</span><span class="NLM_x">, </span> <span class="NLM_fpage">439</span><span class="NLM_x">â</span> <span class="NLM_lpage">452</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=81&publication_year=2001&pages=439-452&author=B.+Vailheauthor=D.+Vittetauthor=J.-J.+Feige&title=In+vitro+models+of+vasculogenesis+and+angiogenesis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVailhe%26aufirst%3DB.%26aulast%3DVittet%26aufirst%3DD.%26aulast%3DFeige%26aufirst%3DJ.-J.%26atitle%3DIn%2520vitro%2520models%2520of%2520vasculogenesis%2520and%2520angiogenesis%26jtitle%3DLab.%2520Invest.%26date%3D2001%26volume%3D81%26spage%3D439%26epage%3D452" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit17b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Ilan, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mahooti, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Madri, J. A.</span><span> </span><span class="NLM_article-title">Distinct signal transduction pathways are utilized during the tube formation and survival phases of <i>in vitro</i> angiogenesis</span> <span class="citation_source-journal">J. Cell Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">111</span><span class="NLM_x">, </span> <span class="NLM_fpage">3621</span><span class="NLM_x">â</span> <span class="NLM_lpage">3631</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=8&amp;doi=10.1021%2Fjm201449n&amp;key=9819353" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=32&amp;doi=10.1021%2Fjm201449n&amp;key=1%3ACAS%3A528%3ADyaK1MXmtlKnsg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=1998&pages=3621-3631&author=N.+Ilanauthor=S.+Mahootiauthor=J.+A.+Madri&title=Distinct+signal+transduction+pathways+are+utilized+during+the+tube+formation+and+survival+phases+of+in+vitro+angiogenesis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17bR"><div class="casContent"><span class="casTitleNuber">17b</span><div class="casTitle"><span class="NLM_cas:atitle">Distinct signal transduction pathways are utilized during the tube formation and survival phases of in vitro angiogenesis</span></div><div class="casAuthors">Ilan, Neta; Mahooti, Sepi; Madri, Joseph A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cell Science</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">3621-3631</span>CODEN:
                <span class="NLM_cas:coden">JNCSAI</span>;
        ISSN:<span class="NLM_cas:issn">0021-9533</span>.
    
            (<span class="NLM_cas:orgname">Company of Biologists Ltd.</span>)
        </div><div class="casAbstract">Angiogenesis, the formation of new blood vessels from preexisting ones, occurs during development, wound healing and cancer and involves stages that orchestrate a network of cooperative interactions.  Peptide growth factors and extracellular matrix (ECM) components are two major groups of angiogenesis mediators.  Among the different ECM proteins, collagens have been well-assocd. with in vivo angiogenesis.  Using human umbilical vein endothelial cells (HUVEC) grown in 3-D collagen gels the authors show that: (1) HUVEC do not survive well in 3-D collagen gels due to rapid induction of apoptosis.  (2) VEGF, a potent in vivo angiogenic factor, fails to induce tube formation.  (3) PMA was effective in inducing tube formation and survival in HUVEC dispersed in 3-D collagen gels, activating MAP kinase, phosphoinositide 3-OH kinase (PI-3-kinase) and Akt/PKB (protein kinase B) pathways.  (4) VEGF was effective in preventing PMA-induced tube-like structure regression after PMA-withdrawal by activating the mitogen activated protein kinase (MAPK), rather than the Akt/PKB, signaling pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqr1l6sVhNXLVg90H21EOLACvtfcHk0lj337nTxZdNDA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXmtlKnsg%253D%253D&md5=48274561f8df6dfe819caf4c83476a10</span></div><a href="/servlet/linkout?suffix=cit17b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DIlan%26aufirst%3DN.%26aulast%3DMahooti%26aufirst%3DS.%26aulast%3DMadri%26aufirst%3DJ.%2BA.%26atitle%3DDistinct%2520signal%2520transduction%2520pathways%2520are%2520utilized%2520during%2520the%2520tube%2520formation%2520and%2520survival%2520phases%2520of%2520in%2520vitro%2520angiogenesis%26jtitle%3DJ.%2520Cell%2520Sci.%26date%3D1998%26volume%3D111%26spage%3D3621%26epage%3D3631" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit17c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Brown, K.; J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maynes, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bezos, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maguire, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ford, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parish, C. R.</span><span> </span><span class="NLM_article-title">A novel <i>in vitro</i> assay for human angiogenesis</span> <span class="citation_source-journal">Lab. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">75</span><span class="NLM_x">, </span> <span class="NLM_fpage">539</span><span class="NLM_x">â</span> <span class="NLM_lpage">555</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=1996&pages=539-555&author=K.%3B+J.+Brownauthor=S.+F.+Maynesauthor=A.+Bezosauthor=D.+J.+Maguireauthor=M.+D.+Fordauthor=C.+R.+Parish&title=A+novel+in+vitro+assay+for+human+angiogenesis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBrown%26aufirst%3DK.%253B%2BJ.%26aulast%3DMaynes%26aufirst%3DS.%2BF.%26aulast%3DBezos%26aufirst%3DA.%26aulast%3DMaguire%26aufirst%3DD.%2BJ.%26aulast%3DFord%26aufirst%3DM.%2BD.%26aulast%3DParish%26aufirst%3DC.%2BR.%26atitle%3DA%2520novel%2520in%2520vitro%2520assay%2520for%2520human%2520angiogenesis%26jtitle%3DLab.%2520Invest.%26date%3D1996%26volume%3D75%26spage%3D539%26epage%3D555" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit17d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Nicosia, R. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hazelton, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qian, X.</span><span> </span><span class="NLM_article-title">Endogenous regulation of angiogenesis in the rat aorta model. Role of vascular endothelial growth factor</span> <span class="citation_source-journal">Am. J. Pathol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">151</span><span class="NLM_x">, </span> <span class="NLM_fpage">1379</span><span class="NLM_x">â</span> <span class="NLM_lpage">1386</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17d&amp;dbid=8&amp;doi=10.1021%2Fjm201449n&amp;key=9358764" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17d&amp;dbid=32&amp;doi=10.1021%2Fjm201449n&amp;key=1%3ACAS%3A528%3ADyaK2sXntlOktrw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=151&publication_year=1997&pages=1379-1386&author=R.+F.+Nicosiaauthor=Y.+J.+Linauthor=D.+Hazeltonauthor=X.+Qian&title=Endogenous+regulation+of+angiogenesis+in+the+rat+aorta+model.+Role+of+vascular+endothelial+growth+factor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17dR"><div class="casContent"><span class="casTitleNuber">17d</span><div class="casTitle"><span class="NLM_cas:atitle">Endogenous regulation of angiogenesis in the rat aorta model: role of vascular endothelial growth factor</span></div><div class="casAuthors">Nicosia, Roberto F.; Lin, Yuzhong J.; Hazelton, Darcie; Qian, Xiaohua</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Pathology</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">151</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1379-1386</span>CODEN:
                <span class="NLM_cas:coden">AJPAA4</span>;
        ISSN:<span class="NLM_cas:issn">0002-9440</span>.
    
            (<span class="NLM_cas:orgname">American Society for Investigative Pathology</span>)
        </div><div class="casAbstract">The purpose of this study was to investigate the role of vascular endothelial growth factor (VEGF) in the rat aorta model of angiogenesis.  Freshly cut aortic rings generated microvascular outgrowths in serum-free collagen gel culture.  Angiogenesis was reduced to 10% when the explants were embedded in collagen 10 to 14 days after excision from the animal.  Immunochem. studies of conditioned medium demonstrated secretion of VEGF by the aortic cultures.  Levels of VEGF decreased during the second week of culture when the explants became quiescent and microvessels stopped growing.  Treatment of quiescent aortic rings with exogenous VEGF stimulated angiogenesis and restored microvascular growth to values obsd. in cultures of freshly cut explants.  Reverse transcriptase polymerase chain reaction of vasoformative collagen gel cultures of rat aorta demonstrated the expression of the alternatively spliced isoforms VEGF165, VEGF189, and the high-affinity VEGF receptor flk-1.  Reverse transcriptase-polymerase chain reaction of rat aorta-derived cell strains confirmed the presence of VEGF165 and VEGF189 in endothelial cells, smooth muscle cells, and fibroblasts.  The flk-1 receptor was expressed by endothelial cells but not by fibroblasts or smooth muscle cells, which is consistent with the endothelial target specificity of VEGF.  The spontaneous angiogenic response of freshly cut aortic rings was inhibited by 70% with a neutralizing antibody against VEGF, whereas nonimmune IgG had no effect.  These findings provide evidence for a VEGF-mediated autocrine/paracrine regulation of angiogenesis in the rat aorta model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGod6ZyQKv01arVg90H21EOLACvtfcHk0lj337nTxZdNDA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXntlOktrw%253D&md5=069671e4eaa9e15c67ce312a953c4a26</span></div><a href="/servlet/linkout?suffix=cit17d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNicosia%26aufirst%3DR.%2BF.%26aulast%3DLin%26aufirst%3DY.%2BJ.%26aulast%3DHazelton%26aufirst%3DD.%26aulast%3DQian%26aufirst%3DX.%26atitle%3DEndogenous%2520regulation%2520of%2520angiogenesis%2520in%2520the%2520rat%2520aorta%2520model.%2520Role%2520of%2520vascular%2520endothelial%2520growth%2520factor%26jtitle%3DAm.%2520J.%2520Pathol.%26date%3D1997%26volume%3D151%26spage%3D1379%26epage%3D1386" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3L8P" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3L8P','PDB','3L8P'); return false;">PDB: 3L8P</a></li></ul></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Fjm201449n&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3A10.1021%2Fjm201449n%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2012.55.issue-2%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/jm201449n" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                2MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright Â© 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">Youâve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"679927118b80193d","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
